<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN"  "JATS-archivearticle1-3-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">102440</article-id><article-id pub-id-type="doi">10.7554/eLife.102440</article-id><article-version article-version-type="publication-state">version of record</article-version><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Developmental Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Genetics and Genomics</subject></subj-group></article-categories><title-group><article-title>Evaluating the transcriptional regulators of arterial gene expression via a catalogue of characterized arterial enhancers</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Nornes</surname><given-names>Svanhild</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5301-5252</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Bruche</surname><given-names>Susann</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-5814-7166</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>Adak</surname><given-names>Niharika</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author"><name><surname>McCracken</surname><given-names>Ian R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes"><name><surname>De Val</surname><given-names>Sarah</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2566-2348</contrib-id><email>Sarah.deval@dpag.ox.ac.uk</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/05t17k830</institution-id><institution>Institute of Developmental and Regenerative Medicine, Department of Physiology, Anatomy and Genetics</institution></institution-wrap><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03cv38k47</institution-id><institution>University Medical Centre Groningen</institution></institution-wrap><addr-line><named-content content-type="city">Groningen</named-content></addr-line><country>Netherlands</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01e473h50</institution-id><institution>Ludwig Institute for Cancer Research Ltd, Nuffield Department of Medicine, University of Oxford</institution></institution-wrap><addr-line><named-content content-type="city">Oxford</named-content></addr-line><country>United Kingdom</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Koltowska</surname><given-names>Katarzyna</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/048a87296</institution-id><institution>Uppsala University</institution></institution-wrap><country>Sweden</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Stainier</surname><given-names>Didier YR</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0165r2y73</institution-id><institution>Max Planck Institute for Heart and Lung Research</institution></institution-wrap><country>Germany</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>17</day><month>01</month><year>2025</year></pub-date><volume>14</volume><elocation-id>e102440</elocation-id><history><date date-type="received" iso-8601-date="2024-08-19"><day>19</day><month>08</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2025-01-15"><day>15</day><month>01</month><year>2025</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at bioRxiv.</event-desc><date date-type="preprint" iso-8601-date="2024-04-30"><day>30</day><month>04</month><year>2024</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2024.04.30.591717"/></event></pub-history><permissions><copyright-statement>© 2025, Nornes et al</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Nornes et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-102440-v2.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-102440-figures-v2.pdf"/><related-article related-article-type="commentary" ext-link-type="doi" xlink:href="10.7554/eLife.106133" id="ra1"/><abstract><p>The establishment and growth of the arterial endothelium require the coordinated expression of numerous genes. However, regulation of this process is not yet fully understood. Here, we combined in silico analysis with transgenic mice and zebrafish models to characterize arterial-specific enhancers associated with eight key arterial identity genes (<italic>Acvrl1</italic>/<italic>Alk1</italic>, <italic>Cxcr4, Cxcl12, Efnb2, Gja4/Cx37, Gja5/Cx40</italic>, <italic>Nrp1,</italic> and <italic>Unc5b</italic>). Next, to elucidate the regulatory pathways upstream of arterial gene transcription, we investigated the transcription factors binding each arterial enhancer compared to a similar assessment of non-arterial endothelial enhancers. These results found that binding of SOXF and ETS factors was a common occurrence at both arterial and pan-endothelial enhancers, suggesting neither are sufficient to direct arterial specificity. Conversely, FOX motifs independent of ETS motifs were over-represented at arterial enhancers. Further, MEF2 and RBPJ binding was enriched but not ubiquitous at arterial enhancers, potentially linked to specific patterns of behaviour within the arterial endothelium. Lastly, there was no shared or arterial-specific signature for WNT-associated TCF/LEF, TGFβ/BMP-associated SMAD1/5 and SMAD2/3, shear stress-associated KLF4, or venous-enriched NR2F2. This cohort of well-characterized and in vivo-verified enhancers can now provide a platform for future studies into the interaction of different transcriptional and signaling pathways with arterial gene expression.</p></abstract><abstract abstract-type="plain-language-summary"><title>eLife digest</title><p>Our blood vessels are a biological transport system that carry oxygen and nutrients to all the cells and tissues of our bodies. Each type of blood vessel has a different structure depending on its role. For example, arteries are large, strong-walled vessels that carry oxygenated blood away from the heart into the rest of the body, while veins carry blood back to the heart and lungs once all the oxygen has been used up.</p><p>All blood vessels contain an inner lining made up of cells termed endothelial cells. These cells are also important for the formation of new blood vessels, which happens via a process called angiogenesis. During angiogenesis, the endothelial lining of new vessels forms first, by ‘sprouting’ or ‘splitting’ from the endothelial cells lining existing vessels.</p><p>We know that angiogenesis is accompanied by changes in gene activity within the new endothelial cells. For example, during the development of new arteries, endothelial cells will turn on genes involved in artery formation. These changes are controlled by biological switches, which involve special proteins (called transcription factors) and DNA sequences close to specific genes (called enhancers). When the right transcription factor interacts with an enhancer for a gene, the gene ‘switches on’.</p><p>Despite this, however, very few enhancers associated with arterial angiogenesis are known, and the mechanisms controlling this process are still poorly understood. Nornes et al. therefore set out to identify more arterial enhancers and study how they worked.</p><p>To identify potential enhancers, Nornes et al. first used computer-based analysis of the DNA surrounding eight genes known to be involved in artery formation. The enhancers were then tested in zebrafish and mice to confirm their ability to switch genes on in artery endothelial cells. These experiments revealed a set of 15 new arterial enhancers, which were tested in further biochemical and genetic studies to determine which transcription factors could interact with them. Several transcription factors previously thought to be involved in artery development did not appear to interact with any of the new enhancers.</p><p>This study sheds new light on the genetic control of blood vessel formation, in particular artery development. Nornes et al. hope that in the future the knowledge gained from these experiments will contribute to a better understanding of angiogenesis during early life, in health and disease.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>arterial enhancer</kwd><kwd>transcriptional regulation</kwd><kwd>arterial gene transcription</kwd><kwd>SOXF transcription factors</kwd><kwd>arteriovenous differentiation</kwd><kwd>vascular development</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd><kwd>Zebrafish</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000274</institution-id><institution>British Heart Foundation</institution></institution-wrap></funding-source><award-id>FS/1735/32929</award-id><principal-award-recipient><name><surname>Nornes</surname><given-names>Svanhild</given-names></name><name><surname>De Val</surname><given-names>Sarah</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000274</institution-id><institution>British Heart Foundation</institution></institution-wrap></funding-source><award-id>FS/SBSRF/22/31037</award-id><principal-award-recipient><name><surname>Nornes</surname><given-names>Svanhild</given-names></name><name><surname>De Val</surname><given-names>Sarah</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000274</institution-id><institution>British Heart Foundation</institution></institution-wrap></funding-source><award-id>FS/IPBSRF/23/27085</award-id><principal-award-recipient><name><surname>McCracken</surname><given-names>Ian R</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000274</institution-id><institution>British Heart Foundation</institution></institution-wrap></funding-source><award-id>RE/18/3/34214</award-id><principal-award-recipient><name><surname>De Val</surname><given-names>Sarah</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100001674</institution-id><institution>Fondation Leducq</institution></institution-wrap></funding-source><award-id>18CVD03</award-id><principal-award-recipient><name><surname>Bruche</surname><given-names>Susann</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100009729</institution-id><institution>Ludwig Institute for Cancer Research</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>De Val</surname><given-names>Sarah</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Identification and characterization of enhancers for eight key arterial genes reveal transcription factors associated with different aspects of endothelial gene expression specificity and provide a tool for a better understanding of arterial differentiation.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>The blood vessel system consists of a highly branched network of tubes lined by endothelial cells (ECs) and hierarchically organized into arteries, veins, and capillaries. The EC layer is the first part of the blood vessel to form, initially via differentiation from mesoderm (vasculogenesis) and later from existing ECs (angiogenesis) (<xref ref-type="bibr" rid="bib63">Payne et al., 2024</xref>). While the first arterial ECs arise during vasculogenesis (<xref ref-type="bibr" rid="bib17">Chong et al., 2011</xref>), single-cell transcriptomics and fate-mapping experiments spanning humans, mice, and zebrafish indicate that most arterial ECs form via angiogenesis from venous and venous-like capillary ECs (<xref ref-type="bibr" rid="bib84">Su et al., 2018</xref>; <xref ref-type="bibr" rid="bib37">Hou et al., 2022</xref>; <xref ref-type="bibr" rid="bib52">McCracken et al., 2022</xref>; <xref ref-type="bibr" rid="bib44">Lee et al., 2021</xref>; <xref ref-type="bibr" rid="bib92">Xu et al., 2014</xref>; <xref ref-type="bibr" rid="bib28">Fujita et al., 2011</xref>; <xref ref-type="bibr" rid="bib39">Kaufman et al., 2015</xref>; <xref ref-type="bibr" rid="bib50">Marín-Juez et al., 2016</xref>; <xref ref-type="bibr" rid="bib53">McCracken et al., 2023</xref>). During this process, a subset of ECs reduce cell-cycling and venous gene transcription, induce arterial gene expression, and migrate against flow to form into new arteries or extend existing ones. While significant alterations to gene transcription occur during this transition, the precise mix of hardwired signalling pathways and environmental stimuli regulating the differentiation of arterial ECs has been challenging to untangle and identify.</p><p>Many components of Notch signalling are selectively expressed in arterial ECs and are essential for arterial formation (e.g. the DLL4 ligand) (<xref ref-type="bibr" rid="bib68">Quillien et al., 2014</xref>). However, the assumed model of Notch signalling directly activating arterial gene expression has recently been challenged by new evidence. In particular, retinal and coronary vessels lacking both endothelial MYC (a driver of metabolism and proliferation) and RBPJ (the nuclear effector of Notch signalling) can still express arterial genes and form arterial structures (<xref ref-type="bibr" rid="bib48">Luo et al., 2021</xref>). This research led to a new paradigm in which Notch drives arterial EC differentiation by reducing metabolism and cell-cycle rather than by directly activating arterial genes (<xref ref-type="bibr" rid="bib48">Luo et al., 2021</xref>). However, cell-cycle changes alone do not necessarily alter arterial identity, and <italic>Myc</italic> loss in retinal EC does not affect arterial patterning (<xref ref-type="bibr" rid="bib89">Wilhelm et al., 2016</xref>). Therefore, Notch-mediated cell-cycle exit likely works alongside other regulators which directly control arterial gene transcription, while the precise role of Notch in directing arterial gene expression remains unclear.</p><p>Although numerous other regulatory pathways have been implicated in arterial transcriptional regulation, their exact contribution has been challenging to establish and none appear essential for arterial EC identity (<xref ref-type="bibr" rid="bib53">McCracken et al., 2023</xref>). Both canonical WNT and TGFβ/BMP signalling pathways have been implicated in arterialization yet ECs lacking β-catenin or SMAD4 still express arterial genes and form arterial structures (<xref ref-type="bibr" rid="bib56">Neal et al., 2019</xref>; <xref ref-type="bibr" rid="bib90">Wythe et al., 2013</xref>). Likewise, blood flow is required for full expression of arterial genes, yet arteries in both early embryonic and coronary vasculatures form prior to blood flow (<xref ref-type="bibr" rid="bib84">Su et al., 2018</xref>; <xref ref-type="bibr" rid="bib44">Lee et al., 2021</xref>; <xref ref-type="bibr" rid="bib25">Fang et al., 2017</xref>; <xref ref-type="bibr" rid="bib38">Hwa et al., 2017</xref>). Our knowledge of the transcription factors activating arterial gene expression is also incomplete. ETS factors are required for arterial gene activity but are also essential for vein-specific and pan-endothelial gene expression, suggesting a more general requirement for endothelial identity (<xref ref-type="bibr" rid="bib57">Neal et al., 2021</xref>). The link between FOXC factors and arteries was partially predicated on binding to <italic>Dll4</italic> regulatory regions later found to lack arterial activity (<xref ref-type="bibr" rid="bib90">Wythe et al., 2013</xref>). DACH1 potentiates arterial differentiation but is widely expressed and cannot alter EC identity (<xref ref-type="bibr" rid="bib69">Raftrey et al., 2021</xref>), while arterial-enriched MECOM is linked to repression of venous gene expression rather than activation of arterial identity genes (<xref ref-type="bibr" rid="bib52">McCracken et al., 2022</xref>). The evidence linking SOXF transcription factors to arterial differentiation is more extensive, with loss of either SOX17 (the SOXF factor most specific to arterial ECs) or SOX7 resulting in arterial defects (<xref ref-type="bibr" rid="bib45">Lilly et al., 2017</xref>; <xref ref-type="bibr" rid="bib41">Kim et al., 2016</xref>; <xref ref-type="bibr" rid="bib18">Corada et al., 2013</xref>; <xref ref-type="bibr" rid="bib95">Zhou et al., 2015</xref>). Whilst losing a single SOXF factor does not entirely compromise the arterial programme, arterial differentiation appears absent after compound <italic>Sox17;Sox18</italic> and <italic>Sox7;Sox17;Sox18</italic> deletion, although this occurs alongside significantly impaired angiogenesis and severe vascular hyperplasia (<xref ref-type="bibr" rid="bib45">Lilly et al., 2017</xref>; <xref ref-type="bibr" rid="bib41">Kim et al., 2016</xref>; <xref ref-type="bibr" rid="bib18">Corada et al., 2013</xref>; <xref ref-type="bibr" rid="bib95">Zhou et al., 2015</xref>). Additionally, the manner in which SOXF factors contribute to the specific activation of arterial genes is still unknown: while SOX17 is considered arterial-specific by late fetogenesis, both SOX7 and SOX18 are more widely expressed, and all SOXF factors bind the same motifs (<xref ref-type="bibr" rid="bib27">Francois et al., 2010</xref>). It is also unclear whether SOXF factors primarily act upstream of Notch signalling (and subsequent cell-cycle-related control of arterial differentiation), or whether they more widely activate arterial gene expression. Direct SOXF binding is best characterized at Notch pathway enhancers <italic>Dll4in3</italic>, <italic>Dll4-12,</italic> and <italic>Notch1+16,</italic> and the arterial defects seen after <italic>Sox17</italic> deletion were attributed to a requirement for SOX17 in activation of <italic>Notch1</italic> and <italic>Dll4 (</italic><xref ref-type="bibr" rid="bib63">Payne et al., 2024</xref>; <xref ref-type="bibr" rid="bib18">Corada et al., 2013</xref>; <xref ref-type="bibr" rid="bib74">Sacilotto et al., 2013</xref>). However, SOXF motifs are also required for the activity of the arterial-specific <italic>ECE1in1</italic> enhancer and are associated with coronary arterial <italic>Nestin</italic> expression (<xref ref-type="bibr" rid="bib29">González-Hernández et al., 2020</xref>; <xref ref-type="bibr" rid="bib71">Robinson et al., 2014</xref>).</p><p>In this article, we identify a cohort of arterial enhancers associated with eight key arterial identity genes, combining in silico analysis with verification and characterization in transgenic models. We then use sequence analysis and DNA-protein binding surveys to investigate the involvement of many endothelial- and arterial-associated transcription factors in arterial enhancer binding, and to compare this pattern with that seen at pan-endothelial and venous enhancers. Our results indicate that ETS and SOXF factors play a general role in endothelial gene transcription, suggest a role for FOX factors more selectively in arterial activation, and link both RBPJ and MEF2 factors to a limited number of arterial genes, potentially related to specific expression patterns. This cohort of well-characterized, in vivo-verified enhancers can also now be used as a platform for future studies into the interaction of different transcriptional and signalling pathways with specific arterial genes and with subtype-specific gene expression within the endothelium more generally. Additionally, our data provides a useful training set for attempts to more accurately classify endothelial enhancers genome-wide.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>In silico identification of putative enhancers for key arterial identity genes</title><p>Transcription factors primarily regulate endothelial gene transcription through binding to enhancers (<italic>cis</italic>-regulatory elements) (<xref ref-type="bibr" rid="bib63">Payne et al., 2024</xref>). Consequently, analysis of enhancer sequences can elucidate the precise combination of transcription factors, and cognate upstream signalling pathways, involved in different patterns of gene expression. One of the main challenges in understanding arterial regulation has been a paucity of characterized enhancers for key arterial genes. For example, of the 16 genes used to define mouse coronary arterial EC identity in single-cell transcriptomics (<xref ref-type="bibr" rid="bib69">Raftrey et al., 2021</xref>), only four have in vivo-verified enhancers (<italic>Dll4</italic>, <italic>Hey1</italic>, <italic>Notch1,</italic> and <italic>Acvrl1</italic>). Three of these are genes in the Notch pathway and are either self-regulated by Notch/RBPJ (<italic>Dll4-12</italic> and <italic>Hey1-18</italic>) (<xref ref-type="bibr" rid="bib74">Sacilotto et al., 2013</xref>; <xref ref-type="bibr" rid="bib88">Watanabe et al., 2020</xref>) or lack specificity during early coronary arterial specification (<italic>Notch1+16</italic>) (<xref ref-type="bibr" rid="bib62">Payne et al., 2019</xref>). The fourth enhancer, for <italic>Acvrl1</italic>, is of a size (9 kb) that precludes analysis (<xref ref-type="bibr" rid="bib79">Seki et al., 2004</xref>). Beyond this, there are only four other in vivo-validated arterial enhancers described in the literature, for <italic>Ece1, Flk1, Sema6d,</italic> and <italic>Sox7</italic>. Of these, only the <italic>Ece1in1</italic> and <italic>Flk1in10</italic> arterial enhancers, both associated with genes not specific to arterial ECs, have been analysed at the level of transcription factor binding (<xref ref-type="bibr" rid="bib71">Robinson et al., 2014</xref>; <xref ref-type="bibr" rid="bib96">Zhou et al., 2017</xref>). It is therefore clear that a better understanding of the regulatory pathways directing arterial differentiation requires the identification and characterization of a larger number of arterial enhancers orchestrating the expression of key arterial identity genes. To identify a cohort of such enhancers, we looked in the loci of eight non-Notch genes: <italic>Acvrl1</italic>(ALK1) <italic>Cxcr4, Cxcl12, Efnb2, Gja4</italic>(CX37)<italic>, Gja5</italic> (CX40), <italic>Nrp1,</italic> and <italic>Unc5b</italic>. Although not a definitive list of arterial identity genes, single-cell transcriptomic analysis indicates these genes are all significantly enriched in arterial ECs (<xref ref-type="bibr" rid="bib37">Hou et al., 2022</xref>; <xref ref-type="bibr" rid="bib69">Raftrey et al., 2021</xref>), and they are commonly used to define arterial EC populations in mouse and human scRNAseq analysis (<xref ref-type="bibr" rid="bib37">Hou et al., 2022</xref>; <xref ref-type="bibr" rid="bib52">McCracken et al., 2022</xref>; <xref ref-type="bibr" rid="bib69">Raftrey et al., 2021</xref>; <xref ref-type="bibr" rid="bib66">Phansalkar et al., 2021</xref>). Additionally, the genes selected here are also equally split between the two arterial subgroups identified by single-cell transcriptomics: <italic>Cxcr4</italic>, <italic>Efnb2</italic>, <italic>Gja4,</italic> and <italic>Unc5b</italic> included in the earlier expressed arterial plexus/pre-arterial EC subgroup, <italic>Acvrl1</italic>, <italic>Cxcl12</italic>, <italic>Gja5,</italic> and <italic>Nrp1</italic> restricted to the mature arterial EC subgroup (<xref ref-type="bibr" rid="bib37">Hou et al., 2022</xref>; <xref ref-type="bibr" rid="bib69">Raftrey et al., 2021</xref>). We did not exclude genes implicated in angiogenesis/expressed in sprouting ECs as these overlapped with genes within the pre-arterial EC subgroup.</p><p>To identify putative enhancers in silico, we used five published datasets detailing different enhancer-associated chromatin marks: (i) open chromatin as assessed by ATAC-seq in primary mouse adult aortic ECs (MAECs) from <xref ref-type="bibr" rid="bib23">Engelbrecht et al., 2020</xref>; (ii) open chromatin as assessed by ATAC-seq in mouse postnatal day 6 (P6) retina ECs (MRECs) from <xref ref-type="bibr" rid="bib94">Yanagida et al., 2020</xref>; (iii) enriched EP300 binding in Tie2Cre+ve cells from embryonic day (E) 11.5 mouse embryos from <xref ref-type="bibr" rid="bib96">Zhou et al., 2017</xref>; (iv) enriched H3K27Ac and/or H3K4Me1 in human umbilical vein ECs (HUVECs, data available on the UCSC Genome Browser; <xref ref-type="bibr" rid="bib73">Rosenbloom et al., 2013</xref>); and (v) open chromatin regions assessed by DNAseI hypersensitivity in HUVECs and dermal-derived neonatal and adult blood microvascular ECs (HMVEC-dBl-neo/ad) comparative to non-ECs (UCSC Genome Browser; <xref ref-type="bibr" rid="bib73">Rosenbloom et al., 2013</xref>; <xref ref-type="fig" rid="fig1">Figure 1</xref>). A retrospective analysis of 32 previously described mammalian in vivo-validated EC enhancers (<xref ref-type="bibr" rid="bib63">Payne et al., 2024</xref>), which included eight arterial enhancers, found that 31/32 were marked by at least one enhancer mark in both human and mouse samples (including 8/8 of arterial enhancers) (see <xref ref-type="table" rid="table1">Table 1</xref>). We analysed the loci of our target arterial genes to identify putative enhancers using these enhancer marks. For arterial genes robustly transcribed in both human and mouse EC datasets (determined by open chromatin/H3K4Me3 at the promoter region), we defined a putative enhancer as a region containing at least one enhancer mark in both mouse and human ECs. Because <italic>Cxcr4</italic>, <italic>Cxcl12</italic>, and <italic>Gja5</italic> were poorly transcribed in the human cell lines studied here, for these genes the putative enhancer definition was relaxed to include regions containing two enhancer marks in mouse ECs with no marks in human cells. Orthologous human enhancer sequences were identified for every enhancer using the Vertebrate Multiz Alignment &amp; Conservation Track on the UCSC Genome Browser. Each putative enhancer was named according to their neighbouring arterial gene and distance from the transcriptional start site (TSS) in mice (e.g. the putative <italic>Efnb2-112</italic> enhancer is 112 kb upstream of the mouse <italic>Efnb2</italic> TSS). In total, this analysis considered over 110 regions and identified 41 putative enhancers for further testing (<xref ref-type="fig" rid="fig1">Figure 1</xref>, <xref ref-type="supplementary-material" rid="table2sdata1">Table 2—source data 1</xref>). We also assessed seven regions previously identified as potential enhancers for <italic>Efnb2</italic>, <italic>Nrp1,</italic> and <italic>Cxcr4</italic> but whose independent activity was never validated in vivo (<xref ref-type="bibr" rid="bib30">Grego-Bessa et al., 2007</xref>; <xref ref-type="bibr" rid="bib93">Yamamizu et al., 2010</xref>; <xref ref-type="bibr" rid="bib86">Tsaryk et al., 2022</xref>; <xref ref-type="bibr" rid="bib83">Stewen et al., 2024</xref>). None of these met our putative enhancer threshold for further testing: two regions were associated with no enhancer marks, three had a single enhancer mark in HUVECs, one had non-specific enhancer marks in human cells only (<italic>Nrp1+76/NRP1A;</italic> <xref ref-type="bibr" rid="bib93">Yamamizu et al., 2010</xref>) and one contained enhancer marks in human ECs only (<italic>Cxcr4-117/CXCR4+125;</italic> <xref ref-type="bibr" rid="bib86">Tsaryk et al., 2022</xref>; <xref ref-type="fig" rid="fig1">Figure 1</xref>, <xref ref-type="supplementary-material" rid="table2sdata1">Table 2—source data 1</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>Analysis of enhancer marks around eight arterial-expressed genes identifies putative arterial enhancers.</title><p>Enhancer marks from mouse tissue include: dark red ‘ATAC adult artery EC’ denotes open chromatin assessed by ATAC-seq in primary adult aortic endothelial cells (ECs) <xref ref-type="bibr" rid="bib23">Engelbrecht et al., 2020</xref>; bright red ‘ATAC P6 EC’ denotes open chromatin assessed by ATAC-seq in postnatal day 6 retinal ECs <xref ref-type="bibr" rid="bib94">Yanagida et al., 2020</xref>; orange ‘EP300 E11 EC’ denotes enriched EP300 binding in Tie2Cre+ve cells in embryonic day 11.5 embryos (<xref ref-type="bibr" rid="bib96">Zhou et al., 2017</xref>). Enhancer marks from human cells include: light blue peaks denotes enriched H3K27Ac and H3K4Me1 in human umbilical vein ECs (HUVECs) (UCSC Genome Browser; <xref ref-type="bibr" rid="bib73">Rosenbloom et al., 2013</xref>); grey heat map denotes open chromatin regions assessed by DNAseI hypersensitivity in HUVECs (upper line) and dermal-derived neonatal and adult blood microvascular ECs (HMVEC-dBl-neo/ad, middle and bottom line) (UCSC Genome Browser). Red, pink, and orange solid boxes indicate regions fitting putative enhancers criteria and selected for analysis (red/pink/orange indicates strong/weak/silent EC activity in transgenic models, see <xref ref-type="table" rid="table2">Table 2</xref> and <xref ref-type="fig" rid="fig2">Figures 2</xref> and <xref ref-type="fig" rid="fig3">3</xref>). Numbers represent approximate distance from TSS. Orange dashed boxes indicates regions below the putative enhancer threshold but included in transgenic assays as controls, grey boxes indicate regions below the putative enhancer threshold and not tested. * indicates that enhancer marks were not specific for ECs but rather found in many cell types.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102440-fig1-v2.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>The mouse Dll4-12 enhancer directs arterial expression of reporter genes in the vasculature of transgenic zebrafish (<bold>A</bold>) and mice (<bold>B</bold>).</title><p>This enhancer was first reported in <xref ref-type="bibr" rid="bib74">Sacilotto et al., 2013</xref> but not tested in zebrafish. (<bold>A</bold>) The Dll4-12:GFP transgene directs arterial endothelial cell expression in mosaic F0 (upper) and stable F1 (middle) transgenic zebrafish at 2 days post fertilization (dpf), arterial specificity is confirmed at 3 dpf by crossing with <italic>tg(kdrl:HRAS-mCherry</italic>) (lower two panels). Grey dashed box specifies region of zoom, a indicates dorsal aorta, v indicates cardinal vein, * indicates intersegmental vessels, and n indicates neural tube expression. (<bold>B</bold>) The mouse <italic>Dll4-12:LacZ</italic> transgene directs arterial expression in a stable transgenic line. Representative whole-mount embryos from the <italic>Dll4-12:lacZ</italic> transgenic line show reporter gene expression (X-gal staining, blue) in the vasculature from embryonic day 9.5 (E9.5) to E15.5.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102440-fig1-figsupp1-v2.tif"/></fig><fig id="fig1s2" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 2.</label><caption><title>Analysis of putative enhancers in F0 mosaic Tol2 transgenic zebrafish identifies 15 enhancers able to drive robust GFP activity in arterial endothelial cells (ECs) (other weaker/ non-arterial enhancers are detailed in <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3</xref>).</title><p>(<bold>A</bold>) Example of the expression of known pan-EC (<italic>kdrl1:HRAS-mCherry</italic>) (<xref ref-type="bibr" rid="bib14">Chi et al., 2008</xref>), arterial (<italic>Dll4in3:GFP</italic>; <xref ref-type="bibr" rid="bib74">Sacilotto et al., 2013</xref>), and vein (<italic>CoupTFII-965:GFP;</italic> <xref ref-type="bibr" rid="bib56">Neal et al., 2019</xref>) enhancers in 2 dpf zebrafish. (<bold>B</bold>) Two representative F0 transgenic zebrafish expressing each of the 15 new strong arterial enhancers alongside a schematic of each transgene. Grey dashed box indicates region of zoom, a indicates dorsal aorta, v indicates cardinal vein, white arrow indicates intersegmental vessels, * indicates expression in neural tube, and # indicates expression in muscle fibres.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102440-fig1-figsupp2-v2.tif"/></fig><fig id="fig1s3" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 3.</label><caption><title>Additional images of transgenic fish expressing the Unc5b-57:GFP, Cxcl12+383:GFP, Efnb2-37, Unc5b+23, Cxcl12+117, Efnb2-112 and Efnb2-159 transgenes.</title><p>(<bold>A,, B</bold>) The <italic>Unc5b-57</italic>:GFP transgene is expressed in the vasculature when investigated in either F0 Tol2 transgenic zebrafish (<bold>A</bold>) or F1/2 stable transgenic zebrafish (<bold>B</bold>). Crossing with the <italic>kdrl:HRAS-mCherry</italic> transgene demonstrates that <italic>Unc5b-57:GFP</italic> expression is restricted to venous locations towards the anterior of the fish. (<bold>C</bold>) Expression pattern driven by the three ‘weak’ enhancers identified in our F0 mosaic Tol2 transgenic zebrafish screen. Grey dashed box indicates region of zoom, a indicates dorsal aorta, v indicates cardinal vein, white arrows indicate intersegmental vessels, * indicates expression in neural tube, and # indicates expression in muscle fibres. (<bold>D</bold>) The <italic>Cxcr4-117:GFP</italic> transgene directs very limited reporter gene expression in transgenic zebrafish. The six transgenic zebrafish shown exhibited the greatest level of GFP expression seen in all injected zebrafish. Grey dashed box indicates region of zoom. (<bold>E</bold>) Expression pattern of the <italic>Efnb2-159</italic> and <italic>Efnb2-112</italic> enhancer:GFP transgenes in 4-week-old juvenile zebrafish fins. Grey dashed box indicates regions of zoom, a fin artery, and v fin vein.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102440-fig1-figsupp3-v2.tif"/></fig><fig id="fig1s4" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 4.</label><caption><title>Enhancer marks in cultured human arterial endothelial cells (ECs) around the eight target arterial gene loci.</title><p>These are shown relative to the enhancer marks in human vein-origin and microvascular-origin ECs used to originally identify putative arterial enhancers in <xref ref-type="fig" rid="fig1">Figure 1</xref>. Red and orange boxes denote the regions identified as putative enhancers in original analysis, grey boxes denote regions below threshold, and numbers represent approximate distance from TSS in mouse sequence. * indicates that enhancer marks were not specific for ECs but rather found in many cell types. Enhancer marks in human vein-origin and microvascular-origin ECs used in original analysis: light blue peaks denote enriched H3K27Ac and H3K4Me1 in human umbilical vein ECs (HUVECs), data from the UCSC Genome Browser <xref ref-type="bibr" rid="bib37">Hou et al., 2022</xref>; grey heat map denotes open chromatin regions assessed by DNAseI hypersensitivity in HUVECs (upper line) and dermal-derived neonatal and adult blood microvascular ECs (HMVEC-dBl-neo/ad, middle and bottom line) from the UCSC Genome Browser (<xref ref-type="bibr" rid="bib37">Hou et al., 2022</xref>). Enhancer marks in human arterial-origin ECs are all shaded green, including very dark green ‘HAEC ATAC-seq’ denoting open chromatin assessed by ATAC-seq in human aortic ECs from <xref ref-type="bibr" rid="bib35">Hogan et al., 2017</xref>; dark green ‘telo-HAEC ATAC-seq’ denoting open chromatin assessed by ATAC-seq in immortalized human aortic ECs from <xref ref-type="bibr" rid="bib77">Schnitzler et al., 2024</xref>; green ‘HAEC H3K27Ac’ denoting enriched H3K27Ac enhancer marks in human aortic ECs from <xref ref-type="bibr" rid="bib35">Hogan et al., 2017</xref>; bright green ‘HUAEC H3K27Ac’ denoting enriched H3K27Ac enhancer marks in human umbilical aortic ECs from <xref ref-type="bibr" rid="bib82">Sissaoui et al., 2020</xref>; and lime green ‘HUAEC p300’ denoting enriched p300 binding peaks in human umbilical aortic ECs from <xref ref-type="bibr" rid="bib82">Sissaoui et al., 2020</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102440-fig1-figsupp4-v2.tif"/></fig></fig-group><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Enhancer marks around 32 known in vivo-characterized endothelial enhancers (all described in <xref ref-type="bibr" rid="bib63">Payne et al., 2024</xref>).</title><p>Red text indicates arterial enhancers.</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Enhancer</th><th align="left" valign="bottom">hg19 coordinates</th><th align="left" valign="bottom">H DNAseI</th><th align="left" valign="bottom">H histone</th><th align="left" valign="bottom">Mm9 coordinates</th><th align="left" valign="bottom">M artery ATAC</th><th align="left" valign="bottom">M retina ATAC</th><th align="left" valign="bottom">M E11 p300</th></tr></thead><tbody><tr><td align="left" valign="bottom"><italic>Apln+28</italic></td><td align="left" valign="bottom">chrX:128,756,756–128,757,160</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">chrX:45,359,306–45,359,632</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom"><italic>Dab2-240</italic></td><td align="left" valign="bottom">chr5:39,755,997–39,756,596</td><td align="left" valign="bottom">Yes<xref ref-type="table-fn" rid="table1fn1">*</xref></td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">chr15:6,009,719–6,010,138</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom"><styled-content style="color: #D50000;"><italic>Dll4in3</italic></styled-content></td><td align="left" valign="bottom">chr15:41,222,881–41,223,570</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">chr2:119,152,838–119,153,684</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom"><styled-content style="color: #D50000;"><italic>Dll4-12</italic></styled-content></td><td align="left" valign="bottom">chr15:41,210,706–41,211,825</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">chr2:119,140,274–119,141,353</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom"><styled-content style="color: #D50000;"><italic>Ece1in1</italic></styled-content></td><td align="left" valign="bottom">chr1:21,606,038–21,607,057</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">chr4:137,475,719–137,476,738</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom"><italic>Egfl7-9</italic></td><td align="left" valign="bottom">chr9:139,540,750–139,541,299</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">chr2:26,427,513–26,427,707</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom"><italic>Egfl7-2</italic></td><td align="left" valign="bottom">chr9:139,550,292–139,550,891</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">chr2:26,434,087–26,434,301</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom"><italic>Emcn-22</italic></td><td align="left" valign="bottom">chr4:101,460,885–101,461,224</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">chr3:136,984,547–136,984,951</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td></tr><tr><td align="left" valign="bottom"><italic>Eng-8</italic></td><td align="left" valign="bottom">chr9:130,624,538–130,624,804</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">chr2:32,493,606–32,493,823</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom"><italic>Eng +9</italic></td><td align="left" valign="bottom">chr9:130,607,199–130,607,657</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">chr2:32,511,282–32,511,641</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom"><italic>Ephb4-2</italic></td><td align="left" valign="bottom">chr7:100,426,337–100,427,259</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">chr5:137,789,910–137,790,581</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom"><italic>Fli1+12</italic></td><td align="left" valign="bottom">chr11:128,575,436–128,575,782</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">chr9:32,337,295–32,337,538</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom"><italic>Flk1+3</italic></td><td align="left" valign="bottom">chr4:55,987,345–55,987,920</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">chr5:76,370,627–76,371,056</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom"><styled-content style="color: #D50000;"><italic>Flk1in10</italic></styled-content></td><td align="left" valign="bottom">chr4:55,972,978–55,973,903</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">chr5:76,357,891–76,358,715</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom"><italic>Flt4+26</italic></td><td align="left" valign="bottom">chr5:180,050,291–180,050,684</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">chr11:49,445,777–49,446,175</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom"><italic>Foxp1+138</italic></td><td align="left" valign="bottom">chr3:71,493,515–71,493,886</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">chr6:99,338,958–99,339,515</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom"><italic>Gata2+9</italic></td><td align="left" valign="bottom">chr3:128,201,971–128,202,273</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">chr6:88,153,077–88,153,386</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom"><styled-content style="color: #D50000;"><italic>Hey1-18</italic></styled-content></td><td align="left" valign="bottom">chr8:80,695,610–80,697,109</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">chr3:8,685,099–8,685,821</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom"><italic>Hlx-3</italic></td><td align="left" valign="bottom">chr1:221,049,978–221,050,354</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">chr1:186,558,918–186,559,303</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom"><italic>Mef2F10</italic></td><td align="left" valign="bottom">chr5:88,110,980–88,111,253</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">chr13:83,721,761–83,722,057</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom"><italic>Mef2F7</italic></td><td align="left" valign="bottom">chr5:88,123,031–88,123,357</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">chr13:83,711,180–83,711,509</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom"><styled-content style="color: #D50000;"><italic>Notch1+16</italic></styled-content></td><td align="left" valign="bottom">chr9:139,424,543–139,424,953</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">chr2:26,346,100–26,346,671</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom"><italic>Notch1+33</italic></td><td align="left" valign="bottom">chr9:139,406,356–139,406,655</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">chr2:26,330,559–26,330,785</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom"><italic>CoupTFII-965</italic></td><td align="left" valign="bottom">chr15:95,908,708–95,909,240</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">chr7:78,456,407–78,456,767</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom"><italic>Nrp1+28</italic></td><td align="left" valign="bottom">chr10:33,590,960–33,591,499</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">chr8:130,911,132–130,911,551</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom"><italic>Nrp2+26</italic></td><td align="left" valign="bottom">chr2:206,573,202–206,573,523</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">chr1:62,776,231–62,776,553</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom"><italic>Pdgfrb +18</italic></td><td align="left" valign="bottom">chr5:149,516,883–149,517,356</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">chr18:61,219,244–61,219,566</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">No</td></tr><tr><td align="left" valign="bottom"><italic>Epcr-5</italic></td><td align="left" valign="bottom">chr20:33,754,176–33,754,585</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">chr2:155,568,588–155,569,127</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom"><styled-content style="color: #D50000;"><italic>Sema6d-55</italic></styled-content></td><td align="left" valign="bottom">chr15:47,958,023–47,958,764</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">chr2:124,380,522–124,381,285</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom"><styled-content style="color: #D50000;"><italic>Sox7+14</italic></styled-content></td><td align="left" valign="bottom">chr8:10,573,085–10,574,291</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">chr14:64,576,271–64,577,533</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom"><italic>Tal +19</italic></td><td align="left" valign="bottom">chr1:47,677,539–47,677,958</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">chr4:114,748,131–114,748,530</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td></tr><tr><td align="left" valign="bottom"><italic>Tal1-4</italic></td><td align="left" valign="bottom">chr1:47,701,050–47,701,347</td><td align="left" valign="bottom">No</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">chr4:114,725,243–114,725,552</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td><td align="left" valign="bottom">Yes</td></tr></tbody></table><table-wrap-foot><fn id="table1fn1"><label>*</label><p> “H DNAseI” indicates open chromatin regions as defined by DNAseI hypersensitivity in HUVECs, HMVEC-dBl-neo and HMVEC-dBl-ad comparative to non-ECs and relative to surrounding region (UCSC genome browser<sup>38</sup>); “H histone” indicates relatively enriched binding of H3K27Ac and/or H3K4Me1 in HUVECs (UCSC genome browser<sup>38</sup>), * indicates this extends to many non-EC lines as well; “M artery ATAC” indicates regions of relatively open chromatin assessed by ATAC-seq in primary mouse adult aortic ECs (MAECs) (Engelbrecht et al<sup>35</sup>); “M retina ATAC” indicates regions of relatively open chromatin assessed by ATAC-seq in mouse postnatal day 6 (P6) retina ECs (MRECs) (Yanagida et al<sup>36</sup>); “M E11 p300” indicates regions relatively enriched for EP300 binding in Tie2Cre+ve cells from embryonic day (E)11.5 mouse embryos (Zhou et al<sup>37</sup>). * indicates that enhancer marks were not specific for ECs but rather found in many cell types.‘M artery ATAC’ indicates regions of relatively open chromatin assessed by ATAC-seq in primary mouse adult aortic ECs (MAECs) <xref ref-type="bibr" rid="bib23">Engelbrecht et al., 2020</xref>; ‘M retina ATAC’ indicates regions of relatively open chromatin assessed by ATAC-seq in mouse postnatal day 6 (P6) retina ECs (MRECs) <xref ref-type="bibr" rid="bib94">Yanagida et al., 2020</xref>; ‘M E11 p300’ indicates regions relatively enriched for EP300 binding in Tie2Cre+ve cells from embryonic day (E) 11.5 mouse embryos (<xref ref-type="bibr" rid="bib96">Zhou et al., 2017</xref>). *indicates that enhancer marks were not specific for ECs but rather found in many cell types.</p></fn></table-wrap-foot></table-wrap><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Summary of putative enhancer activity in mosaic Tol2 transgenic zebrafish.</title><p>‘In vivo classification’ indicates the results of this screen, ‘in silico classification’ indicates designation from dataset from <xref ref-type="bibr" rid="bib82">Sissaoui et al., 2020</xref>, as defined by relative enhancer and promoter marks in HUVECs vs. HUAECs.</p><p><supplementary-material id="table2sdata1"><label>Table 2—source data 1.</label><caption><title>Enhancer marks in different human and mouse ECs at putative enhancer regions within the loci of eight arterial genes.</title><p>‘Selected’ indicates that the region meets our threshold as a putative enhancer, ‘exception’ indicates region did not meet our threshold but was included in transgenic analysis as a control (grey text). Numbers indicate approximate distance from the TSS of the named arterial gene. * indicates that enhancer mark was widely seen beyond endothelial cells. Grey italic text refers to regions previously implicated in enhancer activity, with the /enhancer name ascribed in the original reference. Cxcr4-117/CXCR4-125 is from <xref ref-type="bibr" rid="bib86">Tsaryk et al., 2022</xref> ; Cxcr4-1, Nrp1- 1/NRP1A and Nrp1+76/NRP1B are from <xref ref-type="bibr" rid="bib93">Yamamizu et al., 2010</xref> ; Efnb2+17/EFNB2A and Efnb2+25/EFNB2B are from <xref ref-type="bibr" rid="bib30">Grego-Bessa et al., 2007</xref>; and Efnb2+4/EFNB2R1 and Efnb2+28/EFNB2R4 are from <xref ref-type="bibr" rid="bib83">Stewen et al., 2024</xref>.</p></caption><media mimetype="application" mime-subtype="docx" xlink:href="elife-102440-table2-data1-v2.docx"/></supplementary-material><supplementary-material id="table2sdata2"><label>Table 2—source data 2.</label><caption><title>Genome locations for all enhancer (and human orthologues) investigated in this paper.</title><p>Values given for mm10 represent the core enhancer regions analysed for motif sequences and protein binding.</p></caption><media mimetype="application" mime-subtype="docx" xlink:href="elife-102440-table2-data2-v2.docx"/></supplementary-material></p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Enhancer</th><th align="left" valign="bottom"># Injected/# any EC GFP</th><th align="left" valign="bottom">In vivo classification</th><th align="left" valign="bottom">In silico classification</th></tr></thead><tbody><tr><td align="left" valign="bottom"><italic>Cxcr4-232</italic></td><td align="char" char="." valign="bottom">163/0</td><td align="left" valign="bottom">Inactive</td><td align="left" valign="bottom"><italic>Uncalled</italic></td></tr><tr><td align="left" valign="bottom"><bold><italic>Cxcr4-194</italic></bold></td><td align="char" char="." valign="bottom">46/25</td><td align="left" valign="bottom"><styled-content style="color: #D50000;">Arterial enhancer</styled-content></td><td align="left" valign="bottom"><italic>Uncalled</italic></td></tr><tr><td align="left" valign="bottom"><italic>Cxcr4-130</italic></td><td align="char" char="." valign="bottom">95/0</td><td align="left" valign="bottom">Inactive</td><td align="left" valign="bottom"><italic>Uncalled</italic></td></tr><tr><td align="left" valign="bottom"><italic>Cxcr4-117^</italic></td><td align="char" char="." valign="bottom">209/9<xref ref-type="table-fn" rid="table2fn1">*</xref></td><td align="left" valign="bottom">Inactive</td><td align="left" valign="bottom"><italic>Uncalled</italic></td></tr><tr><td align="left" valign="bottom"><italic>hCxcr4-117^/CXCR4-125</italic></td><td align="char" char="." valign="bottom">81/0</td><td align="left" valign="bottom">Inactive</td><td align="left" valign="bottom"><italic>Uncalled</italic></td></tr><tr><td align="left" valign="bottom"><italic>Cxcr4-113</italic></td><td align="char" char="." valign="bottom">300/0</td><td align="left" valign="bottom">Inactive</td><td align="left" valign="bottom"><styled-content style="color: #9C27B0;"><italic>Common EC enhancer</italic></styled-content></td></tr><tr><td align="left" valign="bottom"><italic>Cxcr4-109</italic></td><td align="char" char="." valign="bottom">89/0</td><td align="left" valign="bottom">Inactive</td><td align="left" valign="bottom"><styled-content style="color: #9C27B0;"><italic>Common EC enhancer</italic></styled-content></td></tr><tr><td align="left" valign="bottom"><italic>Cxcr4+1</italic></td><td align="char" char="." valign="bottom">33/0</td><td align="left" valign="bottom">Inactive</td><td align="left" valign="bottom"><italic>Uncalled</italic></td></tr><tr><td align="left" valign="bottom"><italic>Cxcr4+119</italic></td><td align="char" char="." valign="bottom">187/0</td><td align="left" valign="bottom">Inactive</td><td align="left" valign="bottom"><styled-content style="color: #D50000;"><italic>Arterial enhancer</italic></styled-content></td></tr><tr><td align="left" valign="bottom"><bold><italic>Cxcr4+135</italic></bold></td><td align="char" char="." valign="bottom">69/56</td><td align="left" valign="bottom"><styled-content style="color: #D50000;">Arterial enhancer</styled-content></td><td align="left" valign="bottom"><italic>Uncalled</italic></td></tr><tr><td align="left" valign="bottom"><bold><italic>Cxcr4+151</italic></bold></td><td align="char" char="." valign="bottom">96/50</td><td align="left" valign="bottom"><styled-content style="color: #D50000;">Arterial enhancer</styled-content></td><td align="left" valign="bottom"><italic>Arterial TSS</italic></td></tr><tr><td align="left" valign="bottom"><bold><italic>Efnb2-333</italic></bold></td><td align="char" char="." valign="bottom">152/93</td><td align="left" valign="bottom"><styled-content style="color: #D50000;">Arterial enhancer</styled-content></td><td align="left" valign="bottom"><styled-content style="color: #9C27B0;"><italic>Common EC enhancer</italic></styled-content></td></tr><tr><td align="left" valign="bottom"><bold><italic>Efnb2-159</italic></bold></td><td align="char" char="." valign="bottom">247/217</td><td align="left" valign="bottom"><styled-content style="color: #D50000;">Arterial enhancer</styled-content></td><td align="left" valign="bottom"><styled-content style="color: #9C27B0;"><italic>Common EC enhancer</italic></styled-content></td></tr><tr><td align="left" valign="bottom"><bold><italic>Efnb2-141</italic></bold></td><td align="char" char="." valign="bottom">74/36</td><td align="left" valign="bottom"><styled-content style="color: #D50000;">Arterial enhancer</styled-content></td><td align="left" valign="bottom"><italic>Arterial TSS</italic></td></tr><tr><td align="left" valign="bottom"><bold><italic>Efnb2-112</italic></bold></td><td align="char" char="." valign="bottom">65/30</td><td align="left" valign="bottom"><styled-content style="color: #D50000;">Arterial enhancer</styled-content></td><td align="left" valign="bottom"><italic>Arterial TSS</italic></td></tr><tr><td align="left" valign="bottom"><italic>Efnb2+3</italic></td><td align="char" char="." valign="bottom">92/0</td><td align="left" valign="bottom">Inactive</td><td align="left" valign="bottom"><italic>Common EC TSS</italic></td></tr><tr><td align="left" valign="bottom"><italic><bold>Efnb2+37</bold></italic></td><td align="char" char="." valign="bottom">114/18<xref ref-type="table-fn" rid="table2fn1">*</xref></td><td align="left" valign="bottom"><bold>Weak enhancer</bold><xref ref-type="table-fn" rid="table2fn1">*</xref></td><td align="left" valign="bottom"><styled-content style="color: #9C27B0;"><italic>Common EC enhancer</italic></styled-content></td></tr><tr><td align="left" valign="bottom"><italic>Efnb2+172</italic></td><td align="char" char="." valign="bottom">63/0</td><td align="left" valign="bottom">Inactive</td><td align="left" valign="bottom"><styled-content style="color: #9C27B0;"><italic>Common EC enhancer</italic></styled-content></td></tr><tr><td align="left" valign="bottom"><italic>Efnb2+209</italic></td><td align="char" char="." valign="bottom">158/0</td><td align="left" valign="bottom">Inactive</td><td align="left" valign="bottom"><styled-content style="color: #9C27B0;"><italic>Common EC enhancer</italic></styled-content></td></tr><tr><td align="left" valign="bottom"><italic>Gja4+24</italic></td><td align="char" char="." valign="bottom">52/0</td><td align="left" valign="bottom">Inactive</td><td align="left" valign="bottom"><italic>Uncalled</italic></td></tr><tr><td align="left" valign="bottom"><bold><italic>Gja4+50</italic></bold></td><td align="char" char="." valign="bottom">232/187</td><td align="left" valign="bottom"><styled-content style="color: #D50000;">Arterial enhancer</styled-content></td><td align="left" valign="bottom"><styled-content style="color: #9C27B0;"><italic>Common EC enhancer</italic></styled-content></td></tr><tr><td align="left" valign="bottom"><italic>Gja4+57</italic></td><td align="char" char="." valign="bottom">192/0</td><td align="left" valign="bottom">Inactive</td><td align="left" valign="bottom"><italic>Uncalled</italic></td></tr><tr><td align="left" valign="bottom"><bold><italic>Unc5b-57</italic></bold></td><td align="char" char="." valign="bottom">50/21</td><td align="left" valign="bottom"><styled-content style="color: #366BFB;">Venous enhancer</styled-content></td><td align="left" valign="bottom"><italic>Uncalled</italic></td></tr><tr><td align="left" valign="bottom"><italic>Unc5b+14</italic></td><td align="char" char="." valign="bottom">61/0</td><td align="left" valign="bottom">Inactive</td><td align="left" valign="bottom"><italic>Uncalled</italic></td></tr><tr><td align="left" valign="bottom"><italic><bold>Unc5b+23</bold></italic></td><td align="char" char="." valign="bottom">82/16<xref ref-type="table-fn" rid="table2fn1">*</xref></td><td align="left" valign="bottom"><bold>Weak enhancer</bold><xref ref-type="table-fn" rid="table2fn1">*</xref></td><td align="left" valign="bottom"><styled-content style="color: #D50000;"><italic>Arterial enhancer</italic></styled-content></td></tr><tr><td align="left" valign="bottom"><bold><italic>Unc5b+30</italic></bold></td><td align="char" char="." valign="bottom">96/79</td><td align="left" valign="bottom"><styled-content style="color: #D50000;">Arterial enhancer</styled-content></td><td align="left" valign="bottom"><styled-content style="color: #D50000;"><italic>Arterial enhancer</italic></styled-content></td></tr><tr><td align="left" valign="bottom"><bold><italic>Unc5b+39</italic></bold></td><td align="char" char="." valign="bottom">96/56</td><td align="left" valign="bottom"><styled-content style="color: #D50000;">Arterial enhancer</styled-content></td><td align="left" valign="bottom"><styled-content style="color: #D50000;"><italic>Arterial enhancer</italic></styled-content></td></tr><tr><td align="left" valign="bottom"><italic>Unc5b+43</italic></td><td align="char" char="." valign="bottom">111/0</td><td align="left" valign="bottom">Inactive</td><td align="left" valign="bottom"><styled-content style="color: #D50000;"><italic>Arterial enhancer</italic></styled-content></td></tr><tr><td align="left" valign="bottom"><italic>Acvrl1-5</italic></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib79">Seki et al., 2004</xref></td><td align="left" valign="bottom">Inactive</td><td align="left" valign="bottom"><styled-content style="color: #9C27B0;"><italic>Common EC enhancer</italic></styled-content></td></tr><tr><td align="left" valign="bottom"><italic>Acvrl1-1/p</italic></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib79">Seki et al., 2004</xref></td><td align="left" valign="bottom">Inactive</td><td align="left" valign="bottom"><italic>Common EC TSS</italic></td></tr><tr><td align="left" valign="bottom"><bold><italic>Acvrl1+6</italic></bold></td><td align="char" char="." valign="bottom">127/49</td><td align="left" valign="bottom"><styled-content style="color: #D50000;">Arterial enhancer</styled-content></td><td align="left" valign="bottom"><italic>Common EC TSS</italic></td></tr><tr><td align="left" valign="bottom"><italic>Acvrl1+16</italic></td><td align="char" char="." valign="bottom">205/0</td><td align="left" valign="bottom">Inactive</td><td align="left" valign="bottom"><italic>Common EC TSS</italic></td></tr><tr><td align="left" valign="bottom"><italic>Acvrl1+19</italic></td><td align="char" char="." valign="bottom">95/0</td><td align="left" valign="bottom">Inactive</td><td align="left" valign="bottom"><italic>Common EC TSS</italic></td></tr><tr><td align="left" valign="bottom"><italic>Cxcl12-184</italic></td><td align="char" char="." valign="bottom">64/0</td><td align="left" valign="bottom">Inactive</td><td align="left" valign="bottom"><styled-content style="color: #9C27B0;"><italic>Common EC enhancer</italic></styled-content></td></tr><tr><td align="left" valign="bottom"><italic>Cxcl12-2</italic></td><td align="char" char="." valign="bottom">32/0</td><td align="left" valign="bottom">Inactive</td><td align="left" valign="bottom"><styled-content style="color: #9C27B0;"><italic>Common EC enhancer</italic></styled-content></td></tr><tr><td align="left" valign="bottom"><italic>Cxcl12+239</italic></td><td align="char" char="." valign="bottom">70/1</td><td align="left" valign="bottom">Inactive</td><td align="left" valign="bottom"><italic>Uncalled</italic></td></tr><tr><td align="left" valign="bottom"><italic>Cxcl12+265</italic></td><td align="char" char="." valign="bottom">42/1</td><td align="left" valign="bottom">Inactive</td><td align="left" valign="bottom"><italic>Uncalled</italic></td></tr><tr><td align="left" valign="bottom"><bold><italic>Cxcl12+269</italic></bold></td><td align="char" char="." valign="bottom">163/63</td><td align="left" valign="bottom"><styled-content style="color: #D50000;">Arterial enhancer</styled-content></td><td align="left" valign="bottom"><italic>Uncalled</italic></td></tr><tr><td align="left" valign="bottom"><italic>Cxcl12+298</italic></td><td align="char" char="." valign="bottom">51/0</td><td align="left" valign="bottom">Inactive</td><td align="left" valign="bottom"><styled-content style="color: #9C27B0;"><italic>Common EC enhancer</italic></styled-content></td></tr><tr><td align="left" valign="bottom"><italic>Cxcl12+376</italic></td><td align="char" char="." valign="bottom">149/0</td><td align="left" valign="bottom">Inactive</td><td align="left" valign="bottom"><italic>Uncalled</italic></td></tr><tr><td align="left" valign="bottom"><italic><bold>Cxcl12+383</bold></italic></td><td align="char" char="." valign="bottom">152/37<xref ref-type="table-fn" rid="table2fn1">*</xref></td><td align="left" valign="bottom"><bold>Weak enhancer</bold><xref ref-type="table-fn" rid="table2fn1">*</xref></td><td align="left" valign="bottom"><italic>Uncalled</italic></td></tr><tr><td align="left" valign="bottom"><italic>Cxcl12+439</italic></td><td align="char" char="." valign="bottom">73/0</td><td align="left" valign="bottom">Inactive</td><td align="left" valign="bottom"><styled-content style="color: #9C27B0;"><italic>Common EC enhancer</italic></styled-content></td></tr><tr><td align="left" valign="bottom"><italic>Cxcl12+445</italic></td><td align="char" char="." valign="bottom">145/0</td><td align="left" valign="bottom">Inactive</td><td align="left" valign="bottom"><italic>Common EC TSS</italic></td></tr><tr><td align="left" valign="bottom"><bold><italic>Gja5-7</italic></bold></td><td align="char" char="." valign="bottom">66/39</td><td align="left" valign="bottom"><styled-content style="color: #D50000;">Arterial enhancer</styled-content></td><td align="left" valign="bottom"><styled-content style="color: #D50000;"><italic>Arterial enhancer</italic></styled-content></td></tr><tr><td align="left" valign="bottom"><italic>Gja5-21</italic><xref ref-type="table-fn" rid="table2fn2"><sup>†</sup></xref></td><td align="char" char="." valign="bottom">38/0</td><td align="left" valign="bottom">Inactive</td><td align="left" valign="bottom"><styled-content style="color: #9C27B0;"><italic>Common EC enhancer</italic></styled-content></td></tr><tr><td align="left" valign="bottom"><italic>Gja5-28</italic></td><td align="char" char="." valign="bottom">156/0</td><td align="left" valign="bottom">Inactive</td><td align="left" valign="bottom"><italic>Uncalled</italic></td></tr><tr><td align="left" valign="bottom"><bold><italic>Gja5-78</italic></bold></td><td align="char" char="." valign="bottom">76/62</td><td align="left" valign="bottom"><styled-content style="color: #D50000;">Arterial enhancer</styled-content></td><td align="left" valign="bottom"><styled-content style="color: #9C27B0;"><italic>Common EC enhancer</italic></styled-content></td></tr><tr><td align="left" valign="bottom"><italic>Gja5-93</italic></td><td align="char" char="." valign="bottom">253/0</td><td align="left" valign="bottom">Inactive</td><td align="left" valign="bottom"><styled-content style="color: #D50000;"><italic>Arterial enhancer</italic></styled-content></td></tr><tr><td align="left" valign="bottom"><italic><bold>Nrp1+28</bold></italic></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib22">De Val et al., 2008</xref></td><td align="left" valign="bottom"><styled-content style="color: #9C27B0;">Pan-EC enhancer</styled-content></td><td align="left" valign="bottom"><styled-content style="color: #9C27B0;"><italic>Common EC enhancer</italic></styled-content></td></tr><tr><td align="left" valign="bottom"><italic>Nrp1+76</italic></td><td align="char" char="." valign="bottom">54/0</td><td align="left" valign="bottom"><bold>Inactive</bold></td><td align="left" valign="bottom"><styled-content style="color: #9C27B0;"><italic>Common EC enhancer</italic></styled-content></td></tr><tr><td align="left" valign="bottom"><bold><italic>Nrp1+78</italic></bold></td><td align="char" char="." valign="bottom">191/34</td><td align="left" valign="bottom"><styled-content style="color: #D50000;">Arterial enhancer</styled-content></td><td align="left" valign="bottom"><styled-content style="color: #9C27B0;"><italic>Common EC enhancer</italic></styled-content></td></tr><tr><td align="left" valign="bottom"><italic>Nrp1+91</italic></td><td align="char" char="." valign="bottom">109/0</td><td align="left" valign="bottom">Inactive</td><td align="left" valign="bottom"><styled-content style="color: #9C27B0;"><italic>Common EC enhancer</italic></styled-content></td></tr><tr><td align="left" valign="bottom"><italic>Nrp1+129</italic></td><td align="char" char="." valign="bottom">110/0</td><td align="left" valign="bottom">Inactive</td><td align="left" valign="bottom"><styled-content style="color: #9C27B0;"><italic>Common EC enhancer</italic></styled-content></td></tr><tr><td align="left" valign="bottom"><bold><italic>DLL4-12</italic></bold></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib74">Sacilotto et al., 2013</xref></td><td align="left" valign="bottom"><styled-content style="color: #D50000;">Arterial enhancer</styled-content></td><td align="left" valign="bottom"><styled-content style="color: #9C27B0;"><italic>Common EC enhancer</italic></styled-content></td></tr><tr><td align="left" valign="bottom"><bold><italic>DLL4in3</italic></bold></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib74">Sacilotto et al., 2013</xref></td><td align="left" valign="bottom"><styled-content style="color: #D50000;">Arterial enhancer</styled-content></td><td align="left" valign="bottom"><styled-content style="color: #9C27B0;"><italic>Common EC enhancer</italic></styled-content></td></tr><tr><td align="left" valign="bottom"><bold><italic>ECE1in1</italic></bold></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib71">Robinson et al., 2014</xref></td><td align="left" valign="bottom"><styled-content style="color: #D50000;">Arterial enhancer</styled-content></td><td align="left" valign="bottom"><styled-content style="color: #9C27B0;"><italic>Common EC enhancer</italic></styled-content></td></tr><tr><td align="left" valign="bottom"><bold><italic>Flk1in10</italic></bold></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib6">Becker et al., 2016</xref></td><td align="left" valign="bottom"><styled-content style="color: #D50000;">Arterial enhancer</styled-content></td><td align="left" valign="bottom"><italic>Uncalled</italic></td></tr><tr><td align="left" valign="bottom"><bold><italic>Hey1-18</italic></bold></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib88">Watanabe et al., 2020</xref></td><td align="left" valign="bottom"><styled-content style="color: #D50000;">Arterial enhancer</styled-content></td><td align="left" valign="bottom"><styled-content style="color: #9C27B0;"><italic>Common EC enhancer</italic></styled-content></td></tr><tr><td align="left" valign="bottom"><bold><italic>NOTCH1+16</italic></bold></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib15">Chiang et al., 2017</xref></td><td align="left" valign="bottom"><styled-content style="color: #D50000;">Arterial enhancer</styled-content></td><td align="left" valign="bottom"><styled-content style="color: #9C27B0;"><italic>Common EC enhancer</italic></styled-content></td></tr><tr><td align="left" valign="bottom"><bold><italic>Sema6d-55</italic></bold></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib96">Zhou et al., 2017</xref></td><td align="left" valign="bottom"><styled-content style="color: #D50000;">Arterial enhancer</styled-content></td><td align="left" valign="bottom"><styled-content style="color: #9C27B0;"><italic>Common EC enhancer</italic></styled-content></td></tr><tr><td align="left" valign="bottom"><bold><italic>SOX7+14</italic></bold></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib96">Zhou et al., 2017</xref></td><td align="left" valign="bottom"><styled-content style="color: #D50000;">Arterial enhancer</styled-content></td><td align="left" valign="bottom"><styled-content style="color: #9C27B0;"><italic>Common EC enhancer</italic></styled-content></td></tr></tbody></table><table-wrap-foot><fn id="table2fn1"><label>*</label><p>indicates only limited expression in a very small number of ECs. <italic>Acvrl1-5</italic> and <italic>Acvrl1-1/p</italic> were previously investigated by <xref ref-type="bibr" rid="bib78">Seki et al., 2003</xref>, <italic>Nrp1+28</italic> by <xref ref-type="bibr" rid="bib22">De Val et al., 2008</xref>, <italic>Notch1+16</italic> by <xref ref-type="bibr" rid="bib15">Chiang et al., 2017</xref>, <italic>Dll4-12</italic> and <italic>Dll4in3</italic> by <xref ref-type="bibr" rid="bib74">Sacilotto et al., 2013</xref>, <italic>Flk1in10</italic> by <xref ref-type="bibr" rid="bib6">Becker et al., 2016</xref>, <italic>Sema6d-55</italic> by <xref ref-type="bibr" rid="bib96">Zhou et al., 2017</xref>, <italic>Sox7+14</italic> by <xref ref-type="bibr" rid="bib96">Zhou et al., 2017</xref>; <xref ref-type="bibr" rid="bib3">Andersson et al., 2014</xref>, <italic>Ece1in10</italic> by <xref ref-type="bibr" rid="bib71">Robinson et al., 2014</xref>, and <italic>Hey1-18</italic> by <xref ref-type="bibr" rid="bib88">Watanabe et al., 2020</xref>.</p></fn><fn id="table2fn2"><label>†</label><p>After this analysis but prior to this publication, <italic>Gja5-21</italic> was shown to direct expression in the zebrafish endocardium at 4 dpf (<xref ref-type="bibr" rid="bib16">Chiang et al., 2023</xref>).</p></fn></table-wrap-foot></table-wrap><p>Out of the 41 putative enhancers identified here, 3 had been previously investigated in vivo: <italic>Nrp1</italic>+<italic>28</italic>, which was able to drive robust pan-endothelial expression of the <italic>lacZ</italic> reporter gene in transgenic mouse embryos (<xref ref-type="bibr" rid="bib22">De Val et al., 2008</xref>); and <italic>Acvrl-5</italic> and <italic>Acvrl1-1/p</italic>, which were silent in a similar mouse assay (<xref ref-type="bibr" rid="bib79">Seki et al., 2004</xref>; <xref ref-type="table" rid="table2">Table 2</xref>). Additionally, <italic>Acvrl1+6</italic> is contained within a nine kilobase region known to direct arterial-specific expression of <italic>lacZ</italic> in transgenic mice (<xref ref-type="bibr" rid="bib79">Seki et al., 2004</xref>). However, because of the size of this original piece, we treated the smaller <italic>Acvrl1+6</italic> enhancer as untested.</p></sec><sec id="s2-2"><title>Transgenesis in zebrafish confirms arterial activity for a subset of putative enhancers</title><p>It is well established that DNA sequences associated with enhancer marks do not necessarily act as enhancers (e.g. by independently activating gene transcription). To establish the ability of the 38 untested putative enhancers to drive arterial EC activity, we first analysed the activity of each in F0 Tol2-mediated mosaic transgenic zebrafish embryos (<xref ref-type="bibr" rid="bib40">Kawakami, 2005</xref>). Similar zebrafish assays have been conducted with five of the eight previously identified arterial enhancers, and in each case these mammalian enhancer sequences were able to drive GFP expression in arterial ECs in zebrafish embryos (<xref ref-type="fig" rid="fig1">Figure 1</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>; <xref ref-type="bibr" rid="bib74">Sacilotto et al., 2013</xref>; <xref ref-type="bibr" rid="bib15">Chiang et al., 2017</xref>; <xref ref-type="bibr" rid="bib6">Becker et al., 2016</xref>; <xref ref-type="bibr" rid="bib3">Andersson et al., 2014</xref>). Here, the mouse sequence of each of the 38 putative arterial enhancers was cloned upstream of the E1b minimal promoter and GFP reporter gene and used to generate mosaic transgenic embryos, which were examined at 2 days post fertilization (dpf) (<xref ref-type="bibr" rid="bib40">Kawakami, 2005</xref>). This analysis identified 19 enhancers able to drive GFP expression in ECs of transgenic zebrafish, defined as vascular GFP expression in more than 5% of injected embryos (<xref ref-type="table" rid="table2">Table 2</xref>). Sixteen of these active enhancers were able to drive robust and reproducible patterns of endothelial GFP expression in F0 mosaic transgenics (<xref ref-type="fig" rid="fig1s2">Figure 1—figure supplement 2</xref>) from which we were able to establish stable transgenic zebrafish lines. Of these, 15/16 enhancer:GFP transgenes were clearly expressed in arteries and were therefore selected for further analysis (<xref ref-type="fig" rid="fig2">Figure 2</xref> and <xref ref-type="fig" rid="fig3">Figure 3</xref>, genome coordinates <xref ref-type="supplementary-material" rid="table2sdata2">Table 2—source data 2</xref>). This included at least one enhancer for each of our eight target genes. The outlier, <italic>Unc5b-57</italic>, was active only in the anterior portion of the caudal vein and was excluded from further analysis (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3A–B</xref>). The remaining three enhancers were able to drive only weak GFP and/or were limited to a small number of ECs in all analysed zebrafish (<xref ref-type="table" rid="table2">Table 2</xref>, <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3C</xref>). GFP expression pattern within the vasculature could not be determined and no stable lines could be established; therefore, these weak vascular enhancers were not followed up further. Another 19 putative enhancer regions did not consistently drive detectable GFP expression in ECs (<xref ref-type="table" rid="table2">Table 2</xref>). These were designated inactive regions without developmental enhancer activity.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>Analysis in 2 dpf transgenic zebrafish indicates arterial activity of fifteen novel enhancer:GFP transgenes.</title><p>Grey dashed box indicates region of zoom, da indicates dorsal aorta, cv indicates cardinal vein, dlav indicates dorsal longitudinal anastomotic vessel, white arrow indicates intersegmental vessels, and * indicates expression in neural tube. <italic>tg(Cxcr4-135:GFP</italic>) was crossed with <italic>tg(kdrl:HRAS-mCherry),</italic> which expresses mCherry in all blood vascular ECs and is shown here on the top line as a guide to vessel structure at this timepoint. F1/2 indicates generation of embryo.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102440-fig2-v2.tif"/></fig><fig-group><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Analysis in 3 dpf transgenic zebrafish indicates specificity of arterial expression of each arterial enhancer.</title><p>Stable transgenic zebrafish expressing the 15 strong arterial enhancer:GFP transgenes crossed with <italic>tg(kdrl:HRAS-mCherry),</italic> which expresses mCherry in all blood vascular ECs. Grey dashed box indicates region of zoom, da indicates dorsal aorta, cv indicates cardinal vein, dlav indicates dorsal longitudinal anastomotic vessel, pale pink filled arrows indicates intersegmental arteries, pale blue open arrows indicate intersegmental veins, * indicates expression in neural tube, and F1/2 indicates generation of embryo.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102440-fig3-v2.tif"/></fig><fig id="fig3s1" position="float" specific-use="child-fig"><label>Figure 3—figure supplement 1.</label><caption><title>Analysis of enhancer activity in the 2–3 dpf ocular vasculature.</title><p>(<bold>A</bold>) Schematic diagram of the primary ocular vasculature adapted from <xref ref-type="bibr" rid="bib33">Hashiura et al., 2017</xref>. (<bold>B</bold>) Expression pattern of 15 novel arterial enhancers in the ocular vasculature at 2 dpf and 3 dpf. At 3 dpf, <italic>kdrl:HRAS-mCherry</italic> transgene was crossed with arterial zebrafish lines to enable visualization of all ECs.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102440-fig3-figsupp1-v2.tif"/></fig></fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>Summary of enhancer:GFP expression pattern in the vasculature of stable transgenic zebrafish lines.</title><p>DA dorsal aorta, ISA intersegmental arteries, DLAV dorsal longitudinal anastomotic vessel, CV cardinal vein, ISV intersegmental veins, NT neural tube, NCA nasal ciliary artery, NCAx extends beyond NCA in direction of blood flow, HA hyaloid artery, DCV dorsal ciliary vein, OV optic vein. A fin artery, V fin vein. Letters “s” “m” and “w” equate to strong medium or weak relative expression, *restricted to distal regions, ** restricted to anterior regions, *** restricted to subset of ECs.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Summary of enhancer:GFP expression pattern in the vasculature of stable transgenic zebrafish lines.</title><p>DA dorsal aorta, ISA intersegmental arteries, DLAV dorsal longitudinal anastomotic vessel, CV cardinal vein, ISV intersegmental veins, NT neural tube, NCA nasal ciliary artery, NCAx extends beyond NCA in direction of blood flow, HA hyaloid artery, DCV dorsal ciliary vein, OV optic vein. A fin artery, V fin vein. Letters s m w equate to strong medium or weak relative expression, * restricted to distal regions, ** restricted to anterior regions, *** restricted to subset of ECs.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-102440-fig4-data1-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102440-fig4-v2.tif"/></fig><p>In addition to the 38 putative enhancers identified through our screen, we tested another 11 regions that fell below our enhancer threshold. This included regions with enhancer marks in mice only or human only, regions with only one enhancer mark, and the two regions previously implicated as enhancers (<italic>Nrp1+76</italic> and <italic>Cxcr4-117;</italic> <xref ref-type="bibr" rid="bib86">Tsaryk et al., 2022</xref>). Of these 11 regions, only <italic>Cxcr4-117</italic> was able to drive any detectable expression in ECs. However, this was seen in only 9 of 209 injected embryos (&lt;5%) and was limited to 1–2 ECs in each F0 fish (<xref ref-type="table" rid="table2">Table 2</xref>, <xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3D</xref>). A human version of this enhancer, <italic>CXCR4-125</italic> (identified as an enhancer in <xref ref-type="bibr" rid="bib86">Tsaryk et al., 2022</xref>), was also tested but was not able to drive any detectable GFP expression (<xref ref-type="table" rid="table2">Table 2</xref>), and this enhancer region was therefore not further analysed.</p></sec><sec id="s2-3"><title>Assessing arterial enhancer activity patterns in transgenic models</title><p>We next examined the activity of our 15 strong arterial enhancers in further detail. To determine the expression pattern of these enhancers in stable transgenic zebrafish lines, we first assessed GFP expression in the trunk vasculature at 2–3 dpf (<xref ref-type="fig" rid="fig2">Figures 2</xref>—<xref ref-type="fig" rid="fig4">4</xref>). Interestingly, whilst all 15 enhancers were preferentially active in trunk arteries, the pattern of GFP activity within the arterial tree varied. By 3 dpf, five enhancers were broadly active in both the dorsal aorta and the intersegmental arteries sprouting off the aorta, whilst four enhancers were restricted to the dorsal aorta only, and five were restricted to the intersegmental arteries only. In addition, we saw some differences in arterial specificity. By 3 dpf, 6/9 enhancers active in the dorsal aorta showed no expression in the cardinal vein, whilst the other three were also weakly expressed in anterior or posterior segments of the cardinal vein (<xref ref-type="fig" rid="fig3">Figures 3</xref> and <xref ref-type="fig" rid="fig4">4</xref>). Transgene expression in the intersegmental vessels was more complicated to interpret as these vessels form by angiogenic sprouting from the dorsal aorta and many arterial genes are also expressed during angiogenic sprouting (including <italic>Efnb2</italic>, <italic>Cxcr4</italic>, <italic>Dll4</italic>, <italic>Nrp1,</italic> and <italic>Sox7</italic>). Consequently, GFP expression seen during early intersegmental sprouting could potentially reflect angiogenic or arterial expression (<xref ref-type="bibr" rid="bib74">Sacilotto et al., 2013</xref>; <xref ref-type="bibr" rid="bib93">Yamamizu et al., 2010</xref>). However, our analysis demonstrated that all enhancers active in the intersegmental vessels domain became either arterial-enriched or arterial-specific by 3 dpf: all 12 enhancers active in the intersegmental vessels were strongly enriched in the 3 dpf intersegmental arteries (as defined by direct connections to the dorsal aorta rather than the cardinal vein), with only 4/12 showing weaker expression in some intersegmental veins (<xref ref-type="fig" rid="fig2">Figures 2</xref>—<xref ref-type="fig" rid="fig4">4</xref>). Overall, this analysis suggests that, in the zebrafish trunk vasculature, 10/15 of our enhancers were arterial-specific whilst 5/15 were arterial-enriched.</p><p>Arterial development in the zebrafish trunk at the timepoints investigated primarily occurs via vasculogenesis and arterial-to-arterial sprouting, as opposed to the vein/capillary origin of many mammalian arterial ECs (<xref ref-type="bibr" rid="bib84">Su et al., 2018</xref>; <xref ref-type="bibr" rid="bib37">Hou et al., 2022</xref>; <xref ref-type="bibr" rid="bib70">Red-Horse and Siekmann, 2019</xref>). In order to investigate whether our enhancers were also active in arterial vessels formed directly from venous ECs, we also looked at expression in the developing zebrafish eye. In the zebrafish ocular system, venous ECs from the dorsal ciliary vein (DCV) sprout to form the nasal ciliary artery (<xref ref-type="bibr" rid="bib39">Kaufman et al., 2015</xref>; <xref ref-type="bibr" rid="bib32">Hasan et al., 2017</xref>; <xref ref-type="bibr" rid="bib33">Hashiura et al., 2017</xref>). Analysis of our enhancers in the 2–3 dpf eye found that 11/15 were active in the nasal ciliary artery, of which only two were also expressed in the dorsal ciliary vein (<xref ref-type="fig" rid="fig3s1">Figure 3—figure supplement 1</xref>, <xref ref-type="fig" rid="fig4">Figure 4</xref>). Only four enhancers active in the trunk arteries showed no ocular expression. This did not correspond to any particular arterial expression pattern in the trunk vasculature, suggesting that the two behaviours may not be transcriptionally linked.</p><p>We also investigated arterial enhancer activity in adult zebrafish. For this, we examined uninjured adult dorsal fins from 13 enhancer:GFP adult stable lines, alongside two previously studied arterial enhancers (Dll4in3 and Dll4-12) and the pan-EC marker line <italic>tg</italic>(<italic>fli1a:GFP</italic>) previously used for similar analysis (<xref ref-type="bibr" rid="bib92">Xu et al., 2014</xref>; <xref ref-type="fig" rid="fig4">Figures 4</xref> and <xref ref-type="fig" rid="fig5">5</xref>). 11/13 novel arterial enhancers and 2/2 known arterial enhancers were active in the adult fin arteries and/or arterial sprouts (<xref ref-type="fig" rid="fig5">Figure 5</xref>). Although no adult F1 fish were available for the <italic>Ephb2-112:GFP</italic> and <italic>Efnb2-159:GFP</italic> transgenes, analysis in 4-week-old juveniles also confirmed arterial fin expression (<xref ref-type="fig" rid="fig1s3">Figure 1—figure supplement 3E</xref>). Consequently, it is clear that our developmentally active arterial enhancers are largely also able to direct arterial patterns of expression in the adult, more quiescent, vasculature.</p><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>The majority of developmentally active arterial enhancers remain active in adult zebrafish fins.</title><p>(<bold>A</bold>) Schematic drawing of the zebrafish fin vasculature adapted from <xref ref-type="bibr" rid="bib92">Xu et al., 2014</xref>. (<bold>B</bold>) Expression pattern of the common EC marker line Fli1a:GFP in an adult fin. (C) Expression pattern of 13 novel arterial enhancer:GFP transgenes in adult fins, alongside previously identified arterial enhancers <italic>Dll4in3</italic> and <italic>Dll4-12</italic>. Grey dashed box indicates regions of zoom, a indicates fin artery, v indicates fin vein, * arterial sprout. See also <xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102440-fig5-v2.tif"/></fig><p>Lastly, we investigated whether these enhancers (all mouse sequences) also directed arterial activity in transgenic mice, selecting five enhancers active in zebrafish for further analysis. In each case, the enhancer was able to drive activity of the <italic>lacZ</italic> reporter gene in arterial ECs in E14.5 F0 transgenic mouse embryos in patterns similar to the previously described arterial <italic>Dll4in3:lacZ</italic> transgene (<xref ref-type="fig" rid="fig6">Figure 6</xref>). We additionally tested one enhancer which was only weakly active in transgenic zebrafish (<italic>Efnb2-37</italic>). No endothelial activity was seen for this enhancer in transgenic mice (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1</xref>). In combination, this transgenic zebrafish and mouse analysis indicates that we have successfully identified a cohort of enhancers directing gene expression to arterial ECs, accurately reflecting the expression of their cognate genes in mammals.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Five putative enhancers direct arterial expression in the vasculature of E14.5 transgenic mouse embryos.</title><p>(<bold>A–E</bold>) Two representative F0 embryos expressing each tested putative enhancer alongside a schematic of the transgene and two transverse sections through the embryo body wall and tail. Numbers in bottom left indicate embryos with arterial lacZ/total transgenic embryos. Grey dashed boxes indicate region in zoom, arrow indicates artery. (<bold>F</bold>) shows a representative E14.5 embryo from a stable transgenic line expressing the arterial <italic>Dll4in3:lacZ</italic> transgene alongside similar transverse sections through the embryo body wall and tail. Black line = 100 um.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102440-fig6-v2.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>All transgenic embryos expressing the <italic>Efnb2-37:lacZ</italic> transgene at E14.5 Grey dashed boxes indicate region in zoom.</title><p>No expression is seen in vessels.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102440-fig6-figsupp1-v2.tif"/></fig></fig-group></sec><sec id="s2-4"><title>In vivo enhancer activity does not always correlate with in silico predictions</title><p>We compared our results to a published genome-wide classification of EC regulatory elements, which used assessment of relative H3K27ac and acEP300 occupancy in freshly isolated HUVEC and HUAECs to classify enhancer regions as arterial-enriched, venous-enriched and common (arterial and venous enriched) regulatory elements (<xref ref-type="bibr" rid="bib82">Sissaoui et al., 2020</xref>). Only 3/15 of our in vivo-validated arterial enhancers were classified as arterial enhancers using this assay, with 5/15 classified as common enhancers, 4/15 characterized as TSS, and 3/15 as uncalled (<xref ref-type="table" rid="table2">Table 2</xref>). A similar analysis of the eight previously identified arterial enhancers found none were classified as arterial enhancers (7/8 were marked as common enhancers and 1/8 was uncalled) (<xref ref-type="table" rid="table2">Table 2</xref>). Conversely, 10/19 of the regions that were inactive in our transgenic assays were classified as enhancers in the in vitro assay (8 as common enhancers, 2 as arterial enhancers) (<xref ref-type="table" rid="table2">Table 2</xref>). The low correlation between predicted activity and behaviour in transgenic assays suggests that in silico assessments using enhancer marks in cultured ECs alone may not strongly predict the ability of a putative enhancer region to independently direct gene expression nor the resultant specificity of this expression.</p><p>We also considered whether the use of vein-origin (HUVEC) and microvascular-origin (HMVEC-dBl-neo/ad) ECs in our analysis of human enhancer marks may have affected the accuracy of our putative enhancer selection by expanding our analysis to enhancer marks in arterial-origin ECs. However, analysis of enhancer marks in human aortic endothelial cells (HAEC and telo-HAECs) and human umbilical artery endothelial cells (HUAECs) showed a very similar pattern and identified the same set of putative enhancers as when HUVEC/HMVEC data was considered (<xref ref-type="fig" rid="fig1s4">Figure 1—figure supplement 4</xref>). This suggests that the arteriovenous original of cultured cells did not significantly influence putative enhancer marks, further emphasizing the challenges of using selective enhancer marks in such lines to predict expression patterns in vivo.</p></sec><sec id="s2-5"><title>Assessment of transcription factor motifs and binding patterns at arterial enhancers</title><p>This work so far has identified a cohort of enhancers able to drive strong gene expression selectively to arterial ECs. We next investigated whether this arterial expression pattern was associated with the binding of particular transcription factors. The ability of a transcription factor to bind an enhancer or promoter sequence is commonly established by identifying one or more binding motif(s) within the region of interest, and/or by observing direct binding to the region of interest by chromatin immunoprecipitation (ChIP) or similar methodologies. Here, we combined both approaches. First, we performed HOMER analysis to identify overrepresented motifs within the core regions of all 15 arterial enhancers identified here (≈250–400 bp, centred on enhancer marks and cross-species conservation) alongside all eight previously identified arterial enhancers (a total of 23). This HOMER motif analysis indicated the repeated presence of motifs for ETS (including EC-associated factors ETS1, ERG and ETV2), SOX (including EC-associated SOX17 and SOX7), FOX (including EC-associated FOXO1 and FOXO3), RBPJ (the transcriptional effector of NOTCH signalling), and MEF2 (including EC-associated MEF2A) (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>). We next directly searched the sequences of all 23 core arterial enhancers to accurately determine the frequency of motifs for each of these transcription factors. In addition, we also looked for possible binding of other transcription factors previously implicated in arterial gene expression. The enhancer motif search used a combination of the JASPAR Transcription Factors Track Settings (TFTS) on the UCSC Genome Browser and hand annotation using previously defined consensus motifs (<xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref>). Because the level of conservation of motifs can often be an indication of their importance to enhancer activity, we classified each motif into three categories: strongly conserved (motif conserved to the same depth of the surrounding sequence), weakly conserved (motif conserved in orthologous human enhancer but not to the same depth as the surrounding sequence), and not conserved (motif is not conserved within the orthologous human sequence). In parallel, we compared this motif analysis with a variety of published endothelial ChIP-seq and CUT&amp;RUN datasets to determine where there was evidence of direct binding for each of these transcription factors at each enhancer (see <xref ref-type="fig" rid="fig7">Figure 7</xref> and <xref ref-type="fig" rid="fig8">Figure 8</xref>, <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplements 2</xref>–<xref ref-type="fig" rid="fig7s6">6</xref>, <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplements 1</xref> and <xref ref-type="fig" rid="fig8s2">2</xref>, <xref ref-type="fig" rid="fig9">Figure 9</xref>).</p><fig-group><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>Schematics summarizing the transcription factor motifs found within each arterial (<bold>A</bold>), pan-EC (<bold>B</bold>), and venous (<bold>C</bold>) enhancer.</title><p>All enhancers shown in 3’–5’ orientation relative to the arterial gene TSS. Deep black-lined rectangle boxes indicate strongly conserved motifs for transcription factors (conserved at the same depth as the surrounding enhancer sequence), shallow grey-lined boxes/text indicate weakly conserved motifs (conserved between mouse and human enhancer sequence but not at the same depth as the surrounding sequence), and rounded boxes mark motifs in enhancers conserved only human-mouse. Bold transcription factor names indicate places where ChIP-seq (or similar analysis) confirms binding. See <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplements 2</xref>–<xref ref-type="fig" rid="fig7s6">6</xref> for annotated sequences. Arterial enhancers listed with * are previously published (as detailed in <xref ref-type="bibr" rid="bib63">Payne et al., 2024</xref>), genome locations for each enhancer are provided in <xref ref-type="supplementary-material" rid="table2sdata2">Table 2—source data 2</xref>. Distances between motifs are representative but not scaled.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102440-fig7-v2.tif"/></fig><fig id="fig7s1" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 1.</label><caption><title>Transcription factor motifs associated with arterial enhancers.</title><p>(<bold>A</bold>) Homer known motif enrichment results on core enhancer sequences from all 23 arterial enhancers listed in <xref ref-type="table" rid="table1">Table 1</xref>. Exact sequences include in this analysis are listed in <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplement 2</xref>, and the coordinates in mm10 recorded in <xref ref-type="supplementary-material" rid="table2sdata2">Table 2—source data 2</xref>. (<bold>B</bold>) Table summarizing sequence logos used to guide motif analysis, alongside the source of each logo and EC type (where relevant). (<bold>C</bold>) Exact sequences assigned as motifs for each transcription factor.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102440-fig7-figsupp1-v2.tif"/></fig><fig id="fig7s2" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 2.</label><caption><title>Sequences of core enhancers (3’ to 5’ orientation) listed in <xref ref-type="fig" rid="fig7">Figure 7</xref> alongside annotated transcription factor binding motifs.</title><p>ETS motifs highlighted in green, SOXF motifs in yellow, FOX motifs in darker blue, FOX:ETS motifs in turquoise, RBPJ motifs in red, MEF2 in bright light blue, SMAD4 motifs in light pink, SMAD1/5 GC-rich motifs in darker pink, TCF/LEF (Wnt pathway) in grey, NR2F2 motifs in purple, and KLF4 motifs in orange. The sequences assessed as transcription factor motifs are listed in <xref ref-type="fig" rid="fig8">Figure 8C</xref>. Bold underline strong motifs conserved to the same depth as surrounding sequence (conservation depth indicated after title of each enhancer), bold indicates weak motif conserved between human and mouse but not to the comparable depth of the surrounding sequence, and italic indicates motif just found in mouse sequence.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102440-fig7-figsupp2-v2.tif"/></fig><fig id="fig7s3" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 3.</label><caption><title>Sequences of core enhancers (3’ to 5’ orientation) listed in <xref ref-type="fig" rid="fig7">Figure 7</xref> alongside annotated transcription factor binding motifs.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102440-fig7-figsupp3-v2.tif"/></fig><fig id="fig7s4" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 4.</label><caption><title>Sequences of core enhancers (3’ to 5’ orientation) listed in <xref ref-type="fig" rid="fig7">Figure 7</xref> alongside annotated transcription factor binding motifs.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102440-fig7-figsupp4-v2.tif"/></fig><fig id="fig7s5" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 5.</label><caption><title>Sequences of core enhancers (3’ to 5’ orientation) listed in <xref ref-type="fig" rid="fig7">Figure 7</xref> alongside annotated transcription factor binding motifs.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102440-fig7-figsupp5-v2.tif"/></fig><fig id="fig7s6" position="float" specific-use="child-fig"><label>Figure 7—figure supplement 6.</label><caption><title>Sequences of core enhancers (3’ to 5’ orientation) listed in <xref ref-type="fig" rid="fig7">Figure 7</xref> alongside annotated transcription factor binding motifs.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102440-fig7-figsupp6-v2.tif"/></fig></fig-group><fig-group><fig id="fig8" position="float"><label>Figure 8.</label><caption><title>Binding patterns of 11 vascular-associated transcription factors around each arterial enhancer.</title><p>Red dashed box indicates arterial enhancer region. Tracks show ChIP-seq/CUT&amp;RUN signal for ERG (<xref ref-type="bibr" rid="bib82">Sissaoui et al., 2020</xref>), ETS1 (<xref ref-type="bibr" rid="bib10">Chen et al., 2017</xref>), SOX7, SOX17 and SOX18 (this paper), FOXO1 (<xref ref-type="bibr" rid="bib4">Andrade et al., 2021</xref>), RBPJ (<xref ref-type="bibr" rid="bib87">Wang et al., 2019</xref>), MEF2C (<xref ref-type="bibr" rid="bib49">Maejima et al., 2014</xref>), SMAD1/5 (<xref ref-type="bibr" rid="bib55">Morikawa et al., 2011</xref>), SMAD2 (<xref ref-type="bibr" rid="bib11">Chen et al., 2019</xref>), and NR2F2 (<xref ref-type="bibr" rid="bib82">Sissaoui et al., 2020</xref>) in HUVECs, alongside FOXO1 (<xref ref-type="bibr" rid="bib82">Sissaoui et al., 2020</xref>), and MEF2A (<xref ref-type="bibr" rid="bib1">Akerberg et al., 2019</xref>) in adult mouse hearts.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102440-fig8-v2.tif"/></fig><fig id="fig8s1" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 1.</label><caption><title>Genomic regions around eight previously described arterial enhancers (red dashed box) alongside tracks showing ChIP-seq/CUT&amp;RUN signal for ERG (<xref ref-type="bibr" rid="bib82">Sissaoui et al., 2020</xref>), ETS1 (<xref ref-type="bibr" rid="bib10">Chen et al., 2017</xref>), SOX7, SOX17, and SOX18 (this paper), FOXO1 (<xref ref-type="bibr" rid="bib4">Andrade et al., 2021</xref>), RBPJ (<xref ref-type="bibr" rid="bib87">Wang et al., 2019</xref>), MEF2C (<xref ref-type="bibr" rid="bib49">Maejima et al., 2014</xref>), SMAD1/5 (<xref ref-type="bibr" rid="bib55">Morikawa et al., 2011</xref>), SMAD2 (<xref ref-type="bibr" rid="bib11">Chen et al., 2019</xref>), and NR2F2 (<xref ref-type="bibr" rid="bib82">Sissaoui et al., 2020</xref>) in HUVECs, alongside FOXO1 (<xref ref-type="bibr" rid="bib82">Sissaoui et al., 2020</xref>) and MEF2A (<xref ref-type="bibr" rid="bib1">Akerberg et al., 2019</xref>) in adult mouse hearts.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102440-fig8-figsupp1-v2.tif"/></fig><fig id="fig8s2" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 2.</label><caption><title>Genomic regions around 13 previously described pan-EC enhancers (grey dashed box) and 3 previously described vein enhancers (dark blue dashed box) alongside tracks showing ChIP-seq/CUT&amp;RUN signal for ERG (<xref ref-type="bibr" rid="bib82">Sissaoui et al., 2020</xref>), ETS1 (<xref ref-type="bibr" rid="bib10">Chen et al., 2017</xref>), SOX7, SOX17, and SOX18 (this paper), FOXO1 (<xref ref-type="bibr" rid="bib4">Andrade et al., 2021</xref>), RBPJ (<xref ref-type="bibr" rid="bib87">Wang et al., 2019</xref>), MEF2C (<xref ref-type="bibr" rid="bib49">Maejima et al., 2014</xref>), SMAD1/5 (<xref ref-type="bibr" rid="bib55">Morikawa et al., 2011</xref>), SMAD2 (<xref ref-type="bibr" rid="bib11">Chen et al., 2019</xref>), and NR2F2 (<xref ref-type="bibr" rid="bib82">Sissaoui et al., 2020</xref>) in HUVECs, alongside FOXO1 (<xref ref-type="bibr" rid="bib82">Sissaoui et al., 2020</xref>) and MEF2A (<xref ref-type="bibr" rid="bib1">Akerberg et al., 2019</xref>) in adult mouse hearts.</title></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102440-fig8-figsupp2-v2.tif"/></fig><fig id="fig8s3" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 3.</label><caption><title>Assessment of SOX7, SOX17 and SOX18 CUT&amp;RUN.</title><p>(<bold>A–B, D, F, H</bold>) Venn diagrams assessing overlap of genomic regions called as peaks of various combinations of ChIP-seq and CUT&amp;RUN datasets. (<bold>A</bold>) Comparison of called binding peaks for ERG (<xref ref-type="bibr" rid="bib82">Sissaoui et al., 2020</xref>) and SOX7_mCherry (<xref ref-type="bibr" rid="bib61">Overman et al., 2017</xref>) with marks for enhancers and TSS (<xref ref-type="bibr" rid="bib82">Sissaoui et al., 2020</xref>). (<bold>B</bold>) Comparison of called binding peaks for ERG and SOX17 (new CUT&amp;RUN) with marks for enhancers and TSS. (<bold>D</bold>) Comparison of called binding peaks for ERG and SOX7 (new CUT&amp;RUN) with marks for enhancers and TSS. (<bold>D, F</bold>) Comparison of called binding peaks for ERG and SOX7 (new CUT&amp;RUN) with marks for enhancers and TSS. (<bold>H</bold>) Comparison of called binding peaks for the overlap of called peaks of our SOX7, SOX17, and SOX18 CUT&amp;RUN data with each another and previously published ERG ChIP-seq data. (<bold>C, E, G</bold>) Top motif families called by HOMER in the SOX17 (<bold>C</bold>) and SOX7 (<bold>E</bold>) and SOX18 (<bold>G</bold>) CUT&amp;RUN peaks.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102440-fig8-figsupp3-v2.tif"/></fig><fig id="fig8s4" position="float" specific-use="child-fig"><label>Figure 8—figure supplement 4.</label><caption><title>Gene expression patterns of SOX and FOX transcription factors in ECs from different scRNA-seq datasets.</title><p>(<bold>A</bold>) UMAP visualization of scRNA-seq data of CD31+EC isolated from E12 <italic>BmxCreERT2;Rosa<sup>tdTomato</sup></italic> lineage traced hearts with accompanying gene expression profiles. Raw data obtained from <xref ref-type="bibr" rid="bib20">D’Amato et al., 2022</xref>. (<bold>B</bold>) Chosen gene expression profiles from scRNA-seq data of ApjCreER lineage traced EC isolated from E14.5 hearts. Plots taken from publicly available Shinyapp visualization of data from <xref ref-type="bibr" rid="bib84">Su et al., 2018</xref> . (<bold>C</bold>) UMAP plot and chosen gene expression profiles of CD31+EC from <italic>BmxCreERT2;Rosa<sup>tdTomato</sup></italic> lineage traced from E17.5 hearts. Raw data obtained from <xref ref-type="bibr" rid="bib20">D’Amato et al., 2022</xref> for reanalysis.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102440-fig8-figsupp4-v2.tif"/></fig></fig-group><fig id="fig9" position="float"><label>Figure 9.</label><caption><title>Summary of transcription factor motif and binding patterns at arterial, pan-EC and venous enhancers (<bold>A</bold>), and relative to different expression patterns within the arterial vasculature (<bold>B</bold>).</title><p>(<bold>A</bold>) All known (e.g. published) endothelial enhancers with adequately described expression patterns in transgenic mouse embryos were analysed to determine occurrence of selected TF motifs and direct binding. See <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplement 1</xref> for TF motif information, <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplements 2</xref>–<xref ref-type="fig" rid="fig7s6">6</xref> for annotated enhancer sequences and <xref ref-type="fig" rid="fig8">Figure 8</xref> and <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplements 1</xref> and <xref ref-type="fig" rid="fig8s2">2</xref> for TF binding peaks. Enhancers in bold were identified in this paper, those with * are previously published (as detailed in <sup>1</sup>), genome locations for each enhancer is provided in <xref ref-type="supplementary-material" rid="table2sdata2">Table 2—source data 2</xref>. (<bold>B</bold>) TF binding patterns for each arterial enhancer grouped by expression patterns in the 3 dpf zebrafish trunk. DA dorsal aorta, ISA intersegmental arteries, DLAV dorsal longitudinal anastomotic vessel, CV cardinal vein, ISV intersegmental veins, NT neural tube, NCA nasal ciliary artery, NCAx extends beyond NCA in direction of blood flow, HA hyaloid artery, DCV dorsal ciliary vein, OV optic vein. A fin artery, V fin vein. Letters s m w equate to strong medium or weak relative expression, * restricted to distal regions, ** restricted to anterior regions, *** restricted to subset of ECs.</p><p><supplementary-material id="fig9sdata1"><label>Figure 9—source data 1.</label><caption><title>Summary of transcription factor motif and binding patterns atarterial, pan-EC and venous enhancers, and relative to different expressionpatterns within the arterial vasculature.</title><p>M indicates enhancer contains one of more strongly conserved motifs for designated transcription factor, while <italic>m</italic> indicates weakly conserved motifs. C indicates a binding peak (as assessed by ChIP-seq or similar) for designated transcription factor in an enhancer with a corresponding motif, while <italic>c</italic> indicates a binding peak without a corresponding motif.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-102440-fig9-data1-v2.xlsx"/></supplementary-material></p><p><supplementary-material id="fig9sdata2"><label>Figure 9—source data 2.</label><caption><title>TF binding patterns for each arterial enhancer grouped by expression patterns in the 3 dpf zebrafish trunk.</title><p>C indicates a binding peak (as assessed by ChIP-seq or similar) in an enhancer with a corresponding motif, while <italic>c</italic> indicates a binding peak without a corresponding motif. DA dorsal aorta, ISA intersegmental arteries, DLAV dorsal longitudinal anastomotic vessel, CV cardinal vein, ISV intersegmental veins, NT neural tube, NCA nasal ciliary artery, NCAx extends beyond NCA in direction of blood flow, HA hyaloid artery, DCV dorsal ciliary vein, OV optic vein. A fin artery, V fin vein. Letters s m w equate to strong medium or weak relative expression, * restricted to distal regions, ** restricted to anterior regions, *** restricted to subset of ECs.</p></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-102440-fig9-data2-v2.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-102440-fig9-v2.tif"/></fig></sec><sec id="s2-6"><title>ETS, SOXF, and FOX binding is a common but not unique occurrence at arterial enhancers</title><p>Our motif analysis revealed near-ubiquitous binding sites for ETS, SOXF and FOX transcription factors at all arterial enhancers (<xref ref-type="fig" rid="fig7">Figure 7</xref>, <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplements 2</xref>–<xref ref-type="fig" rid="fig7s6">6</xref>, <xref ref-type="fig" rid="fig9">Figure 9</xref>). For ETS, 23/23 arterial enhancers contained at least one strongly conserved motif. Confirming this motif identification, 18/23 of these enhancers also directly bound ERG and ETS1, two very common EC-associated ETS factors (<xref ref-type="fig" rid="fig8">Figure 8</xref>, <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>). For FOX, 22/23 arterial enhancers contained conserved FOX motifs (22 strongly conserved) with 13/23 directly binding FOXO1 (<xref ref-type="fig" rid="fig8">Figure 8</xref>, <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>). For SOXF, 22/23 arterial enhancers contained conserved motifs (21 strongly conserved). Initial comparison of our enhancer cohort with publicly available information on SOX7 binding (from <xref ref-type="bibr" rid="bib61">Overman et al., 2017</xref>, which used ChIP-seq in HUVECs over-expressing SOX7-mCherry) showed no overlap. However, only 6% of SOX7-mCherry peaks overlapped with EC-associated enhancers or TSS marks and only 4% correlated with ERG binding, an ETS family transcription factor strongly associated with EC gene transcription (<xref ref-type="fig" rid="fig8s3">Figure 8—figure supplement 3A</xref>, ERG and enhancer mark data from <xref ref-type="bibr" rid="bib82">Sissaoui et al., 2020</xref>). Further, no SOX17 ChIP-seq in ECs has been published, despite SOX17 being most closely associated with arterial identity. We therefore performed an assessment of SOX17 binding with antibodies against the endogenous protein using CUT&amp;RUN in HUVECs. In this analysis, 75% of SOX17 binding peaks overlapped with EC enhancer/promoter marks (<xref ref-type="bibr" rid="bib82">Sissaoui et al., 2020</xref>), 73% overlapped with ERG binding (<xref ref-type="bibr" rid="bib82">Sissaoui et al., 2020</xref>), and HOMER analysis identified the SOX17 consensus motif as the most significantly enriched motif (<xref ref-type="fig" rid="fig8s3">Figure 7—figure supplement 3B and C</xref>). Assessment of our 23 arterial enhancer cohort found called SOX17 peaks at 20/23 arterial enhancers, in every case correlating with the presence of strongly conserved SOXF motifs (<xref ref-type="fig" rid="fig8">Figure 8</xref>, <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>, <xref ref-type="fig" rid="fig9">Figure 9</xref>). We also considered whether the pattern of SOX17 binding was different to SOX7 and SOX18, proteins with similar binding motifs but different expression profiles within the vasculature (<xref ref-type="bibr" rid="bib95">Zhou et al., 2015</xref>). For this, we again used CUT&amp;RUN in HUVECs with antibodies against the endogenous SOX7 and SOX18 proteins. In these assays, 91% of SOX17 peaks were also bound by SOX7 and/or SOX18 (86% shared with SOX7, 71% with SOX18, 66% with both) (<xref ref-type="fig" rid="fig8s3">Figure 8—figure supplement 3</xref>). For our arterial enhancers, all 20 SOX17-bound enhancers were also bound by either SOX7 (9/23), SOX18 (2/23) or both SOX7 and SOX18 (9/23) (<xref ref-type="fig" rid="fig4">Figure 4</xref>, <xref ref-type="fig" rid="fig8">Figure 8</xref>, <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplement 1</xref>). These data therefore suggest that binding of the arterial-enriched SOX17 was not a specific event at arterial-selective enhancers and that other SOXF proteins can also recognize and bind the SOX motifs within these enhancers.</p><p>Looked at in isolation, this analysis would strongly suggest that ETS, FOX, and SOXF transcription factors work together to direct arterial-specific gene expression. However, although our enhancers are all specific or highly enriched in arterial ECs, this analysis cannot by itself distinguish between factors that specifically direct arterial expression, and those required for endothelial gene expression more generally. Consequently, to determine if these common ETS, SOXF and FOX binding patterns were unique to arterial enhancers, we expanded our analysis to 16 in vivo-validated endothelial enhancers that were not selectively active in arterial ECs (<xref ref-type="fig" rid="fig7">Figure 7B and C</xref>, <xref ref-type="fig" rid="fig7s5">Figure 7—figure supplements 5</xref> and <xref ref-type="fig" rid="fig7s6">6</xref> and <xref ref-type="fig" rid="fig8s2">Figure 8—figure supplement 2</xref>, <xref ref-type="fig" rid="fig9">Figure 9</xref>). As assessed in transgenic mouse embryos at mid-late gestation, 13 of these enhancers drove relatively equal expression in arterial and venous ECs (pan-EC enhancers), while the activity of the other three was vein-enriched and artery-excluded (vein enhancers) (<xref ref-type="bibr" rid="bib63">Payne et al., 2024</xref>). Unsurprisingly, given their known role in general endothelial gene expression and identity, binding of ETS factors was ubiquitous at pan-EC enhancers and venous enhancers in addition to arterial enhancers. However, despite the association of SOXF factors with arterial identity, 12/13 pan-EC enhancers also directly bound SOXF factors (11/13 bound by SOX17, 11/13 by SOX7, and 9/13 by SOX18), with 9/13 containing strongly conserved SOXF motifs (<xref ref-type="fig" rid="fig8s2">Figure 8—figure supplement 2</xref>, <xref ref-type="fig" rid="fig9">Figure 9</xref>). The binding patterns at venous enhancers were harder to interpret due to a limited number of well-validated enhancers in this category and the activity of the <italic>CoupTFII-965</italic> enhancer in lymphatic ECs in addition to veins. While the <italic>Ephb4-2</italic> or <italic>Mef2cF10</italic> vein enhancers contained no SOXF motifs, the <italic>CoupTFII-965</italic> enhancer contained strongly conserved SOXF motifs and bound all SOXF proteins (<xref ref-type="fig" rid="fig8s2">Figure 8—figure supplement 2</xref>, <xref ref-type="fig" rid="fig9">Figure 9</xref>). Consequently, while the enhancers of some venous genes may lack sensitivity to SOXF factors, our data suggests that SOXF binding is not a unique feature of arterial-restricted gene expression. These observations align with previous studies showing roles for SOXF factors in vasculogenesis and angiogenesis (<xref ref-type="bibr" rid="bib45">Lilly et al., 2017</xref>; <xref ref-type="bibr" rid="bib41">Kim et al., 2016</xref>; <xref ref-type="bibr" rid="bib43">Lee et al., 2014</xref>), and with the expression of SOXF factors throughout the vascular plexus during arterial-venous differentiation in the embryonic heart (<xref ref-type="fig" rid="fig8">Figure 8</xref>, <xref ref-type="fig" rid="fig8s4">Figure 8—figure supplement 4</xref> and <xref ref-type="bibr" rid="bib15">Chiang et al., 2017</xref>; <xref ref-type="bibr" rid="bib81">Sharma et al., 2017</xref>) and postnatal retina (<xref ref-type="bibr" rid="bib95">Zhou et al., 2015</xref>). This also agrees with the severe vascular phenotypes seen after compound loss of SOXF factors, which include EC hyperplasia, loss of angiogenic markers, and inhibited arteriovenous differentiation (<xref ref-type="bibr" rid="bib41">Kim et al., 2016</xref>; <xref ref-type="bibr" rid="bib95">Zhou et al., 2015</xref>).</p><p>Our findings were somewhat less clear for FOX transcription factors. 9/13 pan-EC enhancers contained some kind of FOX motif (compared to 22/23 arterial enhancers). However, the only FOX motif within 6 of these pan-EC enhancers was a composite part of a FOX:ETS motif (a vasculogenic-associated element whose FOX component is often fairly degenerative) <xref ref-type="fig" rid="fig7">Figures 7</xref> and <xref ref-type="fig" rid="fig8">8</xref>, <xref ref-type="fig" rid="fig7s1">Figure 7—figure supplements 1</xref>–<xref ref-type="fig" rid="fig7s6">6</xref>; <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplements 2</xref>–<xref ref-type="fig" rid="fig7s6">6</xref>; <xref ref-type="fig" rid="fig7s4">Figure 7—figure supplements 4</xref>–<xref ref-type="fig" rid="fig7s6">6</xref>; <xref ref-type="fig" rid="fig7s3">Figure 7—figure supplements 3</xref>–<xref ref-type="fig" rid="fig7s6">6</xref>; <xref ref-type="fig" rid="fig7s3">Figure 7—figure supplements 3</xref>–<xref ref-type="fig" rid="fig7s5">5</xref>; <xref ref-type="fig" rid="fig9">Figure 9</xref> This leaves only 3/13 pan-EC enhancers containing independent FOX motifs, compared to 20/23 arterial enhancers, suggesting that FOX binding may be enriched among our arterial enhancer cohort. While this aligns with previous observations linking FOXC1 and FOXC2 with arterial differentiation expression (<xref ref-type="bibr" rid="bib80">Seo et al., 2006</xref>), neither are highly expressed in developing coronary arteries nor commonly identified as arterial-enriched in single cell transcriptomics in developing mouse embryos (<xref ref-type="fig" rid="fig8">Figure 8</xref>, <xref ref-type="fig" rid="fig8s4">Figure 8—figure supplement 4</xref> and <xref ref-type="bibr" rid="bib37">Hou et al., 2022</xref>; <xref ref-type="bibr" rid="bib12">Chen et al., 2024</xref>). In addition to FOXC1/2, FOXO1 is also expressed widely throughout the endothelium and directly bound many of our arterial enhancers, but direct links between deletion or constitutive activation of FOXO1 and changes in arterial differentiation have not yet been reported (e.g.<xref ref-type="bibr" rid="bib89">Wilhelm et al., 2016</xref>).</p></sec><sec id="s2-7"><title>MEF2 binding occurs at a subset of arterial enhancers and may be associated with sprouting</title><p>MEF2 factor binding was overrepresented in arterial enhancers compared to pan-EC enhancers, although it was seen at only a minority of enhancers. In total, 9/23 arterial enhancers contained conserved MEF2 motifs (8 strongly conserved) compared to only 1/13 pan-EC enhancers. This arterial-skewed pattern was repeated in assays of MEF2 factor binding, with direct MEF2 binding found at 8/23 arterial enhancers and only 2/13 pan-EC enhancers (<xref ref-type="fig" rid="fig8">Figure 8</xref>, <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplements 1</xref> and <xref ref-type="fig" rid="fig8s2">2</xref>, <xref ref-type="fig" rid="fig9">Figure 9</xref>). Given the known role of MEF2 factors in angiogenic sprouting and the close link between angiogenesis and arterial differentiation (<xref ref-type="bibr" rid="bib75">Sacilotto et al., 2016</xref>; <xref ref-type="bibr" rid="bib67">Pitulescu et al., 2017</xref>), it is possible that MEF2 factors are regulating gene expression in response to angiogenic rather than arterial cues at these enhancers. This has been already shown for the <italic>Dll4in3</italic> enhancer, where loss of MEF2 binding ablated enhancer activity in angiogenic ECs but not in mature arterial ECs (<xref ref-type="bibr" rid="bib75">Sacilotto et al., 2016</xref>). Supporting this hypothesis, MEF2-bound enhancers were associated with genes expressed in early ‘pre-arterial’ EC and/or involved in angiogenesis (<italic>Cxcr4, Efnb2, Nrp1, Unc5b, Flk1,</italic> and <italic>Dll4</italic>) (<xref ref-type="bibr" rid="bib37">Hou et al., 2022</xref>; <xref ref-type="bibr" rid="bib69">Raftrey et al., 2021</xref>; <xref ref-type="fig" rid="fig9">Figure 9</xref>). To determine if there was a relationship between MEF2 motif/binding and expression pattern, we grouped the enhancers according to zebrafish expression profiles in the trunk and looked at the resultant clusters of TFs (<xref ref-type="fig" rid="fig9">Figure 9</xref>). Strikingly, all five arterial enhancers restricted to the intersegmental vessels were MEF2-bound, indicating a possible angiogenic role as these vessels form by angiogenic sprouting. In addition, the MEF2-bound <italic>Efnb2-333</italic> is active in both compartments in a similar pattern to the Dll4in3. However, MEF2 factors are also associated with transcriptional activation downstream of shear stress, which is a known effector of <italic>Efnb2</italic> and other arterial gene expression (<xref ref-type="bibr" rid="bib38">Hwa et al., 2017</xref>; <xref ref-type="bibr" rid="bib47">Lu et al., 2021</xref>), and the MEF2-bound <italic>Unc5b+30</italic> enhancer was preferentially active in the dorsal aorta only (<xref ref-type="fig" rid="fig2">Figures 2</xref>—<xref ref-type="fig" rid="fig4">4</xref>). Further studies would therefore be required to definitely link MEF2 binding at these enhancers to either an angiogenic or sheer stress response.</p></sec><sec id="s2-8"><title>RBPJ binding indicates a role for Notch in transcription of arterial genes</title><p>RBPJ is the transcriptional effector of the Notch pathway, complexing with the Notch intracellular domain (NICD) and the co-activator MAML in order to directly bind DNA and activate transcription (<xref ref-type="bibr" rid="bib8">Bray, 2006</xref>). Strongly conserved RBPJ motifs were found in 14/23 arterial enhancers and 4/13 pan-EC enhancers, while direct RBPJ binding was confirmed at 6/23 arterial enhancers only (<xref ref-type="fig" rid="fig7">Figures 7</xref> and <xref ref-type="fig" rid="fig8">8</xref>, <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplements 1</xref>–<xref ref-type="fig" rid="fig8s3">3</xref>, <xref ref-type="fig" rid="fig9">Figure 9</xref>). RBPJ motifs are relatively short and share close similarity to the ETS motifs (consensus TGGGAA vs. HGGAAR), potentially explaining the discrepancy between motif and direct binding. Direct RBPJ binding to arterial enhancers has previously only been reported for genes in the Notch pathway, a fact that supported the hypothesis that Notch does not directly induce arterial differentiation through gene activation but instead by reducing their MYC-dependent metabolic and cell-cycle activities (<xref ref-type="bibr" rid="bib48">Luo et al., 2021</xref>). However, here we found good evidence for RBPJ binding at enhancers for <italic>Cxcr4</italic>, <italic>Efnb2</italic>, <italic>Gja4,</italic> and <italic>Unc5b,</italic> suggesting that Notch may directly influence at least some arterial identity genes. In most cases, these genes also contained additional enhancers not directly bound by RBPJ, potentially providing an explanation for the maintenance of some arterial gene expression in the absence of RBPJ/Notch (<xref ref-type="bibr" rid="bib48">Luo et al., 2021</xref>). Additionally, previous studies on the <italic>Dll4in3</italic> enhancer found that loss of RBPJ (and Notch signalling) did not affect enhancer or gene expression unless SOXF factors were also perturbed (<xref ref-type="bibr" rid="bib74">Sacilotto et al., 2013</xref>). Cooperation between SOXF and Notch may also partly explain how the widely expressed SOXF factors enact arterial-specific gene activation, although SOX factors bound arterial enhancers more commonly than RBPJ. An alternative explanation may be that these results instead reflect the known involvement of RBPJ/Notch in angiogenesis. However, whilst all RBPJ-bound arterial enhancers were active in the sprout-formed intersegmental vessels in zebrafish (<xref ref-type="fig" rid="fig9">Figure 9</xref>), neither RBPJ binding or RBPJ motifs were ubiquitous in intersegmental-expressed enhancers.</p></sec><sec id="s2-9"><title>No other arterial or venous-related transcription factors are commonly present or excluded at our arterial enhancers</title><p>Lastly, we investigated potential roles for SMADs (transcription factors downstream of TGFβ/BMP signalling), TCF7/TCF7L1/TCFL2/LEF1 (transcription factors downstream of canonical WNT signalling), and KLF4 (downstream of laminar shear stress). Although the binding motifs for these factors were not overrepresented in our arterial cohort as assessed by HOMER analysis, these pathways have all previously been implicated in arterial gene expression. We also looked for evidence of NR2F2/COUP-TFII binding, a vein and lymphatic-specific transcription factor previously implicated in both activation of venous genes and repression of arterial/Notch genes. This analysis found little evidence supporting a broad role for any of these pathways in arterial gene expression nor a link to any particular expression type within the arterial tree (<xref ref-type="fig" rid="fig7">Figures 7</xref> and <xref ref-type="fig" rid="fig8">8</xref>, <xref ref-type="fig" rid="fig7s2">Figure 7—figure supplements 2</xref>–<xref ref-type="fig" rid="fig7s6">6</xref>, <xref ref-type="fig" rid="fig8s1">Figure 8—figure supplements 1</xref> and <xref ref-type="fig" rid="fig8s2">2</xref>, <xref ref-type="fig" rid="fig9">Figure 9</xref>). NR2F2 motifs were seen in 7/23 arterial enhancers (but only strongly conserved in 4/23) and 3/13 pan-EC enhancers. Largely uncorrelated ChIP-seq peaks were seen at 11/23 arterial enhancers, and at 8/13 pan-EC enhancers. Strongly conserved KLF4 motifs were only seen in 2/23 arterial and 4/13 pan-EC enhancers but none correlated with KLF4 binding. Strongly conserved TCF/LEF motifs were only found in 3/23 arterial enhancers and 2/13 pan-EC enhancers. SMAD1/5-SMAD4 factors downstream of BMP signalling have been previously associated with the expression of venous genes including <italic>Nr2f2</italic> and <italic>Ephb4 (</italic><xref ref-type="bibr" rid="bib56">Neal et al., 2019</xref>; <xref ref-type="bibr" rid="bib83">Stewen et al., 2024</xref>), and all three vein enhancers contained multiple motifs for SMAD factor binding (with 2/3 also directly binding SMAD1/5 and SMAD2 in HUVECS after BMP9/TGFβ stimulation) (<xref ref-type="fig" rid="fig7">Figures 7</xref> and <xref ref-type="fig" rid="fig8">8</xref>, <xref ref-type="fig" rid="fig8s2">Figure 8—figure supplement 2</xref>, <xref ref-type="fig" rid="fig9">Figure 9</xref>). However, here we found that SMAD binding also occurred at arterial enhancers, with 12/23 containing strongly conserved motifs, 8/23 directly binding SMAD1/5 of which three also bound SMAD2. This agrees with the lack of venous-specificity reported for phosphorylated SMAD1/5, which led to the supposition that addition factors work alongside SMAD1/5 to regulate vein specification (<xref ref-type="bibr" rid="bib56">Neal et al., 2019</xref>). An arterial role for SMADs is not without precedent, particularly downstream of TGFβ (e.g.<xref ref-type="bibr" rid="bib60">Ola et al., 2018</xref>; <xref ref-type="bibr" rid="bib9">Chavkin et al., 2022</xref>; <xref ref-type="bibr" rid="bib72">Roman and Hinck, 2017</xref><xref ref-type="bibr" rid="bib72">Roman and Hinck, 2017</xref>; <xref ref-type="bibr" rid="bib19">Daems et al., 2024</xref>). While Tie2:Cre-mediated excision of SMAD4 (effectively knocking out all canonical BMP/TGFβ signalling) did not obviously affect arterial differentiation at E9.5, an earlier or later role cannot be dismissed, as Tie2:Cre becomes active after vasculogenic-driven arterial differentiation occurs, and vein-related lethality occurs in these embryos by E10.5 (<xref ref-type="bibr" rid="bib56">Neal et al., 2019</xref>), prior to most vein/capillary-to-arterial EC differentiation.</p></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Recent years have brought a new appreciation of the vein/capillary origin of most arterial ECs, and an increasing interest in arterialization as a therapeutic aim of regenerative medicine. However, the transcriptional pathways driving arterial differentiation are still incompletely understood. Many factors have contributed to this, including a focus on the Notch signalling pathway and a lack of characterized arterial enhancers for most key arterial genes. The latter has resulted in regulatory pathways being linked to arterial gene expression through proposed binding at promoter regions, although these elements are often poorly characterized or unsupported by functional data (e.g. binding motifs located kilobases away from TSS at regions without promoter or enhancer marks, transcription factor binding not verified by available ChIP-seq datasets). As well as the potential for incorrect assumptions, a reliance on poorly defined enhancer/promoter regions prevents further research building on these initial observations, for example, by looking for associated motifs to identify combinatorial, synergistic, and antagonistic factors or to link with newly discovered pathways or transcription factors. In this paper, we sought to generate a useful and accessible cohort of arterial enhancers with which to study arterial transcriptional regulation more effectively. Alongside <italic>Dll4</italic>, <italic>Notch1,</italic> and <italic>Hey1</italic> (all genes with previously described enhancers included in our analysis), the eight arterial genes focused on here represent the majority of genes used to define arterial identity in single cell transcriptomics in mice and humans (e.g. <xref ref-type="bibr" rid="bib37">Hou et al., 2022</xref>; <xref ref-type="bibr" rid="bib52">McCracken et al., 2022</xref>; <xref ref-type="bibr" rid="bib69">Raftrey et al., 2021</xref>; <xref ref-type="bibr" rid="bib12">Chen et al., 2024</xref>). Further, our choice of targets included genes with essential and well-studied roles in arterial differentiation (e.g. <italic>Efnb2</italic>), implicated in arteriovenous malformations in humans (e.g. <italic>Acvrl1</italic>), associated with processes important for regeneration (<italic>Cxcr4</italic> and <italic>Cxcl12;</italic> <xref ref-type="bibr" rid="bib21">Das et al., 2019</xref>), or commonly used as arterial markers in animal models (e.g. <italic>Gja5</italic>). Thus, our hope was to identify a cohort of arterial enhancers likely to be directly targeted by arterial lineage specification and differentiation factors that represent key stages of arterial development of interest to a wide range of researchers and that we can easily link to previous observations on arterial development in animal models of gene depletion.</p><p>Analysis of single-cell transcriptomic data has indicated that arterial ECs can be further subdivided into two groups, reflecting maturity but also potentially slightly different developmental trajectories (<xref ref-type="bibr" rid="bib37">Hou et al., 2022</xref>; <xref ref-type="bibr" rid="bib69">Raftrey et al., 2021</xref>). The genes studied here cover both subgroups, with <italic>Acvrl1</italic>, <italic>Cxcl12</italic>, <italic>Gja5,</italic> and <italic>Nrp1</italic> primarily restricted to the mature arterial EC subgroup, while <italic>Cxcr4</italic>, <italic>Efnb2</italic>, <italic>Gja4,</italic> and <italic>Unc5b</italic> were also expressed in the less mature/arterial plexus/pre-arterial EC subgroup (<xref ref-type="bibr" rid="bib37">Hou et al., 2022</xref>; <xref ref-type="bibr" rid="bib69">Raftrey et al., 2021</xref>). Although we saw no obvious differences in transcription factor motif and binding between the two sets overall, the genes expressed in both immature and mature subgroups tended to have multiple enhancers with differential expression patterns: there are four <italic>Efnb2</italic> enhancers, of which <italic>Efnb2-141</italic> is largely restricted to the dorsal aorta and Efnb2-159 is restricted to the intersegmental arteries, while <italic>Efnb2-333</italic> and <italic>Efnb2-112</italic> enhancers are more widely active; there are two <italic>Unc5b</italic> arterial enhancers, of which <italic>Unc5b+39</italic> is restricted to the intersegmental arteries while <italic>Unc5b+30</italic> is expressed more widely. It is therefore possible that the upstream signals involved at different stages of arterial differentiation may, to some extent, target separate enhancers. Although this article has focused on transcriptional signatures of arterial versus non-arterial-specific enhancers, future research into the transcriptional differences seen between these differentially expressed arterial enhancers may therefore bring further insights into arterial transcription factors, and the manner in which upstream pathways combine to enact subtle but essential changes in gene expression.</p><p>Alongside a deficit of characterized enhancers, our understanding of vascular transcription is also affected by the considerable redundancy shown by many endothelial transcription factors. In particular, this can complicate analysis of gene disruption in animal models. A good example of this problem is the SOXF factors. SOX7, SOX17, and SOX18 not only show distinct yet overlapping expression patterns, but their ability to functionally compensate for each other can vary on different mouse backgrounds. For example, the phenotype in mice lacking SOX18 varies from essentially normal to complete loss of lymphatic ECs, with lethality depending on the mouse strain and associated variation in the ability of SOX7 and SOX17 to compensate (<xref ref-type="bibr" rid="bib36">Hosking et al., 2009</xref>). SOX17 is the SOXF factor most strongly expressed in arterial ECs, and arterial defects occur after its deletion (<xref ref-type="bibr" rid="bib18">Corada et al., 2013</xref>). This has resulted in the hypothesis that SOX17 selectively activates arterial genes, but this is not well supported by the results here. An alternative explanation could be that SOXF factors are required for endothelial gene expression more generally, potentially as master regulators. This aligns with their robust and primarily endothelial-specific expression (particularly after mid-gestation; <xref ref-type="bibr" rid="bib63">Payne et al., 2024</xref>), and by the widespread presence of SOXF motifs and binding at endothelial enhancers of all varieties. In this second model, the loss of SOX17 may affect the arterial compartment more severely simply because it comprises the majority of arterial SOXF (so the total amount of SOXF factors is more significantly depleted in arteries than elsewhere when SOX17 is deleted), with similar explanations for the consequences of SOX7 depletion on vasculogenesis (<xref ref-type="bibr" rid="bib45">Lilly et al., 2017</xref>) and SOX18 depletion on lymphangiogenesis (<xref ref-type="bibr" rid="bib36">Hosking et al., 2009</xref>; <xref ref-type="bibr" rid="bib26">François et al., 2008</xref>). Alternatively, <xref ref-type="bibr" rid="bib83">Stewen et al., 2024</xref> have recently shown that combined depletion of SOXF factors in cultured ECs significantly reduced <italic>Efnb2</italic> expression while increasing <italic>Ephb4</italic> expression, and instead argue for a more specific role for SOXF factors in arteriovenous differentiation related to elevated SOXF levels in arterial ECs (<xref ref-type="bibr" rid="bib83">Stewen et al., 2024</xref>). While this alone cannot explain the widespread binding of SOXF factors to pan-EC genes, SOXF factors are also crucial during vasculogenesis/early angiogenesis. Therefore, the role of SOXF factors in general, and SOX17 in particular, may instead be to drive a less specific angiogenic/arterial gene expression program. Supporting this, neither the <italic>Ephb4-2</italic> or <italic>Mef2cF7</italic> vein enhancers had SOXF motifs, while the role of SOXF in <italic>CoupTFII-965</italic> regulation may be simply related to its expression in lymphatic ECs. The paucity of defined venous/capillary enhancers currently limits our ability to make conclusions here. However, endothelial SOXF factors are clearly strongly expressed widely in the endothelium at timepoints where a much more limited number of ECs become committed to an arterial fate (perfectly illustrated in the coronary vasculature), suggesting that additional transcriptional regulators must be involved alongside SOXF to enable this exquisitely specific pattern of gene activation. While RBPJ, MEF2, and FOX factors represent obvious potential partners, none would fully explain the specificity of all arterial enhancers and they all have wider roles in the vasculature.</p><p>Complicating analysis of our arterial enhancer cohort is the possibility that all arterial enhancers are not necessarily directly activated by the same regulator(s). Instead, a transcriptional cascade may be started by the activation of just one or two early genes, which then create a more permissive environment (e.g. high concentration or post-translation modification of transcription factors) for later arterial gene expression downstream of more widely expressed transcription factors. This would align with the observed elevated levels of SOXF expression as ECs switch to an arterial fate (<xref ref-type="bibr" rid="bib83">Stewen et al., 2024</xref>) and may suggest that the pathways upstream of SOXF expression play the most important role in arterial gene expression. However, a far more systematic analysis of all three SOXF loci, and the enhancers within, is required to test this hypothesis.</p><p>The relatively simple and cost-effective approach of in silico identification and zebrafish transgenesis of arterial enhancers used here had a success rate around 50%. This could doubtless be further refined (e.g. by including assessments of ERG binding, obtaining enhancer marks from in vivo arterial cells), and made more efficient by limiting verification to F0 transgenic fish or utilizing a higher throughput assay (e.g.<xref ref-type="bibr" rid="bib91">Xiao et al., 2024</xref>). However, a potentially more pressing issue is how to better understand the exact transcriptional regulators of these enhancers, a challenge shared with the gene regulatory field more widely. Transcription factors do not always bind DNA at their consensus motifs, with optimal syntax (order, orientation, and spacing of motifs) often able to compensate for poor binding sites. Additionally, the presence of multiple motifs within a single enhancer, and the ability of many transcription factors to both directly and indirectly bind enhancers, means that enhancer sequence mutational analysis can be very complicated (e.g. <xref ref-type="bibr" rid="bib74">Sacilotto et al., 2013</xref>), whilst restricting this analysis to a single timepoint (usually required to make such an approach practical) can be an issue where angiogenic and arterial programmes overlap. While assessments of direct binding by ChIP-seq or similar approaches can bypass a requirement to understand the exact motifs at an enhancer, neither cultured HUVECs nor iPSC-derived arterial cells recapitulate conditions in vivo, particularly regarding availability of ligands, exposure to shear stress, and other environmental stimuli. Here, for example, the low expression of some of our arterial genes in culture HUVECs and HUAECs has probably affected verification of motifs with ChIP-seq data. Consequently, while this analysis has provided clarity as to some transcription factors involved (and not involved) in arterial gene expression, none of our observations fully explain the shared ability of these short sequences of DNA to direct arterial patterns of expression even when removed from native chromatin context and endogenous promoters. Some of these answers can be expected to come from increasing identification of new or unappreciated transcription factors specifically expressed or specifically modified in either arterial or non-arterial ECs (e.g. MECOM), better appreciation of the consensus motifs and binding patterns of proteins already known to be involved (e.g. DACH1), and improved proteomic techniques. Additionally, new iPSC models of endothelial differentiation offer the opportunity to more easily study the consequences of transcription factor perturbation during angiogenesis and arterial differentiation, and artificial intelligence, improved bioinformatic pathways, and machine learning all offer new avenues for research. It is anticipated that the cohort of in vivo-verified arterial enhancers characterized here will provide a vital platform for these future studies.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Genetic reagent (<italic>Danio rerio</italic>)</td><td align="left" valign="bottom"><italic>tg(kdrl:Has.HRAS-mcherry)<sup>s896</sup></italic></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib14">Chi et al., 2008</xref></td><td align="left" valign="bottom">ZFIN:s896</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. rerio</italic>)</td><td align="left" valign="bottom"><italic>tg(fli1:EGFP)</italic></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib42">Lawson et al., 2001</xref></td><td align="left" valign="bottom">ZFIN:y1</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. rerio</italic>)</td><td align="left" valign="bottom"><italic>tg(Cxcr4-194:EGFP)</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">ZFIN:lcr6</td><td align="left" valign="bottom">Enhancer mm10 chr1:128,785,499–128,786,173</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. rerio</italic>)</td><td align="left" valign="bottom"><italic>tg(Cxcr4+135:EGFP)</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">ZFIN:lcr7</td><td align="left" valign="bottom">Enhancer mm10 chr1:128,456,948–128,457,375</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. rerio</italic>)</td><td align="left" valign="bottom"><italic>tg(Cxcr4+151:EGFP)</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">ZFIN:lcr8</td><td align="left" valign="bottom">Enhancer mm10 chr1:128,440,589–128,441,003</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. rerio</italic>)</td><td align="left" valign="bottom"><italic>tg(Efnb2-333:EGFP)</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">ZFIN:lcr9</td><td align="left" valign="bottom">Enhancer mm10 chr8:8,994,329–8,995,063</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. rerio</italic>)</td><td align="left" valign="bottom"><italic>tg(Efnb2-159:EGFP)</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">ZFIN:lcr10</td><td align="left" valign="bottom">Enhancer mm10 chr8:8,819,219–8,819,856</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. rerio</italic>)</td><td align="left" valign="bottom"><italic>tg(Efnb2-141:EGFP)</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">ZFIN:lcr11</td><td align="left" valign="bottom">Enhancer mm10 chr8:8,801,433–8,802,174</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. rerio</italic>)</td><td align="left" valign="bottom"><italic>tg(Efnb2-112:EGFP)</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">ZFIN:lcr12</td><td align="left" valign="bottom">Enhancer mm10 chr8:8,772,171–8,772,912</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. rerio</italic>)</td><td align="left" valign="bottom"><italic>tg(Gja4-50:EGFP)</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">ZFIN:lcr13</td><td align="left" valign="bottom">Enhancer mm10 chr4:127,263,607–127,264,323</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. rerio</italic>)</td><td align="left" valign="bottom"><italic>tg(Unc5b+30:EGFP)</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">ZFIN:lcr14</td><td align="left" valign="bottom">Enhancer mm10 chr10:60,800,677–60,801,144</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. rerio</italic>)</td><td align="left" valign="bottom"><italic>tg(Unc5b+39:EGFP)</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">ZFIN:lcr15</td><td align="left" valign="bottom">Enhancer mm10 chr10:60,792,705–60,793,377</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. rerio</italic>)</td><td align="left" valign="bottom"><italic>tg(Acvrl1+6:EGFP)</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">ZFIN:lcr16</td><td align="left" valign="bottom">Enhancer mm10 chr15:101,134,018–101,134,405</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. rerio</italic>)</td><td align="left" valign="bottom"><italic>tg(Cxcl12+269:EGFP)</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">ZFIN:lcr17</td><td align="left" valign="bottom">Enhancer mm10 chr6:117,437,567–117,438,123</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. rerio</italic>)</td><td align="left" valign="bottom"><italic>tg(Gja5-78:EGFP)</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">ZFIN:lcr18</td><td align="left" valign="bottom">Enhancer mm10 chr3:96,953,659–96,954,322</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. rerio</italic>)</td><td align="left" valign="bottom"><italic>tg(Gja5-7:EGFP)</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">ZFIN:lcr19</td><td align="left" valign="bottom">Enhancer mm10 chr3:97,025,305–97,025,791</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>D. rerio</italic>)</td><td align="left" valign="bottom"><italic>tg(Nrp1+78:EGFP)</italic></td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">ZFIN:lcr20</td><td align="left" valign="bottom">Enhancer mm10 chr8:128,437,292–128,437,815</td></tr><tr><td align="left" valign="bottom">Genetic reagent (<italic>Mus musculus</italic>)</td><td align="left" valign="bottom"><italic>tg(Dll4in3:lacZ)</italic></td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib74">Sacilotto et al., 2013</xref></td><td align="left" valign="bottom">Tg(Rr393-lacZ)#Sav</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">E1b-GFP-Tol2-Gateway</td><td align="left" valign="bottom">Ahituv; <xref ref-type="bibr" rid="bib7">Birnbaum et al., 2012</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:addgene_37846">AddGene_#37846</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">Hsp68-LacZ-Gateway</td><td align="left" valign="bottom">Ahituv; <xref ref-type="bibr" rid="bib64">Pennacchio et al., 2006</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:addgene_37843">AddGene_#37843</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line (<italic>Homo sapiens</italic>)</td><td align="left" valign="bottom">HUVECs</td><td align="left" valign="bottom">Lonza</td><td align="left" valign="bottom">C2519A</td><td align="left" valign="bottom">Grown in EBM-2 basal medium (Lonza CC-3156) with EBM-2 SingleQuot (Lonza CC-4176)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">IgG control (rabbit monoclonal)</td><td align="left" valign="bottom">Cell Signaling Technology</td><td align="left" valign="bottom">CST 66362</td><td align="left" valign="bottom">1:20<break/>(antibody total amount 0.5 µg)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Sox7 (goat polyclonal)</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">AF2766</td><td align="left" valign="bottom">1:50 (antibody total amount 0.4 µg)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Sox17 (goat polyclonal)</td><td align="left" valign="bottom">R&amp;D Systems</td><td align="left" valign="bottom">AF1924</td><td align="left" valign="bottom">1:40 (antibody total amount 0.5 µg)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Sox18 (mouse monoclonal)</td><td align="left" valign="bottom">Abnova</td><td align="left" valign="bottom">H00054345-M05</td><td align="left" valign="bottom">1:100 (antibody total amount 1 µg)</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">NEBNext(R) Ultra II DNA Library Prep Kit</td><td align="left" valign="bottom">New England Biolabs</td><td align="left" valign="bottom">NEB E7645L</td><td align="left" valign="bottom">Using NEBNext Dual Index Multiplex Oligos NEB E7600S</td></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">ChIP DNA Clean &amp; Concentrator kit</td><td align="left" valign="bottom">Zymo Research</td><td align="left" valign="bottom">D5205</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">Gateway LR Clonase II Enzyme mix</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="char" char="." valign="bottom">11791100</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">CUT&amp;RUN Kit</td><td align="left" valign="bottom">Cell Signaling Technologies</td><td align="left" valign="bottom">CST 86652</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Commercial assay or kit</td><td align="left" valign="bottom">pCR8/GW/TOPO TA Cloning Kit</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">K250020</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">ZEN 2.3 lite (blue edition)</td><td align="left" valign="bottom">Zeiss</td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_023747">SCR_023747</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">nf-core/cutandrun</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib13">Cheshire et al., 2023</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Version 3.1.0</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">Homer</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib34">Heinz et al., 2010</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_023747">SCR_023747</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">vennRanges</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://rdrr.io/github/antonio-mora/vennRanges/#vignettes">https://rdrr.io/github/antonio-mora/vennRanges/#vignettes</ext-link>; <xref ref-type="bibr" rid="bib5">Antonio, 2019</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Version 0.1</td></tr><tr><td align="left" valign="bottom">Software, algorithm</td><td align="left" valign="bottom">FIJI</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib76">Schindelin et al., 2012</xref></td><td align="left" valign="bottom">RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID:SCR_002285">SCR_002285</ext-link></td><td align="left" valign="bottom"/></tr></tbody></table></table-wrap><sec id="s4-1"><title>Animals</title><p>All animal procedures were approved by a local ethical review committee at Oxford University and licensed by the UK Home Office and follow ARRIVE guidelines. All zebrafish were maintained in groups. F0 mosaic transgenic zebrafish embryos were generated using Tol2-mediated integration (<xref ref-type="bibr" rid="bib40">Kawakami, 2005</xref>). The F1 stable transgenic lines were generated from an initial outcross of adult F0 carriers, in each case selecting founder transgenic zebrafish representative of the general expression patterns seen in F0 analysis. An intercross of adult F1 lines produced F2 lines. To enable visualization of the entire vasculature, the adult F1 transgenic lines were intercrossed with the <italic>tg(kdrl:HRAS-mCherry) zebrafish line</italic>. Embryos were maintained in E3 medium (5 mM NaCl; 0.17 mM KCl; 0.33 mM CaCl<sub>2</sub>; 0.33 mM MgSO<sub>4</sub>) at 28.5°C. Some of the embryos were incubated at 30–32°C to modify the speed of embryonic development. Some embryos were also treated with 0.003% phenylthiourea (Merck, P7629) at 24 hpf onwards, to inhibit pigmentation. To image, all embryos were dechorionated and anaesthetized with 0.01% Tricaine methanesulfonate in E3 medium. For analysis of transgenic zebrafish, single embryos were transferred into a flat-bottom 96-well plate, mounted in 0.1% TopVision low-melting point agarose (Thermo Fisher Scientific, R0801) in E3 medium with tricaine methanesulfonate (Merck, A5040). GFP and mCherry reporter gene expression was screened with a Zeiss LSM 980 (Carl Zeiss) confocal microscope at 32–72 hpf. Whole zebrafish were imaged using the ‘tile scan’ command, combined with Z-stack collection, at 488 nm excitation and 510 nm emission for EGFP, and at 561 nm excitation and 610 nm emission for mCherry. The eyes of the zebrafish were imaged similarly, but without tile scanning.</p><p>Adult fin analysis was performed by treating adult (3–14 months old) zebrafish with 5 g/l tricaine methanesulfonate and amputating the caudal fins with a razor blade Fins were transferred to a flat-bottom glass plate and mounted in 0.1% TopVision low-melting point agarose. GFP expression was imaged with a Zeiss LSM 980 confocal microscope as above.</p><p>E14.5 F0 transgenic mouse embryos were generated, dissected, and stained in X-gal by Cyagen Biosciences. Yolk sac was collected separately and used for genotyping. All embryos were imaged using a Leica M165C stereo microscope equipped with a ProGres CF Scan camera and CapturePro software (Jenoptik). For each enhancer, embryos were also sectioned for histological analysis to investigate X-gal staining patterns. For histological analysis, embryos were dehydrated through a series of ethanol washes, cleared by xylene, and paraffin wax-embedded. 5 or 6 μm sections were prepared, dewaxed, and counterstained with nuclear fast red (Electron Microscopy Sciences).</p></sec><sec id="s4-2"><title>Cloning</title><p>All enhancer sequences were generated as custom-made, double-stranded linear DNA fragments (GeneArt Strings, Life Technologies). The sequences of all tested enhancers are provided in Appendix 1. DNA fragments containing the enhancer sequences were cloned into the pCR8 vector using the pCR8/GW/TOPO TA Cloning Kit (Thermo Fisher Scientific, K250020) following the manufacturer’s instructions. Once cloning was confirmed, the enhancer sequence was transferred from the pCR8/GW/enhancer entry vector to a suitable destination vector using Gateway LR Clonase II Enzyme mix (Thermo Fisher Scientific, 11791100) following the manufacturer’s instructions. For zebrafish transgenesis, the enhancer was cloned into the E1b-GFP-Tol2-Gateway vector (<xref ref-type="bibr" rid="bib7">Birnbaum et al., 2012</xref>). For mouse transgenesis, the enhancer was cloned into the hsp68-LacZ-Gateway vector.</p></sec><sec id="s4-3"><title>Enhancer mark assays</title><p>ATAC-seq in primary MAECs (SRX7016284-6) came from <xref ref-type="bibr" rid="bib23">Engelbrecht et al., 2020</xref>, ATAC-seq in mouse postnatal day 6 (P6) retina ECs (MRECs) (SRX7267172-4) came from <xref ref-type="bibr" rid="bib94">Yanagida et al., 2020</xref>, EP300 binding in Tie2Cre+ve cells from embryonic day (E)11.5 mouse embryos (SRX2246376-8) came from <xref ref-type="bibr" rid="bib96">Zhou et al., 2017</xref>, H3K27Ac and H3K4Me1 in HUVECs, and DNAseI hypersensitivity in HUVECs and dermal-derived neonatal and adult blood microvascular ECs (HMVEC-dBl-neo/ad) came from the UCSC Genome Browser (<xref ref-type="bibr" rid="bib73">Rosenbloom et al., 2013</xref>). ATAC-seq (SRX2355049 GSM2394391) and H3K27Ac (SRX2355060 GSM2394402) in cultured HAECs came from <xref ref-type="bibr" rid="bib35">Hogan et al., 2017</xref>, ATAC-seq in telo-HAEC (SRX1689050 GSM6431161) came from <xref ref-type="bibr" rid="bib77">Schnitzler et al., 2024</xref>, and H3K27Ac and p300 ChIP-seq in HUAECs (GSM3673407 and GSM3673413) came from <xref ref-type="bibr" rid="bib82">Sissaoui et al., 2020</xref>.</p></sec><sec id="s4-4"><title>HOMER analysis on arterial enhancers</title><p>Analysis of overrepresented motifs within our validated arterial enhancer cohort was performed with HOMER’s findMotifsGenome tool using the full validated region of the arterial enhancers. The analysis used the hg38 masked genome and otherwise default settings for all other parameters including randomly selected background regions.</p></sec><sec id="s4-5"><title>Transcription factor binding assays</title><p>With the exception of SOX7, SOX17 and SOX18, all transcription factor binding data was previously published, and was assessed in IGV (<xref ref-type="bibr" rid="bib85">Thorvaldsdóttir et al., 2013</xref>) either through downloading from GEO or via ChIP Atlas (<xref ref-type="bibr" rid="bib59">Oki et al., 2018</xref>). In every case, we first verified the correct data was accessed by reproducing images at loci used in the primary publication, and highly recommend this practice for others as errors inevitably occur during data deposition. ERG and NR2F2 binding data in HUVECs (GSM3673462 and GSM3673452) came from <xref ref-type="bibr" rid="bib82">Sissaoui et al., 2020</xref>, ETS1 binding data in HUVECs after 12 hr of VEGFA stimulation (GSM2442778 SRX2452430) came from <xref ref-type="bibr" rid="bib10">Chen et al., 2017</xref>. FOXO1 binding data in HUVECs (GSM3681485/6 SRX5548892) came from <xref ref-type="bibr" rid="bib4">Andrade et al., 2021</xref> and FOXO1 binding in adult untreated mouse hearts (GSM4278011 SRX7586623) came from <xref ref-type="bibr" rid="bib65">Pfleger et al., 2020</xref>. RBPJ binding data in HUVECs after 12 hr of VEGFA stimulation (GSM2947456 SRX3599311) came from <xref ref-type="bibr" rid="bib87">Wang et al., 2019</xref>. SMAD1/5 binding in HUVECs after BMP9 stimulation (GSM684747 SRX045541) was from <xref ref-type="bibr" rid="bib55">Morikawa et al., 2011</xref>, SMAD2 in HUVECs after TGFβ stimulation (GSM3955796 SRX6476491) came from <xref ref-type="bibr" rid="bib11">Chen et al., 2019</xref>. MEF2C binding data in HUVECs (GSM809016 SRX100256) came from <xref ref-type="bibr" rid="bib49">Maejima et al., 2014</xref>, and MEF2A binding data in mouse adult hearts (GSM3518665 SRX5146756) came from <xref ref-type="bibr" rid="bib1">Akerberg et al., 2019</xref>.</p><p>For SOX7, SOX17, and SOX18 CUT&amp;RUN, HUVECs were cultured in EBM-2 basal medium (Lonza CC-3156) supplemented with EBM-2 SingleQuot supplement and growth factor kit (Lonza CC-4176). DNA binding assays were performed using the CUT&amp;RUN Kit from Cell Signaling Technologies (CST 86652) following the manufacturer’s protocol with slight modifications. For SOX7 and SOX17, harvested cells were lightly crosslinked with 0.1% formaldehyde for 2 min and processed with buffers supplemented with 1% Triton X-100 and 0.05% SDS. SOX18 CUT&amp;RUN was performed without crosslinking and with buffers as per standard protocol. Cells were bound to Concanavalin A beads and incubated overnight with antibodies against IgG control (CST 66362), SOX7 (R&amp;D Systems, AF2766), or SOX17 (R&amp;D Systems, AF1924) or SOX18 (Abnova, H00054345-M05) in wash buffer containing 0.05% digitonin. DNA around binding sites was cleaved with pAG-MNase enzyme. For SOX7 and SOX17, the released DNA was reverse-crosslinked with proteinase K and 0.1% SDS overnight at 65°C. DNA fragments were purified with a ChIP DNA Clean &amp; Concentrator kit (Zymo Research D5205). DNA was converted into Illumina-compatible libraries with the NEBNext(R) Ultra(TM) II DNA Library Prep Kit (NEB E7645L) following the protocol described by <xref ref-type="bibr" rid="bib46">Liu, 2019</xref> and using NEBNext Dual Index Multiplex Oligos (NEB E7600S). Libraries were sequenced on a NextSeq2000 (SOX17) or a NovaSeq (SOX7 and SOX18) using paired end reads. Data was processed using the nf-core/cutandrun v3.1 pipeline (10.5281/zenodo.5653535; <xref ref-type="bibr" rid="bib24">Ewels et al., 2020</xref>) with the following adjustments to the default settings: <monospace>--normalisation_mode</monospace> CPM and <monospace>--trim_nextseq</monospace> 20. The CUT&amp;RUN hg38 blacklist (<xref ref-type="bibr" rid="bib58">Nordin et al., 2023</xref>) or hg19 ENCODE blacklist (<xref ref-type="bibr" rid="bib2">Amemiya et al., 2019</xref>) was used during sequence alignment. Peak calling was performed with SEACR (<xref ref-type="bibr" rid="bib54">Meers et al., 2019</xref>) using stringent settings, and by HOMER (<xref ref-type="bibr" rid="bib34">Heinz et al., 2010</xref>) using default settings for transcription factors (-style factor). Motif analysis was performed with HOMER using 200 nt regions around peak centres. Overlap of SOX7, SOX17, and SOX18 hg19-aligned peaks with published mCherry-SOX7 data (<xref ref-type="bibr" rid="bib61">Overman et al., 2017</xref>), HUVEC enhancer marks and TSS (<xref ref-type="bibr" rid="bib82">Sissaoui et al., 2020</xref>) was executed using the vennRanges R package. Data has been deposited to GEO under the accession number GSE283369.</p></sec><sec id="s4-6"><title>Reanalysis of scRNA-seq data</title><p>Publicly available E12 and E17.5 scRNA-seq data from EC isolated from <italic>BmxCreERT2;Rosa<sup>tdTomato</sup></italic> lineage traced murine hearts (<xref ref-type="bibr" rid="bib20">D’Amato et al., 2022</xref>) was obtained from GEO (GSE214942) prior to processing FASTQ files with the 10X Genomics CellRanger pipeline (V7.0.0). RNA-seq reads were aligned to the mm10 genome reference downloaded from 10X Genomics with the addition of the T<italic>dTomato-WPRE</italic> sequence. Exclusion of low-quality cells with either a UMI count &gt;100,000,, total gene count &lt;1500, or a high proportion of reads originating from mitochondrial genes (&gt;10%) was performed using Scater (<xref ref-type="bibr" rid="bib51">McCarthy et al., 2017</xref>). Data normalization was performed using the MultiBatchNormalisation method prior to merging of <italic>TdTomato</italic>-positive and -negative datasets from individual timepoints. The top 2000 most highly variable genes (excluding mitochondrial and ribosomal genes) in the merged datasets were identified using the Seurat FindVariableFeatures method and utilized to calculate principal component analysis. Normalized data was scaled using the ScaleData function. Cell clustering was performed using the standard unsupervised graph-based clustering method implemented within Seurat (V4) (<xref ref-type="bibr" rid="bib31">Hao et al., 2024</xref>). Clusters were visualized in two dimensions using UMAP based non-linear dimensional reduction following the standard Seurat (V4) workflow (<xref ref-type="bibr" rid="bib11">Chen et al., 2019</xref>). Identified clusters were assigned identities based on marker genes shown to be differentially expressed between populations previously identified in the original study (<xref ref-type="bibr" rid="bib87">Wang et al., 2019</xref>). Key markers include <italic>Npr3</italic> (endocardial), <italic>Fabp4</italic> (coronary vascular endothelial), and <italic>Nfatc1</italic> (valvular endothelial). The E12.5 sinus venosus EC cluster was assigned based in <italic>Aplnr</italic> as previously described (<xref ref-type="bibr" rid="bib20">D’Amato et al., 2022</xref>). Arterial and venous EC clusters in the E17.5 datasets were annotated based on their enriched expression of <italic>Gja5</italic> and <italic>Nr2f2</italic>, respectively.</p></sec><sec id="s4-7"><title>Materials availability statement</title><p>The newly created zebrafish lines <italic>tg(Cxcr4-194:EGFP), tg(Cxcr4+135:EGFP), tg(Cxcr4+151:EGFP), tg(Efnb2-333:EGFP), tg(Efnb2-159:EGFP), tg(Efnb2-141:EGFP), tg(Efnb2-112:EGFP), tg(Gja4-50:EGFP), tg(Unc5b+30:EGFP), tg(Unc5b+39:EGFP), tg(Acvrl1+6:EGFP), tg(Cxcl12+269:EGFP), tg(Gja5-78:EGFP), tg(Gja5-7:EGFP)</italic> and <italic>tg(Nrp1+78:EGFP),</italic> and the plasmids used to generate them are all available on request from the corresponding author. The SOX7, SOX17, and SOX18 CUT&amp;RUN data is deposited at GEO under the accession number GSE283369.</p></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Supervision, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Investigation</p></fn><fn fn-type="con" id="con4"><p>Data curation</p></fn><fn fn-type="con" id="con5"><p>Conceptualization, Resources, Data curation, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>All animal procedures were approved by a local ethical review committee at Oxford University and licensed by the UK Home Office, license number PP1224162.</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="mdar"><label>MDAR checklist</label><media xlink:href="elife-102440-mdarchecklist1-v2.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>Cut&amp;Run data for Sox7, Sox17 and Sox 18 have been deposited at GEO under the accession number GSE283369.</p><p>The following dataset was generated:</p><p><element-citation publication-type="data" specific-use="isSupplementedBy" id="dataset1"><person-group person-group-type="author"><name><surname>Nornes</surname><given-names>S</given-names></name><name><surname>Bruche</surname><given-names>S</given-names></name><name><surname>Adak</surname><given-names>N</given-names></name><name><surname>McCracken</surname><given-names>I</given-names></name><name><surname>De Val</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2024">2024</year><data-title>SOX7, SOX17 and SOX18 DNA binding in baseline HUVEC</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE283369">GSE283369</pub-id></element-citation></p><p>The following previously published datasets were used:</p><p><element-citation publication-type="data" specific-use="references" id="dataset2"><person-group person-group-type="author"><name><surname>Engelbrecht</surname><given-names>E</given-names></name><name><surname>Levesque</surname><given-names>MV</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Vanlandewijck</surname><given-names>M</given-names></name><name><surname>Betsholtz</surname><given-names>C</given-names></name><name><surname>Hla</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>Sphingosine 1-phosphate-regulated transcriptomes in heterogenous arterial and lymphatic endothelium of the aorta</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE139065">GSE139065</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset3"><person-group person-group-type="author"><name><surname>Engelbrecht</surname><given-names>E</given-names></name><name><surname>Yanagida</surname><given-names>K</given-names></name><name><surname>Hla</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>Sphingosine 1-phosphate receptor signaling establishes AP-1 transcriptional factor gradients and permits retinal endothelial specialization</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE141440">GSE141440</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset4"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>P</given-names></name><name><surname>Gu</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Akerberg</surname><given-names>BN</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>He</surname><given-names>A</given-names></name><name><surname>Lin</surname><given-names>Z</given-names></name><name><surname>Stevens</surname><given-names>SM</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Wt</surname><given-names>PU</given-names></name></person-group><year iso-8601-date="2017">2017</year><data-title>Mapping cell type-specific transcriptional enhancers using high affinity, lineage-specific p300 bioChIP-seq</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE88789">GSE88789</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset5"><person-group person-group-type="author"><name><surname>Romanoski</surname><given-names>CE</given-names></name><name><surname>Hogan</surname><given-names>NT</given-names></name></person-group><year iso-8601-date="2017">2017</year><data-title>Genome-wide map of HAEC chromatin landscape under resting and TNFa, IL1b, and OxPAPC stimulation, with corresponding transcription factor binding and RNA expression</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE89970">GSE89970</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset6"><person-group person-group-type="author"><name><surname>Schnitzler</surname><given-names>GR</given-names></name><name><surname>Kang</surname><given-names>H</given-names></name><name><surname>Lee-Kim</surname><given-names>V</given-names></name><name><surname>Xr</surname><given-names>MA</given-names></name><name><surname>Zeng</surname><given-names>T</given-names></name><name><surname>Vellarikkal</surname><given-names>SK</given-names></name><name><surname>Zhou</surname><given-names>R</given-names></name><name><surname>Guo</surname><given-names>K</given-names></name><name><surname>Sias-Garcia</surname><given-names>O</given-names></name><name><surname>Bloemendal</surname><given-names>A</given-names></name><name><surname>Munson</surname><given-names>G</given-names></name><name><surname>Guckelberger</surname><given-names>P</given-names></name><name><surname>Nguyen</surname><given-names>TH</given-names></name><name><surname>Bergman</surname><given-names>DT</given-names></name><name><surname>Atri</surname><given-names>D</given-names></name><name><surname>Cheng</surname><given-names>N</given-names></name><name><surname>Cleary</surname><given-names>B</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Finucane</surname><given-names>HK</given-names></name><name><surname>Gupta</surname><given-names>RM</given-names></name><name><surname>Engreitz</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2022">2022</year><data-title>High-content CRISPR screens link coronary artery disease genes to endothelial cell programs [ATACseq]</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE210489">GSE210489</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset7"><person-group person-group-type="author"><name><surname>Lawson</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>Identification and characterization of artery and vein enhancers in the human genome</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE128382">GSE128382</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset8"><person-group person-group-type="author"><name><surname>Huan</surname><given-names>C</given-names></name><name><surname>Day</surname><given-names>DS</given-names></name><name><surname>Fu</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Yan</surname><given-names>P</given-names></name><name><surname>Gu</surname><given-names>F</given-names></name><name><surname>Stevens</surname><given-names>SM</given-names></name><name><surname>Seidman</surname><given-names>JG</given-names></name><name><surname>Han</surname><given-names>Z</given-names></name><name><surname>Park</surname><given-names>PJ</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Wt</surname><given-names>PU</given-names></name></person-group><year iso-8601-date="2016">2016</year><data-title>VEGF promotes RNAPII pausing release through ETS1 to stimulate angiogenesis</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE93030">GSE93030</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset9"><person-group person-group-type="author"><name><surname>Andrade</surname><given-names>J</given-names></name><name><surname>Zimmermann</surname><given-names>B</given-names></name><name><surname>Grosso</surname><given-names>AR</given-names></name><name><surname>Potente</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><data-title>Genome-wide maps of FOXO1 binding sites in human endothelial cells</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE128635">GSE128635</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset10"><person-group person-group-type="author"><name><surname>Pfleger</surname><given-names>J</given-names></name><name><surname>Koch</surname><given-names>WJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><data-title>FoxO1 Binding in Cardiac Hypertrophy</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE144011">GSE144011</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset11"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Garcia</surname><given-names>S</given-names></name><name><surname>Liang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Fu</surname><given-names>Y</given-names></name><name><surname>Yan</surname><given-names>P</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>wang</surname><given-names>J</given-names></name><name><surname>Le</surname><given-names>H</given-names></name><name><surname>Han</surname><given-names>Z</given-names></name><name><surname>Day</surname><given-names>DS</given-names></name><name><surname>Stevens</surname><given-names>SM</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Park</surname><given-names>PJ</given-names></name><name><surname>Sun</surname><given-names>K</given-names></name><name><surname>Yuan</surname><given-names>G</given-names></name><name><surname>Wt</surname><given-names>PU</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2018">2018</year><data-title>Dynamic and integrated transcriptional code orchestrates the angiogenic response [Seq]</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE109625">GSE109625</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset12"><person-group person-group-type="author"><name><surname>Morikawa</surname><given-names>M</given-names></name><name><surname>Koinuma</surname><given-names>D</given-names></name><name><surname>Tsutsumi</surname><given-names>S</given-names></name><name><surname>Vasilaki</surname><given-names>E</given-names></name><name><surname>Heldin</surname><given-names>C</given-names></name><name><surname>Aburatani</surname><given-names>H</given-names></name><name><surname>Miyazono</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2011">2011</year><data-title>SMAD1/5 binding regions of human umbilical vein endothelial cells (HUVECs) treated with BMP</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE27634">GSE27634</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset13"><person-group person-group-type="author"><name><surname>Simons</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>Endothelial TGFb signaling drives vascular inflammation and atherosclerosis [ChIP-Seq]</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE134556">GSE134556</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset14"><person-group person-group-type="author"><name><surname>Maejima</surname><given-names>T</given-names></name><name><surname>Kohro</surname><given-names>T</given-names></name><name><surname>Tsutsumi</surname><given-names>S</given-names></name><name><surname>Yamamoto</surname><given-names>S</given-names></name><name><surname>Kimura</surname><given-names>H</given-names></name><name><surname>Kodama</surname><given-names>T</given-names></name><name><surname>Wada</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2013">2013</year><data-title>Genome-wide maps of MEF2C and H3K27ac localization in HUVECs</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE32644">GSE32644</pub-id></element-citation></p><p><element-citation publication-type="data" specific-use="references" id="dataset15"><person-group person-group-type="author"><name><surname>Akerberg</surname><given-names>BN</given-names></name><name><surname>Gu</surname><given-names>F</given-names></name><name><surname>Wt</surname><given-names>Pu</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>A reference map of cardiac transcription factor chromatin occupancy identifies dynamic and conserved transcriptional enhancers</data-title><source>NCBI Gene Expression Omnibus</source><pub-id pub-id-type="accession" xlink:href="https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE124008">GSE124008</pub-id></element-citation></p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Nadav Ahituv for providing the GW vectors. This work was supported by the BHF (FS/1735/32929 and FS/SBSRF/22/31037 to SDV and SN; FS/IPBSRF/23/27085 to IRM), the Oxford BHF Centre of Research Excellence (RE/18/3/34214), the Fondation Leducq, and Ludwig Cancer Research Ltd.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akerberg</surname><given-names>BN</given-names></name><name><surname>Gu</surname><given-names>F</given-names></name><name><surname>VanDusen</surname><given-names>NJ</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Dong</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Sethi</surname><given-names>I</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Wasson</surname><given-names>L</given-names></name><name><surname>Wen</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Dong</surname><given-names>K</given-names></name><name><surname>Conlon</surname><given-names>FL</given-names></name><name><surname>Zhou</surname><given-names>J</given-names></name><name><surname>Yuan</surname><given-names>G-C</given-names></name><name><surname>Zhou</surname><given-names>P</given-names></name><name><surname>Pu</surname><given-names>WT</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A reference map of murine cardiac transcription factor chromatin occupancy identifies dynamic and conserved enhancers</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>e4907</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-12812-3</pub-id><pub-id pub-id-type="pmid">31659164</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Amemiya</surname><given-names>HM</given-names></name><name><surname>Kundaje</surname><given-names>A</given-names></name><name><surname>Boyle</surname><given-names>AP</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>The ENCODE blacklist: identification of problematic regions of the genome</article-title><source>Scientific Reports</source><volume>9</volume><elocation-id>e9354</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-019-45839-z</pub-id><pub-id pub-id-type="pmid">31249361</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andersson</surname><given-names>R</given-names></name><name><surname>Gebhard</surname><given-names>C</given-names></name><name><surname>Miguel-Escalada</surname><given-names>I</given-names></name><name><surname>Hoof</surname><given-names>I</given-names></name><name><surname>Bornholdt</surname><given-names>J</given-names></name><name><surname>Boyd</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Zhao</surname><given-names>X</given-names></name><name><surname>Schmidl</surname><given-names>C</given-names></name><name><surname>Suzuki</surname><given-names>T</given-names></name><name><surname>Ntini</surname><given-names>E</given-names></name><name><surname>Arner</surname><given-names>E</given-names></name><name><surname>Valen</surname><given-names>E</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Schwarzfischer</surname><given-names>L</given-names></name><name><surname>Glatz</surname><given-names>D</given-names></name><name><surname>Raithel</surname><given-names>J</given-names></name><name><surname>Lilje</surname><given-names>B</given-names></name><name><surname>Rapin</surname><given-names>N</given-names></name><name><surname>Bagger</surname><given-names>FO</given-names></name><name><surname>Jørgensen</surname><given-names>M</given-names></name><name><surname>Andersen</surname><given-names>PR</given-names></name><name><surname>Bertin</surname><given-names>N</given-names></name><name><surname>Rackham</surname><given-names>O</given-names></name><name><surname>Burroughs</surname><given-names>AM</given-names></name><name><surname>Baillie</surname><given-names>JK</given-names></name><name><surname>Ishizu</surname><given-names>Y</given-names></name><name><surname>Shimizu</surname><given-names>Y</given-names></name><name><surname>Furuhata</surname><given-names>E</given-names></name><name><surname>Maeda</surname><given-names>S</given-names></name><name><surname>Negishi</surname><given-names>Y</given-names></name><name><surname>Mungall</surname><given-names>CJ</given-names></name><name><surname>Meehan</surname><given-names>TF</given-names></name><name><surname>Lassmann</surname><given-names>T</given-names></name><name><surname>Itoh</surname><given-names>M</given-names></name><name><surname>Kawaji</surname><given-names>H</given-names></name><name><surname>Kondo</surname><given-names>N</given-names></name><name><surname>Kawai</surname><given-names>J</given-names></name><name><surname>Lennartsson</surname><given-names>A</given-names></name><name><surname>Daub</surname><given-names>CO</given-names></name><name><surname>Heutink</surname><given-names>P</given-names></name><name><surname>Hume</surname><given-names>DA</given-names></name><name><surname>Jensen</surname><given-names>TH</given-names></name><name><surname>Suzuki</surname><given-names>H</given-names></name><name><surname>Hayashizaki</surname><given-names>Y</given-names></name><name><surname>Müller</surname><given-names>F</given-names></name><name><surname>Forrest</surname><given-names>ARR</given-names></name><name><surname>Carninci</surname><given-names>P</given-names></name><name><surname>Rehli</surname><given-names>M</given-names></name><name><surname>Sandelin</surname><given-names>A</given-names></name><collab>The FANTOM Consortium</collab></person-group><year iso-8601-date="2014">2014</year><article-title>An atlas of active enhancers across human cell types and tissues</article-title><source>Nature</source><volume>507</volume><fpage>455</fpage><lpage>461</lpage><pub-id pub-id-type="doi">10.1038/nature12787</pub-id><pub-id pub-id-type="pmid">24670763</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Andrade</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>C</given-names></name><name><surname>Costa</surname><given-names>ASH</given-names></name><name><surname>Choi</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Doddaballapur</surname><given-names>A</given-names></name><name><surname>Sugino</surname><given-names>T</given-names></name><name><surname>Ong</surname><given-names>YT</given-names></name><name><surname>Castro</surname><given-names>M</given-names></name><name><surname>Zimmermann</surname><given-names>B</given-names></name><name><surname>Kaulich</surname><given-names>M</given-names></name><name><surname>Guenther</surname><given-names>S</given-names></name><name><surname>Wilhelm</surname><given-names>K</given-names></name><name><surname>Kubota</surname><given-names>Y</given-names></name><name><surname>Braun</surname><given-names>T</given-names></name><name><surname>Koh</surname><given-names>GY</given-names></name><name><surname>Grosso</surname><given-names>AR</given-names></name><name><surname>Frezza</surname><given-names>C</given-names></name><name><surname>Potente</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Control of endothelial quiescence by FOXO-regulated metabolites</article-title><source>Nature Cell Biology</source><volume>23</volume><fpage>413</fpage><lpage>423</lpage><pub-id pub-id-type="doi">10.1038/s41556-021-00637-6</pub-id><pub-id pub-id-type="pmid">33795871</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Antonio</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><data-title>VennRanges</data-title><version designator="0.1">0.1</version><source>Github</source><ext-link ext-link-type="uri" xlink:href="https://github.com/antonio-mora/vennRanges">https://github.com/antonio-mora/vennRanges</ext-link></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Becker</surname><given-names>PW</given-names></name><name><surname>Sacilotto</surname><given-names>N</given-names></name><name><surname>Nornes</surname><given-names>S</given-names></name><name><surname>Neal</surname><given-names>A</given-names></name><name><surname>Thomas</surname><given-names>MO</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Preece</surname><given-names>C</given-names></name><name><surname>Ratnayaka</surname><given-names>I</given-names></name><name><surname>Davies</surname><given-names>B</given-names></name><name><surname>Bou-Gharios</surname><given-names>G</given-names></name><name><surname>De Val</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>An intronic Flk1 enhancer directs arterial-specific expression via RBPJ-mediated venous repression</article-title><source>Arteriosclerosis, Thrombosis, and Vascular Biology</source><volume>36</volume><fpage>1209</fpage><lpage>1219</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.116.307517</pub-id><pub-id pub-id-type="pmid">27079877</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birnbaum</surname><given-names>RY</given-names></name><name><surname>Clowney</surname><given-names>EJ</given-names></name><name><surname>Agamy</surname><given-names>O</given-names></name><name><surname>Kim</surname><given-names>MJ</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Yamanaka</surname><given-names>T</given-names></name><name><surname>Pappalardo</surname><given-names>Z</given-names></name><name><surname>Clarke</surname><given-names>SL</given-names></name><name><surname>Wenger</surname><given-names>AM</given-names></name><name><surname>Nguyen</surname><given-names>L</given-names></name><name><surname>Gurrieri</surname><given-names>F</given-names></name><name><surname>Everman</surname><given-names>DB</given-names></name><name><surname>Schwartz</surname><given-names>CE</given-names></name><name><surname>Birk</surname><given-names>OS</given-names></name><name><surname>Bejerano</surname><given-names>G</given-names></name><name><surname>Lomvardas</surname><given-names>S</given-names></name><name><surname>Ahituv</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Coding exons function as tissue-specific enhancers of nearby genes</article-title><source>Genome Research</source><volume>22</volume><fpage>1059</fpage><lpage>1068</lpage><pub-id pub-id-type="doi">10.1101/gr.133546.111</pub-id><pub-id pub-id-type="pmid">22442009</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bray</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Notch signalling: a simple pathway becomes complex</article-title><source>Nature Reviews. Molecular Cell Biology</source><volume>7</volume><fpage>678</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.1038/nrm2009</pub-id><pub-id pub-id-type="pmid">16921404</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chavkin</surname><given-names>NW</given-names></name><name><surname>Genet</surname><given-names>G</given-names></name><name><surname>Poulet</surname><given-names>M</given-names></name><name><surname>Jeffery</surname><given-names>ED</given-names></name><name><surname>Marziano</surname><given-names>C</given-names></name><name><surname>Genet</surname><given-names>N</given-names></name><name><surname>Vasavada</surname><given-names>H</given-names></name><name><surname>Nelson</surname><given-names>EA</given-names></name><name><surname>Acharya</surname><given-names>BR</given-names></name><name><surname>Kour</surname><given-names>A</given-names></name><name><surname>Aragon</surname><given-names>J</given-names></name><name><surname>McDonnell</surname><given-names>SP</given-names></name><name><surname>Huba</surname><given-names>M</given-names></name><name><surname>Sheynkman</surname><given-names>GM</given-names></name><name><surname>Walsh</surname><given-names>K</given-names></name><name><surname>Hirschi</surname><given-names>KK</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Endothelial cell cycle state determines propensity for arterial-venous fate</article-title><source>Nature Communications</source><volume>13</volume><elocation-id>e5891</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-022-33324-7</pub-id><pub-id pub-id-type="pmid">36202789</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Fu</surname><given-names>Y</given-names></name><name><surname>Day</surname><given-names>DS</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Liang</surname><given-names>X</given-names></name><name><surname>Gu</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Stevens</surname><given-names>SM</given-names></name><name><surname>Zhou</surname><given-names>P</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>R-Z</given-names></name><name><surname>Smith</surname><given-names>LEH</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Sun</surname><given-names>K</given-names></name><name><surname>Melero-Martin</surname><given-names>JM</given-names></name><name><surname>Han</surname><given-names>Z</given-names></name><name><surname>Park</surname><given-names>PJ</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Pu</surname><given-names>WT</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>VEGF amplifies transcription through ETS1 acetylation to enable angiogenesis</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>383</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-017-00405-x</pub-id><pub-id pub-id-type="pmid">28851877</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>P-Y</given-names></name><name><surname>Qin</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Dahlman</surname><given-names>JE</given-names></name><name><surname>Malagon-Lopez</surname><given-names>J</given-names></name><name><surname>Gujja</surname><given-names>S</given-names></name><name><surname>Cilfone</surname><given-names>NA</given-names></name><name><surname>Kauffman</surname><given-names>KJ</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Sun</surname><given-names>H</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Aryal</surname><given-names>B</given-names></name><name><surname>Canfran-Duque</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Kusters</surname><given-names>P</given-names></name><name><surname>Sehgal</surname><given-names>A</given-names></name><name><surname>Jiao</surname><given-names>Y</given-names></name><name><surname>Anderson</surname><given-names>DG</given-names></name><name><surname>Gulcher</surname><given-names>J</given-names></name><name><surname>Fernandez-Hernando</surname><given-names>C</given-names></name><name><surname>Lutgens</surname><given-names>E</given-names></name><name><surname>Schwartz</surname><given-names>MA</given-names></name><name><surname>Pober</surname><given-names>JS</given-names></name><name><surname>Chittenden</surname><given-names>TW</given-names></name><name><surname>Tellides</surname><given-names>G</given-names></name><name><surname>Simons</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Endothelial TGF-β signalling drives vascular inflammation and atherosclerosis</article-title><source>Nature Metabolism</source><volume>1</volume><fpage>912</fpage><lpage>926</lpage><pub-id pub-id-type="doi">10.1038/s42255-019-0102-3</pub-id><pub-id pub-id-type="pmid">31572976</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>DeLaughter</surname><given-names>DM</given-names></name><name><surname>Trembley</surname><given-names>MA</given-names></name><name><surname>Saifee</surname><given-names>S</given-names></name><name><surname>Xiao</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>P</given-names></name><name><surname>Seidman</surname><given-names>CE</given-names></name><name><surname>Seidman</surname><given-names>JG</given-names></name><name><surname>Pu</surname><given-names>WT</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Molecular and spatial signatures of mouse embryonic endothelial cells at single-cell resolution</article-title><source>Circulation Research</source><volume>134</volume><fpage>529</fpage><lpage>546</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.123.323956</pub-id><pub-id pub-id-type="pmid">38348657</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="software"><person-group person-group-type="author"><name><surname>Cheshire</surname><given-names>C</given-names></name><name><surname>West</surname><given-names>C</given-names></name><name><surname>Rönkkö</surname><given-names>T</given-names></name><name><surname>Patel</surname><given-names>H</given-names></name><name><surname>Hodgetts</surname><given-names>T</given-names></name><name><surname>Ladd</surname><given-names>D</given-names></name><name><surname>Thiery</surname><given-names>A</given-names></name><name><surname>Fields</surname><given-names>C</given-names></name><name><surname>Deu-Pons</surname><given-names>J</given-names></name><name><surname>Ewels</surname><given-names>P</given-names></name><name><surname>Möller</surname><given-names>S</given-names></name><name><surname>Menden</surname><given-names>K</given-names></name><collab>nf-core bot</collab></person-group><year iso-8601-date="2023">2023</year><data-title>Nf-core/cutandrun</data-title><source>Zenodo</source><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.5281/zenodo.7715959">https://doi.org/10.5281/zenodo.7715959</ext-link></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chi</surname><given-names>NC</given-names></name><name><surname>Shaw</surname><given-names>RM</given-names></name><name><surname>De Val</surname><given-names>S</given-names></name><name><surname>Kang</surname><given-names>G</given-names></name><name><surname>Jan</surname><given-names>LY</given-names></name><name><surname>Black</surname><given-names>BL</given-names></name><name><surname>Stainier</surname><given-names>DYR</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Foxn4 directly regulates tbx2b expression and atrioventricular canal formation</article-title><source>Genes &amp; Development</source><volume>22</volume><fpage>734</fpage><lpage>739</lpage><pub-id pub-id-type="doi">10.1101/gad.1629408</pub-id><pub-id pub-id-type="pmid">18347092</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiang</surname><given-names>IK-N</given-names></name><name><surname>Fritzsche</surname><given-names>M</given-names></name><name><surname>Pichol-Thievend</surname><given-names>C</given-names></name><name><surname>Neal</surname><given-names>A</given-names></name><name><surname>Holmes</surname><given-names>K</given-names></name><name><surname>Lagendijk</surname><given-names>A</given-names></name><name><surname>Overman</surname><given-names>J</given-names></name><name><surname>D’Angelo</surname><given-names>D</given-names></name><name><surname>Omini</surname><given-names>A</given-names></name><name><surname>Hermkens</surname><given-names>D</given-names></name><name><surname>Lesieur</surname><given-names>E</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Ratnayaka</surname><given-names>I</given-names></name><name><surname>Corada</surname><given-names>M</given-names></name><name><surname>Bou-Gharios</surname><given-names>G</given-names></name><name><surname>Carroll</surname><given-names>J</given-names></name><name><surname>Dejana</surname><given-names>E</given-names></name><name><surname>Schulte-Merker</surname><given-names>S</given-names></name><name><surname>Hogan</surname><given-names>B</given-names></name><name><surname>Beltrame</surname><given-names>M</given-names></name><name><surname>De Val</surname><given-names>S</given-names></name><name><surname>Francois</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>SoxF factors induce Notch1 expression via direct transcriptional regulation during early arterial development</article-title><source>Development</source><volume>144</volume><fpage>2629</fpage><lpage>2639</lpage><pub-id pub-id-type="doi">10.1242/dev.146241</pub-id><pub-id pub-id-type="pmid">28619820</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiang</surname><given-names>IK</given-names></name><name><surname>Humphrey</surname><given-names>D</given-names></name><name><surname>Mills</surname><given-names>RJ</given-names></name><name><surname>Kaltzis</surname><given-names>P</given-names></name><name><surname>Pachauri</surname><given-names>S</given-names></name><name><surname>Graus</surname><given-names>M</given-names></name><name><surname>Saha</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Young</surname><given-names>P</given-names></name><name><surname>Sim</surname><given-names>CB</given-names></name><name><surname>Davidson</surname><given-names>T</given-names></name><name><surname>Hernandez-Garcia</surname><given-names>A</given-names></name><name><surname>Shaw</surname><given-names>CA</given-names></name><name><surname>Renwick</surname><given-names>A</given-names></name><name><surname>Scott</surname><given-names>DA</given-names></name><name><surname>Porrello</surname><given-names>ER</given-names></name><name><surname>Wong</surname><given-names>ES</given-names></name><name><surname>Hudson</surname><given-names>JE</given-names></name><name><surname>Red-Horse</surname><given-names>K</given-names></name><name><surname>Del Monte-Nieto</surname><given-names>G</given-names></name><name><surname>Francois</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Sox7-positive endothelial progenitors establish coronary arteries and govern ventricular compaction</article-title><source>EMBO Reports</source><volume>24</volume><elocation-id>e55043</elocation-id><pub-id pub-id-type="doi">10.15252/embr.202255043</pub-id><pub-id pub-id-type="pmid">37551717</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chong</surname><given-names>DC</given-names></name><name><surname>Koo</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>K</given-names></name><name><surname>Fu</surname><given-names>S</given-names></name><name><surname>Cleaver</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Stepwise arteriovenous fate acquisition during mammalian vasculogenesis</article-title><source>Developmental Dynamics</source><volume>240</volume><fpage>2153</fpage><lpage>2165</lpage><pub-id pub-id-type="doi">10.1002/dvdy.22706</pub-id><pub-id pub-id-type="pmid">21793101</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corada</surname><given-names>M</given-names></name><name><surname>Orsenigo</surname><given-names>F</given-names></name><name><surname>Morini</surname><given-names>MF</given-names></name><name><surname>Pitulescu</surname><given-names>ME</given-names></name><name><surname>Bhat</surname><given-names>G</given-names></name><name><surname>Nyqvist</surname><given-names>D</given-names></name><name><surname>Breviario</surname><given-names>F</given-names></name><name><surname>Conti</surname><given-names>V</given-names></name><name><surname>Briot</surname><given-names>A</given-names></name><name><surname>Iruela-Arispe</surname><given-names>ML</given-names></name><name><surname>Adams</surname><given-names>RH</given-names></name><name><surname>Dejana</surname><given-names>E</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Sox17 is indispensable for acquisition and maintenance of arterial identity</article-title><source>Nature Communications</source><volume>4</volume><elocation-id>2609</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms3609</pub-id><pub-id pub-id-type="pmid">24153254</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Daems</surname><given-names>M</given-names></name><name><surname>Ponomarev</surname><given-names>LC</given-names></name><name><surname>Simoes-Faria</surname><given-names>R</given-names></name><name><surname>Nobis</surname><given-names>M</given-names></name><name><surname>Scheele</surname><given-names>CLGJ</given-names></name><name><surname>Luttun</surname><given-names>A</given-names></name><name><surname>Ghesquière</surname><given-names>B</given-names></name><name><surname>Zwijsen</surname><given-names>A</given-names></name><name><surname>Jones</surname><given-names>EAV</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Smad1/5 is acetylated in the dorsal aortae of the mouse embryo before the onset of blood flow, driving early arterial gene expression</article-title><source>Cardiovascular Research</source><volume>120</volume><fpage>2078</fpage><lpage>2091</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvae201</pub-id><pub-id pub-id-type="pmid">39253943</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D’Amato</surname><given-names>G</given-names></name><name><surname>Phansalkar</surname><given-names>R</given-names></name><name><surname>Naftaly</surname><given-names>JA</given-names></name><name><surname>Fan</surname><given-names>X</given-names></name><name><surname>Amir</surname><given-names>ZA</given-names></name><name><surname>Rios Coronado</surname><given-names>PE</given-names></name><name><surname>Cowley</surname><given-names>DO</given-names></name><name><surname>Quinn</surname><given-names>KE</given-names></name><name><surname>Sharma</surname><given-names>B</given-names></name><name><surname>Caron</surname><given-names>KM</given-names></name><name><surname>Vigilante</surname><given-names>A</given-names></name><name><surname>Red-Horse</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Endocardium-to-coronary artery differentiation during heart development and regeneration involves sequential roles of Bmp2 and Cxcl12/Cxcr4</article-title><source>Developmental Cell</source><volume>57</volume><fpage>2517</fpage><lpage>2532</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2022.10.007</pub-id><pub-id pub-id-type="pmid">36347256</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Goldstone</surname><given-names>AB</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Farry</surname><given-names>J</given-names></name><name><surname>D’Amato</surname><given-names>G</given-names></name><name><surname>Paulsen</surname><given-names>MJ</given-names></name><name><surname>Eskandari</surname><given-names>A</given-names></name><name><surname>Hironaka</surname><given-names>CE</given-names></name><name><surname>Phansalkar</surname><given-names>R</given-names></name><name><surname>Sharma</surname><given-names>B</given-names></name><name><surname>Rhee</surname><given-names>S</given-names></name><name><surname>Shamskhou</surname><given-names>EA</given-names></name><name><surname>Agalliu</surname><given-names>D</given-names></name><name><surname>de Jesus Perez</surname><given-names>V</given-names></name><name><surname>Woo</surname><given-names>YJ</given-names></name><name><surname>Red-Horse</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A unique collateral artery development program promotes neonatal heart regeneration</article-title><source>Cell</source><volume>176</volume><fpage>1128</fpage><lpage>1142</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2018.12.023</pub-id><pub-id pub-id-type="pmid">30686582</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Val</surname><given-names>S</given-names></name><name><surname>Chi</surname><given-names>NC</given-names></name><name><surname>Meadows</surname><given-names>SM</given-names></name><name><surname>Minovitsky</surname><given-names>S</given-names></name><name><surname>Anderson</surname><given-names>JP</given-names></name><name><surname>Harris</surname><given-names>IS</given-names></name><name><surname>Ehlers</surname><given-names>ML</given-names></name><name><surname>Agarwal</surname><given-names>P</given-names></name><name><surname>Visel</surname><given-names>A</given-names></name><name><surname>Xu</surname><given-names>SM</given-names></name><name><surname>Pennacchio</surname><given-names>LA</given-names></name><name><surname>Dubchak</surname><given-names>I</given-names></name><name><surname>Krieg</surname><given-names>PA</given-names></name><name><surname>Stainier</surname><given-names>DYR</given-names></name><name><surname>Black</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Combinatorial regulation of endothelial gene expression by ets and forkhead transcription factors</article-title><source>Cell</source><volume>135</volume><fpage>1053</fpage><lpage>1064</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2008.10.049</pub-id><pub-id pub-id-type="pmid">19070576</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engelbrecht</surname><given-names>E</given-names></name><name><surname>Levesque</surname><given-names>MV</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Vanlandewijck</surname><given-names>M</given-names></name><name><surname>Nitzsche</surname><given-names>A</given-names></name><name><surname>Niazi</surname><given-names>H</given-names></name><name><surname>Kuo</surname><given-names>A</given-names></name><name><surname>Singh</surname><given-names>SA</given-names></name><name><surname>Aikawa</surname><given-names>M</given-names></name><name><surname>Holton</surname><given-names>K</given-names></name><name><surname>Proia</surname><given-names>RL</given-names></name><name><surname>Kono</surname><given-names>M</given-names></name><name><surname>Pu</surname><given-names>WT</given-names></name><name><surname>Camerer</surname><given-names>E</given-names></name><name><surname>Betsholtz</surname><given-names>C</given-names></name><name><surname>Hla</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Sphingosine 1-phosphate-regulated transcriptomes in heterogenous arterial and lymphatic endothelium of the aorta</article-title><source>eLife</source><volume>9</volume><elocation-id>e52690</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.52690</pub-id><pub-id pub-id-type="pmid">32091396</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ewels</surname><given-names>PA</given-names></name><name><surname>Peltzer</surname><given-names>A</given-names></name><name><surname>Fillinger</surname><given-names>S</given-names></name><name><surname>Patel</surname><given-names>H</given-names></name><name><surname>Alneberg</surname><given-names>J</given-names></name><name><surname>Wilm</surname><given-names>A</given-names></name><name><surname>Garcia</surname><given-names>MU</given-names></name><name><surname>Di Tommaso</surname><given-names>P</given-names></name><name><surname>Nahnsen</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>The nf-core framework for community-curated bioinformatics pipelines</article-title><source>Nature Biotechnology</source><volume>38</volume><fpage>276</fpage><lpage>278</lpage><pub-id pub-id-type="doi">10.1038/s41587-020-0439-x</pub-id><pub-id pub-id-type="pmid">32055031</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fang</surname><given-names>JS</given-names></name><name><surname>Coon</surname><given-names>BG</given-names></name><name><surname>Gillis</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Qiu</surname><given-names>J</given-names></name><name><surname>Chittenden</surname><given-names>TW</given-names></name><name><surname>Burt</surname><given-names>JM</given-names></name><name><surname>Schwartz</surname><given-names>MA</given-names></name><name><surname>Hirschi</surname><given-names>KK</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Shear-induced Notch-Cx37-p27 axis arrests endothelial cell cycle to enable arterial specification</article-title><source>Nature Communications</source><volume>8</volume><elocation-id>2149</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-017-01742-7</pub-id><pub-id pub-id-type="pmid">29247167</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>François</surname><given-names>M</given-names></name><name><surname>Caprini</surname><given-names>A</given-names></name><name><surname>Hosking</surname><given-names>B</given-names></name><name><surname>Orsenigo</surname><given-names>F</given-names></name><name><surname>Wilhelm</surname><given-names>D</given-names></name><name><surname>Browne</surname><given-names>C</given-names></name><name><surname>Paavonen</surname><given-names>K</given-names></name><name><surname>Karnezis</surname><given-names>T</given-names></name><name><surname>Shayan</surname><given-names>R</given-names></name><name><surname>Downes</surname><given-names>M</given-names></name><name><surname>Davidson</surname><given-names>T</given-names></name><name><surname>Tutt</surname><given-names>D</given-names></name><name><surname>Cheah</surname><given-names>KSE</given-names></name><name><surname>Stacker</surname><given-names>SA</given-names></name><name><surname>Muscat</surname><given-names>GEO</given-names></name><name><surname>Achen</surname><given-names>MG</given-names></name><name><surname>Dejana</surname><given-names>E</given-names></name><name><surname>Koopman</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Sox18 induces development of the lymphatic vasculature in mice</article-title><source>Nature</source><volume>456</volume><fpage>643</fpage><lpage>647</lpage><pub-id pub-id-type="doi">10.1038/nature07391</pub-id><pub-id pub-id-type="pmid">18931657</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Francois</surname><given-names>M</given-names></name><name><surname>Koopman</surname><given-names>P</given-names></name><name><surname>Beltrame</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>SoxF genes: key players in the development of the cardio-vascular system</article-title><source>The International Journal of Biochemistry &amp; Cell Biology</source><volume>42</volume><fpage>445</fpage><lpage>448</lpage><pub-id pub-id-type="doi">10.1016/j.biocel.2009.08.017</pub-id><pub-id pub-id-type="pmid">19733255</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujita</surname><given-names>M</given-names></name><name><surname>Cha</surname><given-names>YR</given-names></name><name><surname>Pham</surname><given-names>VN</given-names></name><name><surname>Sakurai</surname><given-names>A</given-names></name><name><surname>Roman</surname><given-names>BL</given-names></name><name><surname>Gutkind</surname><given-names>JS</given-names></name><name><surname>Weinstein</surname><given-names>BM</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Assembly and patterning of the vascular network of the vertebrate hindbrain</article-title><source>Development</source><volume>138</volume><fpage>1705</fpage><lpage>1715</lpage><pub-id pub-id-type="doi">10.1242/dev.058776</pub-id><pub-id pub-id-type="pmid">21429985</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>González-Hernández</surname><given-names>S</given-names></name><name><surname>Gómez</surname><given-names>MJ</given-names></name><name><surname>Sánchez-Cabo</surname><given-names>F</given-names></name><name><surname>Méndez-Ferrer</surname><given-names>S</given-names></name><name><surname>Muñoz-Cánoves</surname><given-names>P</given-names></name><name><surname>Isern</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Sox17 controls emergence and remodeling of nestin-expressing coronary vessels</article-title><source>Circulation Research</source><volume>127</volume><fpage>e252</fpage><lpage>e270</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.120.317121</pub-id><pub-id pub-id-type="pmid">32921258</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Grego-Bessa</surname><given-names>J</given-names></name><name><surname>Luna-Zurita</surname><given-names>L</given-names></name><name><surname>del Monte</surname><given-names>G</given-names></name><name><surname>Bolós</surname><given-names>V</given-names></name><name><surname>Melgar</surname><given-names>P</given-names></name><name><surname>Arandilla</surname><given-names>A</given-names></name><name><surname>Garratt</surname><given-names>AN</given-names></name><name><surname>Zang</surname><given-names>H</given-names></name><name><surname>Mukouyama</surname><given-names>Y-S</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Shou</surname><given-names>W</given-names></name><name><surname>Ballestar</surname><given-names>E</given-names></name><name><surname>Esteller</surname><given-names>M</given-names></name><name><surname>Rojas</surname><given-names>A</given-names></name><name><surname>Pérez-Pomares</surname><given-names>JM</given-names></name><name><surname>de la Pompa</surname><given-names>JL</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Notch signaling is essential for ventricular chamber development</article-title><source>Developmental Cell</source><volume>12</volume><fpage>415</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2006.12.011</pub-id><pub-id pub-id-type="pmid">17336907</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hao</surname><given-names>Y</given-names></name><name><surname>Stuart</surname><given-names>T</given-names></name><name><surname>Kowalski</surname><given-names>MH</given-names></name><name><surname>Choudhary</surname><given-names>S</given-names></name><name><surname>Hoffman</surname><given-names>P</given-names></name><name><surname>Hartman</surname><given-names>A</given-names></name><name><surname>Srivastava</surname><given-names>A</given-names></name><name><surname>Molla</surname><given-names>G</given-names></name><name><surname>Madad</surname><given-names>S</given-names></name><name><surname>Fernandez-Granda</surname><given-names>C</given-names></name><name><surname>Satija</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Dictionary learning for integrative, multimodal and scalable single-cell analysis</article-title><source>Nature Biotechnology</source><volume>42</volume><fpage>293</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1038/s41587-023-01767-y</pub-id><pub-id pub-id-type="pmid">37231261</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hasan</surname><given-names>SS</given-names></name><name><surname>Tsaryk</surname><given-names>R</given-names></name><name><surname>Lange</surname><given-names>M</given-names></name><name><surname>Wisniewski</surname><given-names>L</given-names></name><name><surname>Moore</surname><given-names>JC</given-names></name><name><surname>Lawson</surname><given-names>ND</given-names></name><name><surname>Wojciechowska</surname><given-names>K</given-names></name><name><surname>Schnittler</surname><given-names>H</given-names></name><name><surname>Siekmann</surname><given-names>AF</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Endothelial Notch signalling limits angiogenesis via control of artery formation</article-title><source>Nature Cell Biology</source><volume>19</volume><fpage>928</fpage><lpage>940</lpage><pub-id pub-id-type="doi">10.1038/ncb3574</pub-id><pub-id pub-id-type="pmid">28714969</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hashiura</surname><given-names>T</given-names></name><name><surname>Kimura</surname><given-names>E</given-names></name><name><surname>Fujisawa</surname><given-names>S</given-names></name><name><surname>Oikawa</surname><given-names>S</given-names></name><name><surname>Nonaka</surname><given-names>S</given-names></name><name><surname>Kurosaka</surname><given-names>D</given-names></name><name><surname>Hitomi</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Live imaging of primary ocular vasculature formation in zebrafish</article-title><source>PLOS ONE</source><volume>12</volume><elocation-id>e0176456</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0176456</pub-id><pub-id pub-id-type="pmid">28445524</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heinz</surname><given-names>S</given-names></name><name><surname>Benner</surname><given-names>C</given-names></name><name><surname>Spann</surname><given-names>N</given-names></name><name><surname>Bertolino</surname><given-names>E</given-names></name><name><surname>Lin</surname><given-names>YC</given-names></name><name><surname>Laslo</surname><given-names>P</given-names></name><name><surname>Cheng</surname><given-names>JX</given-names></name><name><surname>Murre</surname><given-names>C</given-names></name><name><surname>Singh</surname><given-names>H</given-names></name><name><surname>Glass</surname><given-names>CK</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities</article-title><source>Molecular Cell</source><volume>38</volume><fpage>576</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2010.05.004</pub-id><pub-id pub-id-type="pmid">20513432</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hogan</surname><given-names>NT</given-names></name><name><surname>Whalen</surname><given-names>MB</given-names></name><name><surname>Stolze</surname><given-names>LK</given-names></name><name><surname>Hadeli</surname><given-names>NK</given-names></name><name><surname>Lam</surname><given-names>MT</given-names></name><name><surname>Springstead</surname><given-names>JR</given-names></name><name><surname>Glass</surname><given-names>CK</given-names></name><name><surname>Romanoski</surname><given-names>CE</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Transcriptional networks specifying homeostatic and inflammatory programs of gene expression in human aortic endothelial cells</article-title><source>eLife</source><volume>6</volume><elocation-id>e22536</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.22536</pub-id><pub-id pub-id-type="pmid">28585919</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hosking</surname><given-names>B</given-names></name><name><surname>François</surname><given-names>M</given-names></name><name><surname>Wilhelm</surname><given-names>D</given-names></name><name><surname>Orsenigo</surname><given-names>F</given-names></name><name><surname>Caprini</surname><given-names>A</given-names></name><name><surname>Svingen</surname><given-names>T</given-names></name><name><surname>Tutt</surname><given-names>D</given-names></name><name><surname>Davidson</surname><given-names>T</given-names></name><name><surname>Browne</surname><given-names>C</given-names></name><name><surname>Dejana</surname><given-names>E</given-names></name><name><surname>Koopman</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Sox7 and Sox17 are strain-specific modifiers of the lymphangiogenic defects caused by Sox18 dysfunction in mice</article-title><source>Development</source><volume>136</volume><fpage>2385</fpage><lpage>2391</lpage><pub-id pub-id-type="doi">10.1242/dev.034827</pub-id><pub-id pub-id-type="pmid">19515696</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hou</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Dong</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name><name><surname>Chang</surname><given-names>Z</given-names></name><name><surname>Ding</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Zeng</surname><given-names>Y</given-names></name><name><surname>Xin</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>B</given-names></name><name><surname>Ni</surname><given-names>Y</given-names></name><name><surname>Ning</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Fan</surname><given-names>X</given-names></name><name><surname>Hou</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Wen</surname><given-names>L</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Tang</surname><given-names>F</given-names></name><name><surname>Lan</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Heterogeneity in endothelial cells and widespread venous arterialization during early vascular development in mammals</article-title><source>Cell Research</source><volume>32</volume><fpage>333</fpage><lpage>348</lpage><pub-id pub-id-type="doi">10.1038/s41422-022-00615-z</pub-id><pub-id pub-id-type="pmid">35079138</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hwa</surname><given-names>JJ</given-names></name><name><surname>Beckouche</surname><given-names>N</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Kram</surname><given-names>Y</given-names></name><name><surname>Lindskog</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>RA</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Abnormal arterial-venous fusions and fate specification in mouse embryos lacking blood flow</article-title><source>Scientific Reports</source><volume>7</volume><elocation-id>e11965</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-017-12353-z</pub-id><pub-id pub-id-type="pmid">28931948</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaufman</surname><given-names>R</given-names></name><name><surname>Weiss</surname><given-names>O</given-names></name><name><surname>Sebbagh</surname><given-names>M</given-names></name><name><surname>Ravid</surname><given-names>R</given-names></name><name><surname>Gibbs-Bar</surname><given-names>L</given-names></name><name><surname>Yaniv</surname><given-names>K</given-names></name><name><surname>Inbal</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Development and origins of zebrafish ocular vasculature</article-title><source>BMC Developmental Biology</source><volume>15</volume><elocation-id>e18</elocation-id><pub-id pub-id-type="doi">10.1186/s12861-015-0066-9</pub-id><pub-id pub-id-type="pmid">25888280</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kawakami</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Transposon tools and methods in zebrafish</article-title><source>Developmental Dynamics</source><volume>234</volume><fpage>244</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.1002/dvdy.20516</pub-id><pub-id pub-id-type="pmid">16110506</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>K</given-names></name><name><surname>Kim</surname><given-names>I-K</given-names></name><name><surname>Yang</surname><given-names>JM</given-names></name><name><surname>Lee</surname><given-names>E</given-names></name><name><surname>Koh</surname><given-names>BI</given-names></name><name><surname>Song</surname><given-names>S</given-names></name><name><surname>Park</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Choi</surname><given-names>C</given-names></name><name><surname>Kim</surname><given-names>JW</given-names></name><name><surname>Kubota</surname><given-names>Y</given-names></name><name><surname>Koh</surname><given-names>GY</given-names></name><name><surname>Kim</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>SoxF transcription factors are positive feedback regulators of VEGF signaling</article-title><source>Circulation Research</source><volume>119</volume><fpage>839</fpage><lpage>852</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.116.308483</pub-id><pub-id pub-id-type="pmid">27528602</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawson</surname><given-names>ND</given-names></name><name><surname>Scheer</surname><given-names>N</given-names></name><name><surname>Pham</surname><given-names>VN</given-names></name><name><surname>Kim</surname><given-names>CH</given-names></name><name><surname>Chitnis</surname><given-names>AB</given-names></name><name><surname>Campos-Ortega</surname><given-names>JA</given-names></name><name><surname>Weinstein</surname><given-names>BM</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Notch signaling is required for arterial-venous differentiation during embryonic vascular development</article-title><source>Development</source><volume>128</volume><fpage>3675</fpage><lpage>3683</lpage><pub-id pub-id-type="doi">10.1242/dev.128.19.3675</pub-id><pub-id pub-id-type="pmid">11585794</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>S-H</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Song</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>K</given-names></name><name><surname>Saunders</surname><given-names>TL</given-names></name><name><surname>Yoon</surname><given-names>JK</given-names></name><name><surname>Koh</surname><given-names>GY</given-names></name><name><surname>Kim</surname><given-names>I</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Notch pathway targets proangiogenic regulator Sox17 to restrict angiogenesis</article-title><source>Circulation Research</source><volume>115</volume><fpage>215</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.115.303142</pub-id><pub-id pub-id-type="pmid">24755984</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>H-W</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>L</given-names></name><name><surname>Choi</surname><given-names>W</given-names></name><name><surname>Gonzalez</surname><given-names>D</given-names></name><name><surname>Jin</surname><given-names>S-W</given-names></name><name><surname>Simons</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Role of venous endothelial cells in developmental and pathologic angiogenesis</article-title><source>Circulation</source><volume>144</volume><fpage>1308</fpage><lpage>1322</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.121.054071</pub-id><pub-id pub-id-type="pmid">34474596</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lilly</surname><given-names>AJ</given-names></name><name><surname>Mazan</surname><given-names>A</given-names></name><name><surname>Scott</surname><given-names>DA</given-names></name><name><surname>Lacaud</surname><given-names>G</given-names></name><name><surname>Kouskoff</surname><given-names>V</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>SOX7 expression is critically required in FLK1-expressing cells for vasculogenesis and angiogenesis during mouse embryonic development</article-title><source>Mechanisms of Development</source><volume>146</volume><fpage>31</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.mod.2017.05.004</pub-id><pub-id pub-id-type="pmid">28577909</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2019">2019</year><source>Library prep for CUT&amp;RUN with nebnext ultra</source><publisher-name>protocol</publisher-name><pub-id pub-id-type="doi">10.17504/protocols.io.bagaibse</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>YW</given-names></name><name><surname>Martino</surname><given-names>N</given-names></name><name><surname>Gerlach</surname><given-names>BD</given-names></name><name><surname>Lamar</surname><given-names>JM</given-names></name><name><surname>Vincent</surname><given-names>PA</given-names></name><name><surname>Adam</surname><given-names>AP</given-names></name><name><surname>Schwarz</surname><given-names>JJ</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>MEF2 (myocyte enhancer factor 2) is essential for endothelial homeostasis and the atheroprotective gene expression program</article-title><source>Arteriosclerosis, Thrombosis, and Vascular Biology</source><volume>41</volume><fpage>1105</fpage><lpage>1123</lpage><pub-id pub-id-type="doi">10.1161/ATVBAHA.120.314978</pub-id><pub-id pub-id-type="pmid">33406884</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luo</surname><given-names>W</given-names></name><name><surname>Garcia-Gonzalez</surname><given-names>I</given-names></name><name><surname>Fernández-Chacón</surname><given-names>M</given-names></name><name><surname>Casquero-Garcia</surname><given-names>V</given-names></name><name><surname>Sanchez-Muñoz</surname><given-names>MS</given-names></name><name><surname>Mühleder</surname><given-names>S</given-names></name><name><surname>Garcia-Ortega</surname><given-names>L</given-names></name><name><surname>Andrade</surname><given-names>J</given-names></name><name><surname>Potente</surname><given-names>M</given-names></name><name><surname>Benedito</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Arterialization requires the timely suppression of cell growth</article-title><source>Nature</source><volume>589</volume><fpage>437</fpage><lpage>441</lpage><pub-id pub-id-type="doi">10.1038/s41586-020-3018-x</pub-id><pub-id pub-id-type="pmid">33299176</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maejima</surname><given-names>T</given-names></name><name><surname>Inoue</surname><given-names>T</given-names></name><name><surname>Kanki</surname><given-names>Y</given-names></name><name><surname>Kohro</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Ohta</surname><given-names>Y</given-names></name><name><surname>Kimura</surname><given-names>H</given-names></name><name><surname>Kobayashi</surname><given-names>M</given-names></name><name><surname>Taguchi</surname><given-names>A</given-names></name><name><surname>Tsutsumi</surname><given-names>S</given-names></name><name><surname>Iwanari</surname><given-names>H</given-names></name><name><surname>Yamamoto</surname><given-names>S</given-names></name><name><surname>Aruga</surname><given-names>H</given-names></name><name><surname>Dong</surname><given-names>S</given-names></name><name><surname>Stevens</surname><given-names>JF</given-names></name><name><surname>Poh</surname><given-names>HM</given-names></name><name><surname>Yamamoto</surname><given-names>K</given-names></name><name><surname>Kawamura</surname><given-names>T</given-names></name><name><surname>Mimura</surname><given-names>I</given-names></name><name><surname>Suehiro</surname><given-names>J</given-names></name><name><surname>Sugiyama</surname><given-names>A</given-names></name><name><surname>Kaneki</surname><given-names>K</given-names></name><name><surname>Shibata</surname><given-names>H</given-names></name><name><surname>Yoshinaka</surname><given-names>Y</given-names></name><name><surname>Doi</surname><given-names>T</given-names></name><name><surname>Asanuma</surname><given-names>A</given-names></name><name><surname>Tanabe</surname><given-names>S</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>Minami</surname><given-names>T</given-names></name><name><surname>Hamakubo</surname><given-names>T</given-names></name><name><surname>Sakai</surname><given-names>J</given-names></name><name><surname>Nozaki</surname><given-names>N</given-names></name><name><surname>Aburatani</surname><given-names>H</given-names></name><name><surname>Nangaku</surname><given-names>M</given-names></name><name><surname>Ruan</surname><given-names>X</given-names></name><name><surname>Tanabe</surname><given-names>H</given-names></name><name><surname>Ruan</surname><given-names>Y</given-names></name><name><surname>Ihara</surname><given-names>S</given-names></name><name><surname>Endo</surname><given-names>A</given-names></name><name><surname>Kodama</surname><given-names>T</given-names></name><name><surname>Wada</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Direct evidence for pitavastatin induced chromatin structure change in the KLF4 gene in endothelial cells</article-title><source>PLOS ONE</source><volume>9</volume><elocation-id>e96005</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0096005</pub-id><pub-id pub-id-type="pmid">24797675</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marín-Juez</surname><given-names>R</given-names></name><name><surname>Marass</surname><given-names>M</given-names></name><name><surname>Gauvrit</surname><given-names>S</given-names></name><name><surname>Rossi</surname><given-names>A</given-names></name><name><surname>Lai</surname><given-names>S-L</given-names></name><name><surname>Materna</surname><given-names>SC</given-names></name><name><surname>Black</surname><given-names>BL</given-names></name><name><surname>Stainier</surname><given-names>DYR</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Fast revascularization of the injured area is essential to support zebrafish heart regeneration</article-title><source>PNAS</source><volume>113</volume><fpage>11237</fpage><lpage>11242</lpage><pub-id pub-id-type="doi">10.1073/pnas.1605431113</pub-id><pub-id pub-id-type="pmid">27647901</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCarthy</surname><given-names>DJ</given-names></name><name><surname>Campbell</surname><given-names>KR</given-names></name><name><surname>Lun</surname><given-names>ATL</given-names></name><name><surname>Wills</surname><given-names>QF</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Scater: pre-processing, quality control, normalization and visualization of single-cell RNA-seq data in R</article-title><source>Bioinformatics</source><volume>33</volume><fpage>1179</fpage><lpage>1186</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btw777</pub-id><pub-id pub-id-type="pmid">28088763</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCracken</surname><given-names>IR</given-names></name><name><surname>Dobie</surname><given-names>R</given-names></name><name><surname>Bennett</surname><given-names>M</given-names></name><name><surname>Passi</surname><given-names>R</given-names></name><name><surname>Beqqali</surname><given-names>A</given-names></name><name><surname>Henderson</surname><given-names>NC</given-names></name><name><surname>Mountford</surname><given-names>JC</given-names></name><name><surname>Riley</surname><given-names>PR</given-names></name><name><surname>Ponting</surname><given-names>CP</given-names></name><name><surname>Smart</surname><given-names>N</given-names></name><name><surname>Brittan</surname><given-names>M</given-names></name><name><surname>Baker</surname><given-names>AH</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Mapping the developing human cardiac endothelium at single-cell resolution identifies MECOM as a regulator of arteriovenous gene expression</article-title><source>Cardiovascular Research</source><volume>118</volume><fpage>2960</fpage><lpage>2972</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvac023</pub-id><pub-id pub-id-type="pmid">35212715</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McCracken</surname><given-names>IR</given-names></name><name><surname>Baker</surname><given-names>AH</given-names></name><name><surname>Smart</surname><given-names>N</given-names></name><name><surname>De Val</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>Transcriptional regulators of arterial and venous identity in the developing mammalian embryo</article-title><source>Current Opinion in Physiology</source><volume>35</volume><elocation-id>e100691</elocation-id><pub-id pub-id-type="doi">10.1016/j.cophys.2023.100691</pub-id><pub-id pub-id-type="pmid">38328689</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Meers</surname><given-names>MP</given-names></name><name><surname>Tenenbaum</surname><given-names>D</given-names></name><name><surname>Henikoff</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Peak calling by Sparse Enrichment Analysis for CUT&amp;RUN chromatin profiling</article-title><source>Epigenetics &amp; Chromatin</source><volume>12</volume><elocation-id>e42</elocation-id><pub-id pub-id-type="doi">10.1186/s13072-019-0287-4</pub-id><pub-id pub-id-type="pmid">31300027</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Morikawa</surname><given-names>M</given-names></name><name><surname>Koinuma</surname><given-names>D</given-names></name><name><surname>Tsutsumi</surname><given-names>S</given-names></name><name><surname>Vasilaki</surname><given-names>E</given-names></name><name><surname>Kanki</surname><given-names>Y</given-names></name><name><surname>Heldin</surname><given-names>C-H</given-names></name><name><surname>Aburatani</surname><given-names>H</given-names></name><name><surname>Miyazono</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>ChIP-seq reveals cell type-specific binding patterns of BMP-specific Smads and a novel binding motif</article-title><source>Nucleic Acids Research</source><volume>39</volume><fpage>8712</fpage><lpage>8727</lpage><pub-id pub-id-type="doi">10.1093/nar/gkr572</pub-id><pub-id pub-id-type="pmid">21764776</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neal</surname><given-names>A</given-names></name><name><surname>Nornes</surname><given-names>S</given-names></name><name><surname>Payne</surname><given-names>S</given-names></name><name><surname>Wallace</surname><given-names>MD</given-names></name><name><surname>Fritzsche</surname><given-names>M</given-names></name><name><surname>Louphrasitthiphol</surname><given-names>P</given-names></name><name><surname>Wilkinson</surname><given-names>RN</given-names></name><name><surname>Chouliaras</surname><given-names>KM</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Plant</surname><given-names>K</given-names></name><name><surname>Sholapurkar</surname><given-names>R</given-names></name><name><surname>Ratnayaka</surname><given-names>I</given-names></name><name><surname>Herzog</surname><given-names>W</given-names></name><name><surname>Bond</surname><given-names>G</given-names></name><name><surname>Chico</surname><given-names>T</given-names></name><name><surname>Bou-Gharios</surname><given-names>G</given-names></name><name><surname>De Val</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Venous identity requires BMP signalling through ALK3</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>e453</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-08315-w</pub-id><pub-id pub-id-type="pmid">30692543</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Neal</surname><given-names>A</given-names></name><name><surname>Nornes</surname><given-names>S</given-names></name><name><surname>Louphrasitthiphol</surname><given-names>P</given-names></name><name><surname>Sacilotto</surname><given-names>N</given-names></name><name><surname>Preston</surname><given-names>MD</given-names></name><name><surname>Fleisinger</surname><given-names>L</given-names></name><name><surname>Payne</surname><given-names>S</given-names></name><name><surname>De Val</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>ETS factors are required but not sufficient for specific patterns of enhancer activity in different endothelial subtypes</article-title><source>Developmental Biology</source><volume>473</volume><fpage>1</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2021.01.002</pub-id><pub-id pub-id-type="pmid">33453264</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nordin</surname><given-names>A</given-names></name><name><surname>Zambanini</surname><given-names>G</given-names></name><name><surname>Pagella</surname><given-names>P</given-names></name><name><surname>Cantù</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2023">2023</year><article-title>The CUT&amp;RUN suspect list of problematic regions of the genome</article-title><source>Genome Biology</source><volume>24</volume><elocation-id>185</elocation-id><pub-id pub-id-type="doi">10.1186/s13059-023-03027-3</pub-id><pub-id pub-id-type="pmid">37563719</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Oki</surname><given-names>S</given-names></name><name><surname>Ohta</surname><given-names>T</given-names></name><name><surname>Shioi</surname><given-names>G</given-names></name><name><surname>Hatanaka</surname><given-names>H</given-names></name><name><surname>Ogasawara</surname><given-names>O</given-names></name><name><surname>Okuda</surname><given-names>Y</given-names></name><name><surname>Kawaji</surname><given-names>H</given-names></name><name><surname>Nakaki</surname><given-names>R</given-names></name><name><surname>Sese</surname><given-names>J</given-names></name><name><surname>Meno</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>ChIP-Atlas: a data-mining suite powered by full integration of public ChIP-seq data</article-title><source>EMBO Reports</source><volume>19</volume><elocation-id>e46255</elocation-id><pub-id pub-id-type="doi">10.15252/embr.201846255</pub-id><pub-id pub-id-type="pmid">30413482</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ola</surname><given-names>R</given-names></name><name><surname>Künzel</surname><given-names>SH</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Genet</surname><given-names>G</given-names></name><name><surname>Chakraborty</surname><given-names>R</given-names></name><name><surname>Pibouin-Fragner</surname><given-names>L</given-names></name><name><surname>Martin</surname><given-names>K</given-names></name><name><surname>Sessa</surname><given-names>W</given-names></name><name><surname>Dubrac</surname><given-names>A</given-names></name><name><surname>Eichmann</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>SMAD4 prevents flow induced arteriovenous malformations by inhibiting casein kinase 2</article-title><source>Circulation</source><volume>138</volume><fpage>2379</fpage><lpage>2394</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.118.033842</pub-id><pub-id pub-id-type="pmid">29976569</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Overman</surname><given-names>J</given-names></name><name><surname>Fontaine</surname><given-names>F</given-names></name><name><surname>Moustaqil</surname><given-names>M</given-names></name><name><surname>Mittal</surname><given-names>D</given-names></name><name><surname>Sierecki</surname><given-names>E</given-names></name><name><surname>Sacilotto</surname><given-names>N</given-names></name><name><surname>Zuegg</surname><given-names>J</given-names></name><name><surname>Robertson</surname><given-names>AAB</given-names></name><name><surname>Holmes</surname><given-names>K</given-names></name><name><surname>Salim</surname><given-names>AA</given-names></name><name><surname>Mamidyala</surname><given-names>S</given-names></name><name><surname>Butler</surname><given-names>MS</given-names></name><name><surname>Robinson</surname><given-names>AS</given-names></name><name><surname>Lesieur</surname><given-names>E</given-names></name><name><surname>Johnston</surname><given-names>W</given-names></name><name><surname>Alexandrov</surname><given-names>K</given-names></name><name><surname>Black</surname><given-names>BL</given-names></name><name><surname>Hogan</surname><given-names>BM</given-names></name><name><surname>De Val</surname><given-names>S</given-names></name><name><surname>Capon</surname><given-names>RJ</given-names></name><name><surname>Carroll</surname><given-names>JS</given-names></name><name><surname>Bailey</surname><given-names>TL</given-names></name><name><surname>Koopman</surname><given-names>P</given-names></name><name><surname>Jauch</surname><given-names>R</given-names></name><name><surname>Cooper</surname><given-names>MA</given-names></name><name><surname>Gambin</surname><given-names>Y</given-names></name><name><surname>Francois</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Pharmacological targeting of the transcription factor SOX18 delays breast cancer in mice</article-title><source>eLife</source><volume>6</volume><elocation-id>e21221</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.21221</pub-id><pub-id pub-id-type="pmid">28137359</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Payne</surname><given-names>S</given-names></name><name><surname>Gunadasa-Rohling</surname><given-names>M</given-names></name><name><surname>Neal</surname><given-names>A</given-names></name><name><surname>Redpath</surname><given-names>AN</given-names></name><name><surname>Patel</surname><given-names>J</given-names></name><name><surname>Chouliaras</surname><given-names>KM</given-names></name><name><surname>Ratnayaka</surname><given-names>I</given-names></name><name><surname>Smart</surname><given-names>N</given-names></name><name><surname>De Val</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Regulatory pathways governing murine coronary vessel formation are dysregulated in the injured adult heart</article-title><source>Nature Communications</source><volume>10</volume><elocation-id>e3276</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-019-10710-2</pub-id><pub-id pub-id-type="pmid">31332177</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Payne</surname><given-names>S</given-names></name><name><surname>Neal</surname><given-names>A</given-names></name><name><surname>De Val</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Transcription factors regulating vasculogenesis and angiogenesis</article-title><source>Developmental Dynamics</source><volume>253</volume><fpage>28</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1002/dvdy.575</pub-id><pub-id pub-id-type="pmid">36795082</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pennacchio</surname><given-names>LA</given-names></name><name><surname>Ahituv</surname><given-names>N</given-names></name><name><surname>Moses</surname><given-names>AM</given-names></name><name><surname>Prabhakar</surname><given-names>S</given-names></name><name><surname>Nobrega</surname><given-names>MA</given-names></name><name><surname>Shoukry</surname><given-names>M</given-names></name><name><surname>Minovitsky</surname><given-names>S</given-names></name><name><surname>Dubchak</surname><given-names>I</given-names></name><name><surname>Holt</surname><given-names>A</given-names></name><name><surname>Lewis</surname><given-names>KD</given-names></name><name><surname>Plajzer-Frick</surname><given-names>I</given-names></name><name><surname>Akiyama</surname><given-names>J</given-names></name><name><surname>De Val</surname><given-names>S</given-names></name><name><surname>Afzal</surname><given-names>V</given-names></name><name><surname>Black</surname><given-names>BL</given-names></name><name><surname>Couronne</surname><given-names>O</given-names></name><name><surname>Eisen</surname><given-names>MB</given-names></name><name><surname>Visel</surname><given-names>A</given-names></name><name><surname>Rubin</surname><given-names>EM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>In vivo enhancer analysis of human conserved non-coding sequences</article-title><source>Nature</source><volume>444</volume><fpage>499</fpage><lpage>502</lpage><pub-id pub-id-type="doi">10.1038/nature05295</pub-id><pub-id pub-id-type="pmid">17086198</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pfleger</surname><given-names>J</given-names></name><name><surname>Coleman</surname><given-names>RC</given-names></name><name><surname>Ibetti</surname><given-names>J</given-names></name><name><surname>Roy</surname><given-names>R</given-names></name><name><surname>Kyriazis</surname><given-names>ID</given-names></name><name><surname>Gao</surname><given-names>E</given-names></name><name><surname>Drosatos</surname><given-names>K</given-names></name><name><surname>Koch</surname><given-names>WJ</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Genomic binding patterns of forkhead box protein O1 reveal its unique role in cardiac hypertrophy</article-title><source>Circulation</source><volume>142</volume><fpage>882</fpage><lpage>898</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.120.046356</pub-id><pub-id pub-id-type="pmid">32640834</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Phansalkar</surname><given-names>R</given-names></name><name><surname>Krieger</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Kolluru</surname><given-names>SS</given-names></name><name><surname>Jones</surname><given-names>RC</given-names></name><name><surname>Quake</surname><given-names>SR</given-names></name><name><surname>Weissman</surname><given-names>I</given-names></name><name><surname>Bernstein</surname><given-names>D</given-names></name><name><surname>Winn</surname><given-names>VD</given-names></name><name><surname>D’Amato</surname><given-names>G</given-names></name><name><surname>Red-Horse</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Coronary blood vessels from distinct origins converge to equivalent states during mouse and human development</article-title><source>eLife</source><volume>10</volume><elocation-id>e70246</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.70246</pub-id><pub-id pub-id-type="pmid">34910626</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pitulescu</surname><given-names>ME</given-names></name><name><surname>Schmidt</surname><given-names>I</given-names></name><name><surname>Giaimo</surname><given-names>BD</given-names></name><name><surname>Antoine</surname><given-names>T</given-names></name><name><surname>Berkenfeld</surname><given-names>F</given-names></name><name><surname>Ferrante</surname><given-names>F</given-names></name><name><surname>Park</surname><given-names>H</given-names></name><name><surname>Ehling</surname><given-names>M</given-names></name><name><surname>Biljes</surname><given-names>D</given-names></name><name><surname>Rocha</surname><given-names>SF</given-names></name><name><surname>Langen</surname><given-names>UH</given-names></name><name><surname>Stehling</surname><given-names>M</given-names></name><name><surname>Nagasawa</surname><given-names>T</given-names></name><name><surname>Ferrara</surname><given-names>N</given-names></name><name><surname>Borggrefe</surname><given-names>T</given-names></name><name><surname>Adams</surname><given-names>RH</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Dll4 and Notch signalling couples sprouting angiogenesis and artery formation</article-title><source>Nature Cell Biology</source><volume>19</volume><fpage>915</fpage><lpage>927</lpage><pub-id pub-id-type="doi">10.1038/ncb3555</pub-id><pub-id pub-id-type="pmid">28714968</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quillien</surname><given-names>A</given-names></name><name><surname>Moore</surname><given-names>JC</given-names></name><name><surname>Shin</surname><given-names>M</given-names></name><name><surname>Siekmann</surname><given-names>AF</given-names></name><name><surname>Smith</surname><given-names>T</given-names></name><name><surname>Pan</surname><given-names>L</given-names></name><name><surname>Moens</surname><given-names>CB</given-names></name><name><surname>Parsons</surname><given-names>MJ</given-names></name><name><surname>Lawson</surname><given-names>ND</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Distinct Notch signaling outputs pattern the developing arterial system</article-title><source>Development</source><volume>141</volume><fpage>1544</fpage><lpage>1552</lpage><pub-id pub-id-type="doi">10.1242/dev.099986</pub-id><pub-id pub-id-type="pmid">24598161</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raftrey</surname><given-names>B</given-names></name><name><surname>Williams</surname><given-names>I</given-names></name><name><surname>Rios Coronado</surname><given-names>PE</given-names></name><name><surname>Fan</surname><given-names>X</given-names></name><name><surname>Chang</surname><given-names>AH</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Roth</surname><given-names>R</given-names></name><name><surname>Trimm</surname><given-names>E</given-names></name><name><surname>Racelis</surname><given-names>R</given-names></name><name><surname>D’Amato</surname><given-names>G</given-names></name><name><surname>Phansalkar</surname><given-names>R</given-names></name><name><surname>Nguyen</surname><given-names>A</given-names></name><name><surname>Chai</surname><given-names>T</given-names></name><name><surname>Gonzalez</surname><given-names>KM</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Ang</surname><given-names>LT</given-names></name><name><surname>Loh</surname><given-names>KM</given-names></name><name><surname>Bernstein</surname><given-names>D</given-names></name><name><surname>Red-Horse</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Dach1 extends artery networks and protects against cardiac injury</article-title><source>Circulation Research</source><volume>129</volume><fpage>702</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.120.318271</pub-id><pub-id pub-id-type="pmid">34383559</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Red-Horse</surname><given-names>K</given-names></name><name><surname>Siekmann</surname><given-names>AF</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Veins and arteries build hierarchical branching patterns differently: bottom-up versus top-down</article-title><source>BioEssays</source><volume>41</volume><elocation-id>e1800198</elocation-id><pub-id pub-id-type="doi">10.1002/bies.201800198</pub-id><pub-id pub-id-type="pmid">30805984</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>AS</given-names></name><name><surname>Materna</surname><given-names>SC</given-names></name><name><surname>Barnes</surname><given-names>RM</given-names></name><name><surname>De Val</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>S-M</given-names></name><name><surname>Black</surname><given-names>BL</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>An arterial-specific enhancer of the human endothelin converting enzyme 1 (ECE1) gene is synergistically activated by Sox17, FoxC2, and Etv2</article-title><source>Developmental Biology</source><volume>395</volume><fpage>379</fpage><lpage>389</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2014.08.027</pub-id><pub-id pub-id-type="pmid">25179465</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roman</surname><given-names>BL</given-names></name><name><surname>Hinck</surname><given-names>AP</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>ALK1 signaling in development and disease: new paradigms</article-title><source>Cellular and Molecular Life Sciences</source><volume>74</volume><fpage>4539</fpage><lpage>4560</lpage><pub-id pub-id-type="doi">10.1007/s00018-017-2636-4</pub-id><pub-id pub-id-type="pmid">28871312</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rosenbloom</surname><given-names>KR</given-names></name><name><surname>Sloan</surname><given-names>CA</given-names></name><name><surname>Malladi</surname><given-names>VS</given-names></name><name><surname>Dreszer</surname><given-names>TR</given-names></name><name><surname>Learned</surname><given-names>K</given-names></name><name><surname>Kirkup</surname><given-names>VM</given-names></name><name><surname>Wong</surname><given-names>MC</given-names></name><name><surname>Maddren</surname><given-names>M</given-names></name><name><surname>Fang</surname><given-names>R</given-names></name><name><surname>Heitner</surname><given-names>SG</given-names></name><name><surname>Lee</surname><given-names>BT</given-names></name><name><surname>Barber</surname><given-names>GP</given-names></name><name><surname>Harte</surname><given-names>RA</given-names></name><name><surname>Diekhans</surname><given-names>M</given-names></name><name><surname>Long</surname><given-names>JC</given-names></name><name><surname>Wilder</surname><given-names>SP</given-names></name><name><surname>Zweig</surname><given-names>AS</given-names></name><name><surname>Karolchik</surname><given-names>D</given-names></name><name><surname>Kuhn</surname><given-names>RM</given-names></name><name><surname>Haussler</surname><given-names>D</given-names></name><name><surname>Kent</surname><given-names>WJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>ENCODE data in the UCSC Genome Browser: year 5 update</article-title><source>Nucleic Acids Research</source><volume>41</volume><fpage>D56</fpage><lpage>D63</lpage><pub-id pub-id-type="doi">10.1093/nar/gks1172</pub-id><pub-id pub-id-type="pmid">23193274</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sacilotto</surname><given-names>N</given-names></name><name><surname>Monteiro</surname><given-names>R</given-names></name><name><surname>Fritzsche</surname><given-names>M</given-names></name><name><surname>Becker</surname><given-names>PW</given-names></name><name><surname>Sanchez-Del-Campo</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Pinheiro</surname><given-names>P</given-names></name><name><surname>Ratnayaka</surname><given-names>I</given-names></name><name><surname>Davies</surname><given-names>B</given-names></name><name><surname>Goding</surname><given-names>CR</given-names></name><name><surname>Patient</surname><given-names>R</given-names></name><name><surname>Bou-Gharios</surname><given-names>G</given-names></name><name><surname>De Val</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Analysis of Dll4 regulation reveals a combinatorial role for Sox and Notch in arterial development</article-title><source>PNAS</source><volume>110</volume><fpage>11893</fpage><lpage>11898</lpage><pub-id pub-id-type="doi">10.1073/pnas.1300805110</pub-id><pub-id pub-id-type="pmid">23818617</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sacilotto</surname><given-names>N</given-names></name><name><surname>Chouliaras</surname><given-names>KM</given-names></name><name><surname>Nikitenko</surname><given-names>LL</given-names></name><name><surname>Lu</surname><given-names>YW</given-names></name><name><surname>Fritzsche</surname><given-names>M</given-names></name><name><surname>Wallace</surname><given-names>MD</given-names></name><name><surname>Nornes</surname><given-names>S</given-names></name><name><surname>García-Moreno</surname><given-names>F</given-names></name><name><surname>Payne</surname><given-names>S</given-names></name><name><surname>Bridges</surname><given-names>E</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Biggs</surname><given-names>D</given-names></name><name><surname>Ratnayaka</surname><given-names>I</given-names></name><name><surname>Herbert</surname><given-names>SP</given-names></name><name><surname>Molnár</surname><given-names>Z</given-names></name><name><surname>Harris</surname><given-names>AL</given-names></name><name><surname>Davies</surname><given-names>B</given-names></name><name><surname>Bond</surname><given-names>GL</given-names></name><name><surname>Bou-Gharios</surname><given-names>G</given-names></name><name><surname>Schwarz</surname><given-names>JJ</given-names></name><name><surname>De Val</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>MEF2 transcription factors are key regulators of sprouting angiogenesis</article-title><source>Genes &amp; Development</source><volume>30</volume><fpage>2297</fpage><lpage>2309</lpage><pub-id pub-id-type="doi">10.1101/gad.290619.116</pub-id><pub-id pub-id-type="pmid">27898394</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schindelin</surname><given-names>J</given-names></name><name><surname>Arganda-Carreras</surname><given-names>I</given-names></name><name><surname>Frise</surname><given-names>E</given-names></name><name><surname>Kaynig</surname><given-names>V</given-names></name><name><surname>Longair</surname><given-names>M</given-names></name><name><surname>Pietzsch</surname><given-names>T</given-names></name><name><surname>Preibisch</surname><given-names>S</given-names></name><name><surname>Rueden</surname><given-names>C</given-names></name><name><surname>Saalfeld</surname><given-names>S</given-names></name><name><surname>Schmid</surname><given-names>B</given-names></name><name><surname>Tinevez</surname><given-names>J-Y</given-names></name><name><surname>White</surname><given-names>DJ</given-names></name><name><surname>Hartenstein</surname><given-names>V</given-names></name><name><surname>Eliceiri</surname><given-names>K</given-names></name><name><surname>Tomancak</surname><given-names>P</given-names></name><name><surname>Cardona</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Fiji: an open-source platform for biological-image analysis</article-title><source>Nature Methods</source><volume>9</volume><fpage>676</fpage><lpage>682</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2019</pub-id><pub-id pub-id-type="pmid">22743772</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schnitzler</surname><given-names>GR</given-names></name><name><surname>Kang</surname><given-names>H</given-names></name><name><surname>Fang</surname><given-names>S</given-names></name><name><surname>Angom</surname><given-names>RS</given-names></name><name><surname>Lee-Kim</surname><given-names>VS</given-names></name><name><surname>Ma</surname><given-names>XR</given-names></name><name><surname>Zhou</surname><given-names>R</given-names></name><name><surname>Zeng</surname><given-names>T</given-names></name><name><surname>Guo</surname><given-names>K</given-names></name><name><surname>Taylor</surname><given-names>MS</given-names></name><name><surname>Vellarikkal</surname><given-names>SK</given-names></name><name><surname>Barry</surname><given-names>AE</given-names></name><name><surname>Sias-Garcia</surname><given-names>O</given-names></name><name><surname>Bloemendal</surname><given-names>A</given-names></name><name><surname>Munson</surname><given-names>G</given-names></name><name><surname>Guckelberger</surname><given-names>P</given-names></name><name><surname>Nguyen</surname><given-names>TH</given-names></name><name><surname>Bergman</surname><given-names>DT</given-names></name><name><surname>Hinshaw</surname><given-names>S</given-names></name><name><surname>Cheng</surname><given-names>N</given-names></name><name><surname>Cleary</surname><given-names>B</given-names></name><name><surname>Aragam</surname><given-names>K</given-names></name><name><surname>Lander</surname><given-names>ES</given-names></name><name><surname>Finucane</surname><given-names>HK</given-names></name><name><surname>Mukhopadhyay</surname><given-names>D</given-names></name><name><surname>Gupta</surname><given-names>RM</given-names></name><name><surname>Engreitz</surname><given-names>JM</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Convergence of coronary artery disease genes onto endothelial cell programs</article-title><source>Nature</source><volume>626</volume><fpage>799</fpage><lpage>807</lpage><pub-id pub-id-type="doi">10.1038/s41586-024-07022-x</pub-id><pub-id pub-id-type="pmid">38326615</pub-id></element-citation></ref><ref id="bib78"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seki</surname><given-names>T</given-names></name><name><surname>Yun</surname><given-names>J</given-names></name><name><surname>Oh</surname><given-names>SP</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Arterial endothelium-specific activin receptor-like kinase 1 expression suggests its role in arterialization and vascular remodeling</article-title><source>Circulation Research</source><volume>93</volume><fpage>682</fpage><lpage>689</lpage><pub-id pub-id-type="doi">10.1161/01.RES.0000095246.40391.3B</pub-id><pub-id pub-id-type="pmid">12970115</pub-id></element-citation></ref><ref id="bib79"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seki</surname><given-names>T</given-names></name><name><surname>Hong</surname><given-names>KH</given-names></name><name><surname>Yun</surname><given-names>J</given-names></name><name><surname>Kim</surname><given-names>SJ</given-names></name><name><surname>Oh</surname><given-names>SP</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Isolation of a regulatory region of activin receptor-like kinase 1 gene sufficient for arterial endothelium-specific expression</article-title><source>Circulation Research</source><volume>94</volume><fpage>e72</fpage><lpage>e77</lpage><pub-id pub-id-type="doi">10.1161/01.RES.0000127048.81744.31</pub-id><pub-id pub-id-type="pmid">15059937</pub-id></element-citation></ref><ref id="bib80"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Seo</surname><given-names>S</given-names></name><name><surname>Fujita</surname><given-names>H</given-names></name><name><surname>Nakano</surname><given-names>A</given-names></name><name><surname>Kang</surname><given-names>M</given-names></name><name><surname>Duarte</surname><given-names>A</given-names></name><name><surname>Kume</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>The forkhead transcription factors, Foxc1 and Foxc2, are required for arterial specification and lymphatic sprouting during vascular development</article-title><source>Developmental Biology</source><volume>294</volume><fpage>458</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1016/j.ydbio.2006.03.035</pub-id><pub-id pub-id-type="pmid">16678147</pub-id></element-citation></ref><ref id="bib81"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>B</given-names></name><name><surname>Ho</surname><given-names>L</given-names></name><name><surname>Ford</surname><given-names>GH</given-names></name><name><surname>Chen</surname><given-names>HI</given-names></name><name><surname>Goldstone</surname><given-names>AB</given-names></name><name><surname>Woo</surname><given-names>YJ</given-names></name><name><surname>Quertermous</surname><given-names>T</given-names></name><name><surname>Reversade</surname><given-names>B</given-names></name><name><surname>Red-Horse</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Alternative progenitor cells compensate to rebuild the coronary vasculature in elabela- and apj-deficient hearts</article-title><source>Developmental Cell</source><volume>42</volume><fpage>655</fpage><lpage>666</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2017.08.008</pub-id><pub-id pub-id-type="pmid">28890073</pub-id></element-citation></ref><ref id="bib82"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sissaoui</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Yan</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>R</given-names></name><name><surname>Yukselen</surname><given-names>O</given-names></name><name><surname>Kucukural</surname><given-names>A</given-names></name><name><surname>Zhu</surname><given-names>LJ</given-names></name><name><surname>Lawson</surname><given-names>ND</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Genomic characterization of endothelial enhancers reveals a multifunctional role for NR2F2 in regulation of arteriovenous gene expression</article-title><source>Circulation Research</source><volume>126</volume><fpage>875</fpage><lpage>888</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.119.316075</pub-id><pub-id pub-id-type="pmid">32065070</pub-id></element-citation></ref><ref id="bib83"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stewen</surname><given-names>J</given-names></name><name><surname>Kruse</surname><given-names>K</given-names></name><name><surname>Godoi-Filip</surname><given-names>AT</given-names></name><name><surname>Jeong</surname><given-names>HW</given-names></name><name><surname>Adams</surname><given-names>S</given-names></name><name><surname>Berkenfeld</surname><given-names>F</given-names></name><name><surname>Stehling</surname><given-names>M</given-names></name><name><surname>Red-Horse</surname><given-names>K</given-names></name><name><surname>Adams</surname><given-names>RH</given-names></name><name><surname>Pitulescu</surname><given-names>ME</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Eph-ephrin signaling couples endothelial cell sorting and arterial specification</article-title><source>Nature Communications</source><volume>15</volume><elocation-id>2539</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-024-46300-0</pub-id><pub-id pub-id-type="pmid">38570531</pub-id></element-citation></ref><ref id="bib84"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Su</surname><given-names>T</given-names></name><name><surname>Stanley</surname><given-names>G</given-names></name><name><surname>Sinha</surname><given-names>R</given-names></name><name><surname>D’Amato</surname><given-names>G</given-names></name><name><surname>Das</surname><given-names>S</given-names></name><name><surname>Rhee</surname><given-names>S</given-names></name><name><surname>Chang</surname><given-names>AH</given-names></name><name><surname>Poduri</surname><given-names>A</given-names></name><name><surname>Raftrey</surname><given-names>B</given-names></name><name><surname>Dinh</surname><given-names>TT</given-names></name><name><surname>Roper</surname><given-names>WA</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Quinn</surname><given-names>KE</given-names></name><name><surname>Caron</surname><given-names>KM</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Miquerol</surname><given-names>L</given-names></name><name><surname>Butcher</surname><given-names>EC</given-names></name><name><surname>Weissman</surname><given-names>I</given-names></name><name><surname>Quake</surname><given-names>S</given-names></name><name><surname>Red-Horse</surname><given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Single-cell analysis of early progenitor cells that build coronary arteries</article-title><source>Nature</source><volume>559</volume><fpage>356</fpage><lpage>362</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0288-7</pub-id><pub-id pub-id-type="pmid">29973725</pub-id></element-citation></ref><ref id="bib85"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thorvaldsdóttir</surname><given-names>H</given-names></name><name><surname>Robinson</surname><given-names>JT</given-names></name><name><surname>Mesirov</surname><given-names>JP</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration</article-title><source>Briefings in Bioinformatics</source><volume>14</volume><fpage>178</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1093/bib/bbs017</pub-id><pub-id pub-id-type="pmid">22517427</pub-id></element-citation></ref><ref id="bib86"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsaryk</surname><given-names>R</given-names></name><name><surname>Yucel</surname><given-names>N</given-names></name><name><surname>Leonard</surname><given-names>EV</given-names></name><name><surname>Diaz</surname><given-names>N</given-names></name><name><surname>Bondareva</surname><given-names>O</given-names></name><name><surname>Odenthal-Schnittler</surname><given-names>M</given-names></name><name><surname>Arany</surname><given-names>Z</given-names></name><name><surname>Vaquerizas</surname><given-names>JM</given-names></name><name><surname>Schnittler</surname><given-names>H</given-names></name><name><surname>Siekmann</surname><given-names>AF</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Shear stress switches the association of endothelial enhancers from ETV/ETS to KLF transcription factor binding sites</article-title><source>Scientific Reports</source><volume>12</volume><elocation-id>4795</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-022-08645-8</pub-id><pub-id pub-id-type="pmid">35314737</pub-id></element-citation></ref><ref id="bib87"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Garcia</surname><given-names>SP</given-names></name><name><surname>Liang</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Yan</surname><given-names>P</given-names></name><name><surname>Yu</surname><given-names>H</given-names></name><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Le</surname><given-names>H</given-names></name><name><surname>Han</surname><given-names>Z</given-names></name><name><surname>Luo</surname><given-names>X</given-names></name><name><surname>Day</surname><given-names>DS</given-names></name><name><surname>Stevens</surname><given-names>SM</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Park</surname><given-names>PJ</given-names></name><name><surname>Liu</surname><given-names>Z-J</given-names></name><name><surname>Sun</surname><given-names>K</given-names></name><name><surname>Yuan</surname><given-names>G-C</given-names></name><name><surname>Pu</surname><given-names>WT</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>A dynamic and integrated epigenetic program at distal regions orchestrates transcriptional responses to VEGFA</article-title><source>Genome Research</source><volume>29</volume><fpage>193</fpage><lpage>207</lpage><pub-id pub-id-type="doi">10.1101/gr.239053.118</pub-id><pub-id pub-id-type="pmid">30670628</pub-id></element-citation></ref><ref id="bib88"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname><given-names>Y</given-names></name><name><surname>Seya</surname><given-names>D</given-names></name><name><surname>Ihara</surname><given-names>D</given-names></name><name><surname>Ishii</surname><given-names>S</given-names></name><name><surname>Uemoto</surname><given-names>T</given-names></name><name><surname>Kubo</surname><given-names>A</given-names></name><name><surname>Arai</surname><given-names>Y</given-names></name><name><surname>Isomoto</surname><given-names>Y</given-names></name><name><surname>Nakano</surname><given-names>A</given-names></name><name><surname>Abe</surname><given-names>T</given-names></name><name><surname>Shigeta</surname><given-names>M</given-names></name><name><surname>Kawamura</surname><given-names>T</given-names></name><name><surname>Saito</surname><given-names>Y</given-names></name><name><surname>Ogura</surname><given-names>T</given-names></name><name><surname>Nakagawa</surname><given-names>O</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Importance of endothelial Hey1 expression for thoracic great vessel development and its distal enhancer for Notch-dependent endothelial transcription</article-title><source>The Journal of Biological Chemistry</source><volume>295</volume><fpage>17632</fpage><lpage>17645</lpage><pub-id pub-id-type="doi">10.1074/jbc.RA120.015003</pub-id><pub-id pub-id-type="pmid">33454003</pub-id></element-citation></ref><ref id="bib89"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilhelm</surname><given-names>K</given-names></name><name><surname>Happel</surname><given-names>K</given-names></name><name><surname>Eelen</surname><given-names>G</given-names></name><name><surname>Schoors</surname><given-names>S</given-names></name><name><surname>Oellerich</surname><given-names>MF</given-names></name><name><surname>Lim</surname><given-names>R</given-names></name><name><surname>Zimmermann</surname><given-names>B</given-names></name><name><surname>Aspalter</surname><given-names>IM</given-names></name><name><surname>Franco</surname><given-names>CA</given-names></name><name><surname>Boettger</surname><given-names>T</given-names></name><name><surname>Braun</surname><given-names>T</given-names></name><name><surname>Fruttiger</surname><given-names>M</given-names></name><name><surname>Rajewsky</surname><given-names>K</given-names></name><name><surname>Keller</surname><given-names>C</given-names></name><name><surname>Brüning</surname><given-names>JC</given-names></name><name><surname>Gerhardt</surname><given-names>H</given-names></name><name><surname>Carmeliet</surname><given-names>P</given-names></name><name><surname>Potente</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>FOXO1 couples metabolic activity and growth state in the vascular endothelium</article-title><source>Nature</source><volume>529</volume><fpage>216</fpage><lpage>220</lpage><pub-id pub-id-type="doi">10.1038/nature16498</pub-id><pub-id pub-id-type="pmid">26735015</pub-id></element-citation></ref><ref id="bib90"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wythe</surname><given-names>JD</given-names></name><name><surname>Dang</surname><given-names>LTH</given-names></name><name><surname>Devine</surname><given-names>WP</given-names></name><name><surname>Boudreau</surname><given-names>E</given-names></name><name><surname>Artap</surname><given-names>ST</given-names></name><name><surname>He</surname><given-names>D</given-names></name><name><surname>Schachterle</surname><given-names>W</given-names></name><name><surname>Stainier</surname><given-names>DYR</given-names></name><name><surname>Oettgen</surname><given-names>P</given-names></name><name><surname>Black</surname><given-names>BL</given-names></name><name><surname>Bruneau</surname><given-names>BG</given-names></name><name><surname>Fish</surname><given-names>JE</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>ETS factors regulate Vegf-dependent arterial specification</article-title><source>Developmental Cell</source><volume>26</volume><fpage>45</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2013.06.007</pub-id><pub-id pub-id-type="pmid">23830865</pub-id></element-citation></ref><ref id="bib91"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Morton</surname><given-names>SU</given-names></name><name><surname>Kim</surname><given-names>SW</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Gorham</surname><given-names>JM</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Berkson</surname><given-names>PJ</given-names></name><name><surname>Mazumdar</surname><given-names>N</given-names></name><name><surname>Cao</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Hagen</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>P</given-names></name><name><surname>Richter</surname><given-names>F</given-names></name><name><surname>Shen</surname><given-names>Y</given-names></name><name><surname>Ward</surname><given-names>T</given-names></name><name><surname>Gelb</surname><given-names>BD</given-names></name><name><surname>Seidman</surname><given-names>JG</given-names></name><name><surname>Seidman</surname><given-names>CE</given-names></name><name><surname>Pu</surname><given-names>WT</given-names></name></person-group><year iso-8601-date="2024">2024</year><article-title>Functional dissection of human cardiac enhancers and noncoding de novo variants in congenital heart disease</article-title><source>Nature Genetics</source><volume>56</volume><fpage>420</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1038/s41588-024-01669-y</pub-id><pub-id pub-id-type="pmid">38378865</pub-id></element-citation></ref><ref id="bib92"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>C</given-names></name><name><surname>Hasan</surname><given-names>SS</given-names></name><name><surname>Schmidt</surname><given-names>I</given-names></name><name><surname>Rocha</surname><given-names>SF</given-names></name><name><surname>Pitulescu</surname><given-names>ME</given-names></name><name><surname>Bussmann</surname><given-names>J</given-names></name><name><surname>Meyen</surname><given-names>D</given-names></name><name><surname>Raz</surname><given-names>E</given-names></name><name><surname>Adams</surname><given-names>RH</given-names></name><name><surname>Siekmann</surname><given-names>AF</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Arteries are formed by vein-derived endothelial tip cells</article-title><source>Nature Communications</source><volume>5</volume><elocation-id>5758</elocation-id><pub-id pub-id-type="doi">10.1038/ncomms6758</pub-id><pub-id pub-id-type="pmid">25502622</pub-id></element-citation></ref><ref id="bib93"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamamizu</surname><given-names>K</given-names></name><name><surname>Matsunaga</surname><given-names>T</given-names></name><name><surname>Uosaki</surname><given-names>H</given-names></name><name><surname>Fukushima</surname><given-names>H</given-names></name><name><surname>Katayama</surname><given-names>S</given-names></name><name><surname>Hiraoka-Kanie</surname><given-names>M</given-names></name><name><surname>Mitani</surname><given-names>K</given-names></name><name><surname>Yamashita</surname><given-names>JK</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Convergence of Notch and beta-catenin signaling induces arterial fate in vascular progenitors</article-title><source>The Journal of Cell Biology</source><volume>189</volume><fpage>325</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1083/jcb.200904114</pub-id><pub-id pub-id-type="pmid">20404113</pub-id></element-citation></ref><ref id="bib94"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yanagida</surname><given-names>K</given-names></name><name><surname>Engelbrecht</surname><given-names>E</given-names></name><name><surname>Niaudet</surname><given-names>C</given-names></name><name><surname>Jung</surname><given-names>B</given-names></name><name><surname>Gaengel</surname><given-names>K</given-names></name><name><surname>Holton</surname><given-names>K</given-names></name><name><surname>Swendeman</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>CH</given-names></name><name><surname>Levesque</surname><given-names>MV</given-names></name><name><surname>Kuo</surname><given-names>A</given-names></name><name><surname>Fu</surname><given-names>Z</given-names></name><name><surname>Smith</surname><given-names>LEH</given-names></name><name><surname>Betsholtz</surname><given-names>C</given-names></name><name><surname>Hla</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>SpHingosine 1-phosphate receptor signaling establishes ap-1 gradients to allow for retinal endothelial cell specialization</article-title><source>Developmental Cell</source><volume>52</volume><fpage>779</fpage><lpage>793</lpage><pub-id pub-id-type="doi">10.1016/j.devcel.2020.01.016</pub-id><pub-id pub-id-type="pmid">32059774</pub-id></element-citation></ref><ref id="bib95"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Williams</surname><given-names>J</given-names></name><name><surname>Smallwood</surname><given-names>PM</given-names></name><name><surname>Nathans</surname><given-names>JS</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Sox7, Sox17, and Sox18 cooperatively regulate vascular development in the mouse retina</article-title><source>PLOS ONE</source><volume>10</volume><elocation-id>e0143650</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0143650</pub-id><pub-id pub-id-type="pmid">26630461</pub-id></element-citation></ref><ref id="bib96"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>P</given-names></name><name><surname>Gu</surname><given-names>F</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Akerberg</surname><given-names>BN</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>K</given-names></name><name><surname>He</surname><given-names>A</given-names></name><name><surname>Lin</surname><given-names>Z</given-names></name><name><surname>Stevens</surname><given-names>SM</given-names></name><name><surname>Zhou</surname><given-names>B</given-names></name><name><surname>Pu</surname><given-names>WT</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Mapping cell type-specific transcriptional enhancers using high affinity, lineage-specific Ep300 bioChIP-seq</article-title><source>eLife</source><volume>6</volume><elocation-id>e22039</elocation-id><pub-id pub-id-type="doi">10.7554/eLife.22039</pub-id><pub-id pub-id-type="pmid">28121289</pub-id></element-citation></ref></ref-list></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.102440.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Koltowska</surname><given-names>Katarzyna</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/048a87296</institution-id><institution>Uppsala University</institution></institution-wrap><country>Sweden</country></aff></contrib></contrib-group></front-stub><body><p>This work represents a significant milestone in understanding the regulatory logic underlying arterial identity. It offers an exceptional repository of validated arterial enhancers that drive expression across different vascular compartments. Moreover, it identifies the upstream transcription factor binding sites within these arterial enhancers. As such, this study will be of broad interest to developmental biologists, vascular researchers, and cell biologists.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.102440.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Koltowska</surname><given-names>Katarzyna</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/048a87296</institution-id><institution>Uppsala University</institution></institution-wrap><country>Sweden</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.</p></boxed-text><p>[Editors' note: this paper was reviewed by <ext-link ext-link-type="uri" xlink:href="https://www.reviewcommons.org/">Review Commons</ext-link>.]</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.102440.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>1. General Statements</p></disp-quote><p>We thank all three reviewers for their overwhelmingly positive reviews. As they noted, this paper not only advances our knowledge of the pathways regulating arterial differentiation, but also provides a valuable and easy-to-access resource that will be appreciated by a wide range of researchers. This obviously includes those interested in arterial differentiation, vascular development and associated diseases. However, we also anticipate this resource will be used more widely, for example providing an interesting and well validated enhancer cohort resource for epigenetic researchers interested in enhancer action and specificity more generally, and as a useful training set for testing bioinformatic/AI pipelines.</p><p>While resource papers more often focus on generating large novel datasets or analysis pipelines, this can leave a gap between the existence of data and the ability of researchers to apply it to their ongoing studies. This problem is clearly evident in the vascular field, where it is common to see otherwise strong research papers rely on outdated analysis of promoter/intronic regions to link their upstream pathways to transcriptional activation. Additionally, conclusions from complex pan-genomic analyses are often made without ever verifying any “enhancer” regions in transgenic models, influenced by prohibitory costs and perceived complexity of such analysis. As well as the potential for errors and incorrect assumptions, a reliance on poorly defined enhancer/promoter regions prevents further researchers building on these initial observations, to the general detriment to the field. Here, we have not only provided a detailed and standardized characterization of all known vascular enhancers but also an accessible enhancer analysis blueprint for others to follow. This permits all researchers easy access the sequence and transcriptional profile for every enhancer/gene/transcription factor investigated here, whilst also enabling them to follow a similar pathway to identify, annotate and characterize novel enhancers for any gene of interest. We note that the bioRxiv version of our paper has already been cited by Coronado et al., medRxiv https://doi.org/10.1101/ 2023.10.27.23297507, where it enabled them to easily link a GWAS association at a non-coding region near the chemokine CXCL12 with a validated arterial enhancer (Cxcl12-269). No doubt the enhancer annotation provided in our paper will also enable these researchers to better examine the various linkage SNPs overlapping Cxcl12-269 to more directly link phenotype to transcriptional motif changes.</p><p>We would like to conclude with three comments from our reviewers which emphasizes the strength of this paper. Reviewer 1: “This work represents a significant milestone in the systematic understanding of how arterial gene expression is regulated. Overall, this study offers a powerful resource for understanding arterial gene regulation and conducting genome-wide studies of arterial enhancers”. Reviewer 2: “This very well-done study…advances our knowledge on the field of vascular biology as it not only proposes potential enhancers but also goes on to validation of the enhancers”. Reviewer 3: “This novel work establishes an important foundation for future understanding of how TFs may interact to determine arterial specification”.</p><p>This Revision Plan covers all issues/comments made by the reviewers, although some of the text has been abbreviated. We have also separately submitted a non-abbreviated point-by-point response to reviewers.</p><disp-quote content-type="editor-comment"><p>2. Description of the planned revisions</p><p>Reviewer 1: The co-localization of the enhancer expression in the endothelium was done using endothelial marks expressed in both venous and arterial EC (kdrl). To fully distinguish if the expression is venous or arterial endothelial compartment colocalization with Tg expressed in arterial (flt1) or venous (lyve1) EC would be informative. In addition, it is striking that cxc4+135 drives the expression in nearly every ISV as cxcl12+269 only every other. Similarly, not all the enhancers are enriched in the DA to the same level. Is there biological significance to this? could authors discuss these results further? The pattern of expression of the unc5b-identified enhancer is also striking, does this reflect the known roles of unc5b in the vascular formation?</p></disp-quote><p>Planned Revision 1. Updated Figure 3 and new Table to better describe and characterize the expression of the arterial enhancers in transgenic zebrafish.</p><p>We agree with the reviewer that a more detailed description of arterial-venous specificity of each enhancer could be included. The diversity of enhancer expression patterns within the arterial compartment is notable (and really very interesting) and could be discussed in greater depth.</p><p>In the original manuscript, the expression pattern of each enhancer within the vasculature was primarily assessed at 2 days post fertilization (2dpf) in Figure 1-2. This identified arteries using direction of blood flow and known anatomical information, as arterial development in 2pdf zebrafish is very stereotypical and already well characterized. The original Figure 3A includes a more detailed assessment of arterial-venous specificity at 3dpf for four arterial enhancers (Cxcr4+135, Cxcr4+151, Gja5-78 and Gja57, chosen as enhancers representing the four types of expression patterns seen). We will now extend this more detailed analysis to all arterial enhancer:GFP lines. This analysis uses kdrl-mCherry to mark the entire vasculature comparative to the expression of the arterial enhancers (GFP). This allows us to clearly identify the intersegmental arteries (as opposed to intersegmental veins) by looking for direct connection to the dorsal aorta, and by assessing the direction of blood flow within these vessels. This analysis is done at 3dpf to give time for the intersegmental arteries to acquire identity and connect definitively with the dorsal aorta, and for the diminishment of any GFP expression originating from the initial sprouting from the dorsal aorta. By extending this analysis to the other arterial enhancer zebrafish lines shown in Figure 2, we will be able to more clearly classify the activity of each enhancer within different vascular beds. Detailed expression information will also be recorded in a new Table better detailing the timing and specificity of activity of each enhancer.</p><p>We chose not to use arterial or venous “marker lines” (e.g. Flt1:reporter or Lyve1:reporter) for the simple reason that these are also enhancer:reporter transgenes, and therefore are not necessarily definitive of the arterial or venous lineage per se (e.g. Flt1:GFP expression is controlled by the transcription factors binding the Flt1 enhancer in the same way that Cxcr4+135 and the others are, with the added caveat that the transcriptional regulation of the Flt1 and Lyve enhancers are not well defined).</p><p>We felt that morphological determination based on direct connections and blood flow direction was therefore more accurate.</p><p>The extension of Figure 3A to all enhancer lines will also permit us to more clearly classify the activity of each arterial enhancer within different beds and at different time points. Currently there were no clear links between a particular transcription factor motif/binding and expression pattern, something that is discussed briefly in the original Results and Discussion sections. However, the expansion of Figure 3A to all enhancers, and the creation of a Table summarizing this more systematically will make the link (or lack of one) between expression patterns within the arterial tree and TF motifs easier to appreciate and discuss.</p><disp-quote content-type="editor-comment"><p>Reviewer 2 Major Comment 4. The analysis of the enhancers is only done during development. Is the activity of these enhancers maintained through life or only important for artery vs vein determination? Is the expression of the different enhancer reporters maintained into adulthood?</p></disp-quote><p>Planned Revision 2. Analysis of expression of arterial enhancers in adult transgenic zebrafish fins.</p><p>We agree this would be interesting to ascertain. To address this, we will include an examination of the activity of each arterial enhancer:GFP transgene in adult fish fins in the fully revised version of this paper. The vessels in the adult fin are accessible for analysis without the need to cross the fish into a <italic>casper</italic> background, which would be beyond the timescale of this project. We have already conducted a feasibility study on four arterial enhancers:GFP lines (Gja5-7:GFP, Gja5-78:GFP, Gja4+40:GFP and Efnb2-333:GFP), which found that all four were active and arterial-specific in the adult zebrafish fin.</p><disp-quote content-type="editor-comment"><p>Reviewer 3 Major Comment 3: SoxF family TFs. Among the 3 members of SoxF TFs, only Sox17 and Sox7 were assessed. Though not specific, Sox18 is highly expressed in the arteries. On the contrary, Sox7 is highly expressed in the vein and shows weak expression in arterial ECs (PMID: 26630461).</p></disp-quote><p>Planned Revision 3. Inclusion of SOX18 ChIP-seq data in analysis</p><p>We agree. We will conduct a new ChIP-seq/CUT&amp;RUN analysis and include assessment of SOX18 binding in our final revised manuscript. We have identified a suitable antibody for this analysis.</p><disp-quote content-type="editor-comment"><p>Reviewer 3 Comment 4: Figure 4 e14.5 mouse embryos. If the observation aims to assess the dorsal aorta, it would be better to use mouse embryos at mid-gestation (e9.5-10.5), when the paired DAs are formed with arterial identity but haven't been remodelled and fused as one single aorta. The morphological data in this figure would be better to show the colocalization of LacZ expression and an arterial marker (e.g. Sox17) using immulfluorescence staining instead of purely lacZ.</p></disp-quote><p>Planned Revision 4. Include images from sections through e14.5 embryos to demonstrate expression patterns</p><p>We are unable to perform immunofluorescence in the e14.5 transgenic embryos due to the fixation and staining solutions used for X-gal staining (which was done by an external company and could not be altered), but agree additional data would better demonstrate arterial endothelial specificity. We will expand the analysis of sectioned embryos (currently restricted to just the Efnb2-333:LacZ transgene) to all enhancers shown in Figure 4. This analysis has some limitations due to infiltration of the X-gal solution to deeper tissues, but is anticipated it will clearly show enhancer activity in arterial endothelial cells rather than venous ECs or smooth muscle cells.</p><p>It is important to emphasize that this experiment was primarily conducted to demonstrate that our enhancers were arterial enriched in both zebrafish and mouse transgenesis. We feel this is clearly shown with the e14.5 transgenic embryos as originally shown. We chose e14.5 because it matched the timepoints used for the single cell transcriptomics from which we selected the target arterial identity genes, and feel it is also a good match to 2-3 dpf zebrafish in terms of arterial differentiation mechanisms. We agree that E9-10 would have also been an additional useful timepoint, but we do not have the resources to generate this data nor consider it essential for the conclusions of our work here.</p><disp-quote content-type="editor-comment"><p>3. Description of the revisions that have already been incorporated in the transferred manuscript</p><p>Reviewer 1:</p><p>In literature, the term 'deep conservation' refers to evolutionary conservation (genomic sequence preservation) in a wide range of species. Therefore, the additional classification presented by the authors based on the surrounding sequence is not clear. As, the KLF motifs in the Ece1in1, which is conserved between mouse and human, are defined as &quot;deeply conserved&quot;. However, the FLK motif in the following enhancer, Flk1in10 (one line below), gets classified as non-deeply conserved, despite also being conserved between mouse and human. Thus, in the current form, there is a contradiction in the way the authors use the term 'deeply conserved' and the accepted meaning of this term. To avoid confusion, it would be important to revise this nomenclature.</p></disp-quote><p>Incorporated Revision 1. Change in nomenclature to alter the term “deep conservation” to “strong conservation” and new text to better describe this.</p><p>We have altered our nomenclature. This is explained in the relevant Results sections: “Because the level of conservation of motifs can often be an indication of their importance to enhancer activity, we classified each motif into three categories: strongly conserved (motif conserved to the same depth of the surrounding sequence), weakly conserved (motif conserved in orthologous human enhancer but not to the same depth as the surrounding sequence) and not conserved (motif is not conserved within the orthologous human sequence)”.</p><p>Two enhancers (Unc5b-57 and Cdh1-1) were only conserved human-mouse, therefore each TF motif within these enhancers could be annotated as both weakly and strongly conserved. As the reviewer noted, this does create confusion. We have now adjusted Figure 5 to use a distinct shape for motifs for which no distinction between weak and strong motif can be made. This does not cover Ece1in1, which is conserved human-mouse-tenrec but was erroneously originally labelled human-mouse only. This error has been corrected.</p><disp-quote content-type="editor-comment"><p>Reviewer 1 Minor comment: Figure 1 and 2 for non-zebrafish readers it would be useful to indicate in Figures 1 and 2 the non EC expression that can be observed in the embryos.</p></disp-quote><p>Incorporated Revision 2. Improved labeling in Figure 1 and Figure 2.</p><p>In addition to arterial expression, a number of the enhancer:GFP transgenes also showed GFP expression within the neural tube. In addition, some transient transgenic embryos also showed ectopic expression in muscle fibers. These have now been clearly labelled on the images in Figure 1 and 2.</p><disp-quote content-type="editor-comment"><p>Reviewer 2 Major Comment 2:</p><p>The human data comes from vein endothelial or microvasculature endothelial cells. Specially because some of the enhancers identified by the authors drive also vein expression, could the authors discriminate whether this is due to the identification coming from vein cells. Is there available data from HAECs? Would this not be conceptually more correct that using vein endothelial cells data? This should be at least discussed in the paper.</p></disp-quote><p>Incorporated Revision 3. Inclusion of enhancer marks from HAECs, telo-HAECs and HAUECs</p><p>We have now included a comparison with enhancer marks from HAECs, telo-HAECs and HUAECs as a new Figure 1—figure supplement 4. The enhancer marks seen in these cells were very similar to those in the HUVEC and microvascular cells already surveyed. Had enhancer marks within HAECs/telo-HAEC/HUAECs been included as a human enhancer mark in our initial survey, it would have been unlikely to have altered our analysis, although we agree it would have made it more conceptually correct. We chose not to go back and engineer this into our original enhancer selection rational however as we felt it would be intellectually dishonest. A paragraph has been added to the Results section about this analysis:</p><p>“We also considered whether the use of vein-origin (HUVEC) and microvascular-origin (HMVEC-dBl-neo/ad) ECs in our analysis of human enhancer marks may have affected the accuracy of our putative enhancer selection by expanding our analysis to enhancer marks in arterial-origin ECs. However, analysis of enhancer marks in human aortic endothelial cells (HAEC and telo-HAECs) and human umbilical artery endothelial cells (HUAECs) showed a very similar pattern, and identified the same set of putative enhancers as when HUVEC/HMVEC data was considered (Figure 1 – supplemental figure 4). This suggests that the arteriovenous original of cultured cells did not significantly influence putative enhancers marks, further emphasizing the challenges of using selecNve enhancer marks in such lines to predict expression patterns in vivo.”</p><disp-quote content-type="editor-comment"><p>Reviewer 4 Major Comment 1.</p><p>Choice of arterial genes is slightly biased. Acvrl1/Alk1 is not enriched in arterial ECs. Sema3G, which is highly expressed in arterial ECs, is missing. UNC5B is enriched in arterial ECs but also expressed by sprouting ECs (PMID: 38866944).</p></disp-quote><p>Incorporated Revision 4. Better explanation of choice of arterial genes</p><p>The choice of arterial genes was already discussed in the Results and Discussion section. However, we have now edited the first Results section to better explain gene selection: “It is therefore clear that a better understanding of the regulatory pathways directing arterial differentiation requires the identification and characterization of a larger number of arterial enhancers directing the expression of key arterial identity genes. To identify a cohort of such enhancers, we looked in the loci of eight non-Notch genes: Acvrl1(ALK1) Cxcr4, Cxcl12, Efnb2, Gja4(CX37), Gja5 (CX40), Nrp1 and Unc5b. Although not a definitive list of arterial identity genes, single cell transcriptomic analysis indicates these genes are all significantly enriched in arterial ECs4,20, and are commonly used to define arterial EC populations in mouse and human scRNAseq analysis<sup>4,5,20,54</sup>. Additionally, single-cell transcriptomic data indicates that arterial ECs can be divided into two subgroups<sup>4,20</sup>. The genes selected here are equally split between subgroups (Acvrl1, Cxcl12, Gja5 and Nrp1 from the mature arterial EC subgroup, Cxcr4, Efnb2, Gja4 and Unc5b from the less mature/arterial plexus/pre-arterial EC subgroup)<sup>4,20</sup>. We did not exclude genes also implicated in angiogenesis/expressed in sprouting ECs, as these genes formed that vast majority of those associated with the less mature EC subgroup”. Discussions about the overlap with angiogenic/sprouting genes can also be found in the original Results section (angiogenic expression of arterial genes is discussed within the <italic>MEF2</italic> and RBPJ sections) and in the Discussion (paragraph 2, referring to different expression patterns within arterial ECs).</p><p>When we started this project, scRNA-seq datasets in the developing endothelial vasculature were less available than now. Consequently, we initially based our choice of genes on data from Raftrey <italic>et al.,</italic> Circ Res 2021 (available earlier on bioRxiv), which was focused on mouse coronary arterial ECs at the timepoints that arteries differentiate. This found <italic>Acvrl1</italic> to be arterial enriched (not a novel observation, many publications treat <italic>Acvrl1</italic> as arterial specific or arterial-enriched) and did not list <italic>Sema3g</italic>. We also considered a wider dataset from mouse and human mid-gestation embryos when available (Hou <italic>et al.,</italic> Cell Research 2022). However, it is important to note that we did not aim to investigate every arterial enriched gene, rather to use these datasets to help identify loci associated with gene expression patterns which indicated a high likelihood of containing arterial enhancers active during arterial differentiation.</p><p>Sc-RNAseq data from both Raftery et al., and Hou et al., indicated that arterial ECs are subdivided into two groups, reflecting maturity but also potentially slightly different developmental trajectories. The genes studied here were therefore selected to evenly cover both subgroups, with <italic>Acvrl1</italic>, <italic>Cxcl12</italic>, <italic>Gja5</italic> and <italic>Nrp1</italic> primarily restricted to the mature arterial EC subgroup, while <italic>Cxcr4</italic>, <italic>Efnb2</italic>, <italic>Gja4</italic> and <italic>Unc5b</italic> were also expressed in the less mature/arterial plexus/pre-arterial EC subgroup. It is notable that genes within the latter subgroup are also associated with angiogenic/sprouting ECs (<italic>Dll4</italic> also belongs to this subgroup), which likely indicates biological links between angiogenesis and arterial identity rather than a problem in gene choice and specificity.</p><p>Incorporated Revision 5. Consideration of two additional putative enhancers Efnb2-159 and Cxc4+119<italic>.</italic></p><p>This was not in response to reviewers but instead in response to an error spotted during revision. The putative arterial enhancers Efnb2-159 and Cxcr4+119 were initially omitted in error yet both regions reach the standard of testable putative enhancers (this has been noted in small changes to Figure S1 and Table S2). When tested in zebrafish transient transgenic embryos, Cxcr4+119 was inactive whilst Efnb2-159 was active in arterial endothelial cells. The relevant tables and figures have been adjusted to reflect these changes, the most significant of which are the inclusion of Efnb2-159 positive zebrafish in Figure 1 (and the necessity to create an additional supplemental Figure (S3) to accommodate the increased number of images), and analysis of Efnb2-159 transcription factor motifs/binding as part of Figure 5 and 6. This brings the total of novel robust arterial enhancers identified here to 16, and the total of validated arterial enhancers in all literature to 24. No conclusions were altered by the inclusion of this data.</p><disp-quote content-type="editor-comment"><p>Reviewer 1 Minor Comment:</p><p>Details on how the corresponding non-coding regions between mice and humans were established are missing, what alignment tool was used?</p></disp-quote><p>Incorporated Revision 6. Altered text to address missing or incorrect pieces of information</p><p>This information has now been included in the relevant Results section: “Orthologous human enhancer sequences were identified for every enhancer using the Vertebrate Multiz Alignment &amp; Conservation Track on the UCSC genome browser”</p><disp-quote content-type="editor-comment"><p>Reviewer 1 Minor Comment:</p><p>Not sufficient details are provided for the re-analysis of siRNA data. E.g., which clustering method was used? How the clusters were assigned to cell identities?</p></disp-quote><p>The information detailing the re-analysis of scRNA data has now been expanded in the methods section.</p><disp-quote content-type="editor-comment"><p>Reviewer 1 Minor Comment:</p><p>Details about the first HOMER analysis (in the assessment of transcription factor motifs and binding patterns at arterial enhancers) seem to be missing from the methods section.</p></disp-quote><p>This has now been included in the methods section.</p><disp-quote content-type="editor-comment"><p>Reviewer 1 Minor Comment:</p><p>Pg 12: &quot;For ETS, 23/23 arterial enhancers contained at least one conserved motif (all &quot;deeply&quot; conserved to the same depth as the surrounding enhancer, see S7)&quot;. Is it S8, where conservation is indicated?</p></disp-quote><p>We have corrected this error in the text – no figure actually needed to be referenced here as the previous sentence contained the full list of relevant figures to this statement (Table 2 and Figures 5 and S9, previously called S8, are the places to see this information).</p><disp-quote content-type="editor-comment"><p>Reviewer 1 Minor Comment Table S1:</p><p>Please, indicate in the legend what the asterisk in the H DNAseI column stands for</p></disp-quote><p>The asterisk indicates where DNaseI hypersensitivity is also seen in multiple non-EC lines. This explanation has been added to the legend.</p><disp-quote content-type="editor-comment"><p>Reviewer 3 Minor inaccuracy in Intro/paragraph 3:</p><p>Though sox17 is reported as indispensable for arterial specification (PMID: 24153254), losing a single SoxF factor does not seem to completely compromise the arterial program (PMID: 24153254, PMID: 26630461). A combined loss of Sox17/18, or Sox 7/17/18, seems to do the job (PMID: 26630461).</p></disp-quote><p>We have altered this section to “The evidence linking SOXF transcription factors to arterial differentiation is more extensive, with loss of either SOX17 (the SOXF factor most specific to arterial ECs) or SOX7 resulting in arterial defects<sup>21–24</sup>. Whilst losing a single SOXF factor does not entirely compromise the arterial program, arterial differentiation appears absent after compound Sox17;Sox18 and Sox7;Sox17;Sox18 deletion, although this occurs alongside significantly impaired angiogenesis and severe vascular hyperplasia<sup>21–24</sup>.” PMID 24153254 is reference 23, PMID 26630461 is reference 24.</p><disp-quote content-type="editor-comment"><p>4. Description of analyses that authors prefer not to carry out</p><p>Reviewer 1 Minor Comment Figure S8:</p><p>The phrasing &quot;conserved to animal&quot; in Figure S8 is misleading. There is no difference in something being conserved to tenrec or manatee, as both are Afrotherians. Hence, the data show that both Efnb2-141 and Ephb4-2 were present in the common ancestor of Afrotherians and humans, namely the ancestor of all placentals. Instead, it would be good to indicate the phylogenetic group for which the presence of the enhancer can be inferred (in this case, Placentalia).</p></disp-quote><p>Whilst I appreciate the point, it is the exact sequence that is important here – obviously tenrec and manatee are similar species but still contain differences in nucleotide sequences. The information about conservation leads the reader to the exact species with which the comparison is being made. We tried to restrict this to just one species per phylogenetic group (e.g. tenrec, opossum, chicken, zebrafish) but occasionally this was not possible.</p><disp-quote content-type="editor-comment"><p>Reviewer 2 Major Comment 1:</p><p>In their identification of enhancers, the authors consider a candidate every enhancer that has a putative mark in both mouse and human. Nevertheless, all the human data comes from in vitro analysis. Considering how much cell culture affects endothelial cell identity, inducing effects like EndoMT, would this have any effect on the enhancer selection? Would it be possible to search any human in vivo data? Would this allow for even stronger and more relevant sequences?</p></disp-quote><p>We agree that the use of human endothelial cells in culture raises some potential issues. However, we stress that the mouse EC enhancer marks, which played a key role in defining putative enhancers, come from in vivo analysis (E11 embryos, P6 retina and adult aorta), limiting the potential for significant impact from cell culture-induced issues. Whilst we would have enthusiastically incorporated human in vivo data had it been available, our approach was still indisputably successful at identifying arterial enriched/specific enhancers.</p><p>We consider it unlikely that culture/identity-related problems with human cultured ECs led to a significant undercount of enhancers, in part because comparatively few regions with enhancer marks in mouse in vivo ECs were excluded due to the absence of human enhancer marks. In fact, <italic>Cxcr4</italic>, <italic>Cxcl12</italic>, and <italic>Gja5</italic> were poorly transcribed in the human cell lines studied here and consequently only enhancer marks in mouse were used to define putative enhancers for these three genes (this is clearly stated in the Results section). If a similar rational had applied to the remaining five genes, only an additional six putative enhancers would have been tested (one for <italic>Gja4</italic>, two for <italic>Nrp1</italic> and three for <italic>Unc5b</italic>). However, we felt it made sense to include analysis of human enhancer marks for these five genes, as all were expressed in the human ECs used (as indicated by H3K1Me3 and DNaseI hypersensitivity at promoter regions) and orthologous human enhancers were identified for all. Additionally, our retrospective analysis of previously described mammalian in vivo-validated EC enhancers (Table S1 in the original manuscription, including eight arterial enhancers) found that all 32 were marked by at least one enhancer mark in human samples (1/32 did not contain mouse enhancer marks). We also tested eleven regions that did not reach our putative enhancer threshold, including five with only mouse marks. None of these directed expression in transgenic analysis.</p><disp-quote content-type="editor-comment"><p>Reviewer 2 Major Comment 3:</p><p>Although the authors use the mouse embryo to further validate their finding beyond the zebrafish, the expression are a bit different. While on the fish the enhancers label smaller vessels of arterial identity, in the mouse, only bigger arteries are marked. Is this defined by the time of the analysis?</p></disp-quote><p>This experiment was conducted to demonstrate that activity of these enhancers are arterial enriched in both zebrafish and mouse, and feel this is clearly shown by the current data. Whilst I do not really agree that the expression pattern is different (for example, the Gja5 enhancers are more restricted to the major arteries in both zebrafish and mouse, compared to the more widely expressed Efnb2-333), this is challenging to ascertain at a single time-point in a transient transgenic mouse assay. Whilst it would be potentially interesting to better assess the activity of these enhancers over time in mice, this would be an expensive and lengthy experiment (multiple stable lines would need to be established and characterized for each enhancer) which would not add a notable benefit to this paper.</p><disp-quote content-type="editor-comment"><p>Reviewer 3 Major Comment 2:</p><p>Exclusion of Notch genes. Although the reason for choosing non-notch genes and excluding notch genes for screening is addressed in this paper, it would be interesting to examine how the arterial enhancers identified in this study are present in the Notch genes, especially Dll4 (enriched in arterial and sprouting ECs) and Jag1 (enriched in arterial ECs).</p></disp-quote><p>Previous work from our lab and others has already examined arterial enhancers for many Notch pathway genes. We already included these enhancers (including two for <italic>Dll4</italic>, one for <italic>Notch1</italic> and one of <italic>Hey1</italic>) in all our later analysis (Figure 5-6 and relevant supplemental figures). Whilst <italic>Jag1</italic> is not included in this analysis, we do not feel additional enhancer identification is needed to support the conclusions of this paper.</p></body></sub-article></article>